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Small-molecule probes to explore cancer 
 
Abstract 
 
Small molecules play important roles in therapeutics and drug discovery. 
Significant progress has been made by the chemical biology community to discover 
small-molecule probes to explore biological processes and to treat disease. This thesis 
describes both the discovery of novel probes for the Hedgehog (Hh) pathway and the 
application of small molecules in identifying cancer dependencies.  
In a phenotypic screen for inhibitors of Hh signaling, a pathway sometimes 
deregulated in cancer, several previously annotated molecules were identified that, in 
addition to their original targets, were shown to have activity in this pathway. 
Furthermore, two potent small-molecule inhibitors, BRD50837 and BRD9526, were 
discovered. Analysis of structure–activity relationships (SAR) demonstrated striking 
stereochemistry-based SAR. This feature suggested a specific and selective interaction 
of these compounds with their cellular target(s). Further studies revealed that their 
mechanism of action displayed similarities to that of cyclopamine, a commonly used Hh 
probe that targets the Smoothened receptor, and yet differed strikingly in other aspects. 
Early insights into the probes’ mechanisms of action shed light onto the nature of these 
novel compounds. 
 iv 
 
To advance the application of small molecules in cancer, an unbiased screen 
was performed using 242 genomically characterized cancer cell lines (CCLs) that were 
profiled using a set of 354 small molecules to discover novel oncogene and non-
oncogene dependencies. Enrichment correlations between small-molecule sensitivity 
and genetic features were calculated. This allowed for known dependencies to be 
confirmed and generated several novel hypotheses. A public resource was created 
based on these efforts (http://www.broadinstitute.org/ctrp).  
To address the challenge of interpreting genomic alteration/compound sensitivity 
relationships, genomic characterizations were prioritized using recurrent mutations, 
overlap with patient data, and annotation of fusion genes. This prioritized approach 
demonstrated that small-molecule sensitivity can be differential across mutations in the 
same gene, and allowed for identification of novel and specific dependencies. For 
example, pan- and PI3K--specific inhibitors appear to be more potent in PIK3CA 
E542K-mutated CCLs than other PIK3CA-mutated CCLs.  
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MY head knocks against the stars. 
My feet are on the hilltops. 
My finger-tips are in the valleys and shores of universal life. 
Down in the sounding foam of primal things I reach my 
hands and play with pebbles of destiny. 
I have been to hell and back many times. 
I know all about heaven, for I have talked with God. 
I dabble in the blood and guts of the terrible. 
I know the passionate seizure of beauty 
And the marvelous rebellion of man at all signs reading 
"Keep Off." 
 
My name is Truth and I am the most elusive captive in the 
universe. 
- Carl Sandburg (“Who am I?”) 
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Chapter One 
 
Introduction to small-molecule probe development 
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Small-molecule probe development 
Small molecules are omnipresent in nature. They play important but diverse roles 
in biology including, but not limited to, functioning as signaling molecules,1,2 
metabolites,3 and even warfare agents between different biological species.4,5 They are 
therefore a great part in the chemistry of life and have been described as an important 
piece of the central dogma of life.6 It is thus unsurprising that they have been used both 
as tools in biology and as drugs in medicine.7 As probes, small molecules have helped 
to elucidate the underlying biology of cells and of diseases: for example, colchicine and 
taxol helped illuminate the cytoskeleton,8,9 and cyclosporine A, FK506, and rapamycin 
helped understand immune system signaling and how to manipulate it.10 Some probes 
even subsequently become FDA-approved drugs, such as in the case of the 
immunosuppressant rapamycin.11 Small-molecule probes, therefore, play an important 
role in our understanding of biology and in drug discovery, and their development will 
continue to help us treat patients. 
Small-molecule probe development has become an important part of medicinal 
research and is done by both academia and pharmaceutical industry. Because these 
tools are being used to generate and prove hypotheses about biology and diseases, it is 
important that they are reliable in their mechanism of action. Therefore, quality-control 
measures have been defined. For example, the Molecular Libraries Screening Centers 
Network (MLSCN) defined the criteria for a small molecule to be a probe to be: it must 
have a potency of at least 100 nM, selectivity of at least tenfold over related targets, and 
aqueous solubility. It furthermore needed to be an improvement over already existing 
probes.12 Other important criteria are cell permeability and potency in cellular assays to 
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ensure target engagement in biological systems as well as in vitro.13 Drugs do not 
necessarily fulfill the stringent criteria of selectivity, a characteristic that might even be 
beneficial if several small-molecule/target interactions are needed to create the desired 
effect in the human body.12 However, in order to dissect cellular biology in the most 
detail possible, probes are more useful the more they fulfill the criteria. 
The discovery of small-molecule probes, like that of drug candidates, can be 
done using high-throughput screening. Screens can, very broadly, be divided into two 
classes: biochemical and cell-based screens.14 Biochemical screens generally are of a 
more directed nature: the protein to be targeted will be screened for directly, for 
example by using purified enzymes or small-molecule microarrays.15 Advantages for 
this type of screen are that the target is known beforehand and therefore, mechanism of 
action is known. Disadvantages include that the compounds may not be cell-permeable 
or active in the cell-based system, or that the compounds have different or additional 
effects and targets in a cellular setting, thus compromising their usefulness as tools. 
Cell-based screens allow for modulators of different proteins in a pathway to be found 
(using reporter-gene-based assays for example), or even for modulators of a phenotype 
(phenotypic assays), which could in theory result in modulators of any member of the 
proteome. These approaches allow for more targets within a pathway to be screened 
simultaneously and they also allow for the discovery of previously not-considered 
targets. Their major disadvantage lies in the requirement for subsequent target 
identification which can be difficult and time-consuming. While there is no clear 
prescribed method to identify the target, advances in proteomics, genetics, and 
bioinformatics, have led to a toolbox to manage this task.16,17 While these methods are 
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important to elucidate the mechanism-of-action of a probe or drug, they can also help to 
determine possible off-targets. 
 
The Sonic Hedgehog signaling pathway 
One example where probe development and pathway elucidation have gone 
hand-in-hand is in the case of the Sonic Hedgehog (Shh) signaling pathway. This 
signaling pathway is necessary for embryonic development and plays an important role 
in growth, patterning, and morphology of insects and vertebrates.18,19 Deficiencies in 
Hedgehog (Hh) signaling during development can cause diseases such as 
holoprosencephaly.20 Additionally, aberrant activation of the pathway through somatic 
mutations in genes encoding members of the pathway are known to drive the 
development and maintenance of several cancers, such as basal cell carcinoma (BCC), 
pancreatic cancer, and medulloblastoma.21-24 
Research on the pathway has been ongoing since the 1970s when researchers 
identified genes which, when mutated, affected the segmental pattern of Drosophila 
melanogaster larvae.25 Since then much research into its members and signaling 
mechanism has been done, but understanding of the pathway is still not complete and 
the picture is becoming increasingly complex. In the classical “canonical” signaling 
model the pathway is activated by one of three extracellular secreted proteins: Desert 
Hedgehog, Indian Hedgehog, or, most commonly, Sonic Hedgehog (Shh) (Figure 1.1a). 
This protein binds the transmembrane receptor Patched (Ptch). In the absence of ligand 
binding, Ptch represses Smoothened (Smo), a G-protein coupled transmembrane 
receptor (Figure 1.1b). In a still unknown way, the Shh/Ptch complex leads to a 
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derepression of Smo, resulting in its translocation to the primary cilium. The 
transcriptional regulator of the pathway, Gli, is usually sequestered in a repressor 
complex with, among others, Suppressor of Fused (SuFu), which results in degradation 
to its inactive form. Translocation of Smo to the primary cilium results in a release of Gli 
from the repressor complex and translocation of the activated transcription factor to the 
nucleus where genes involved in cell proliferation and differentiation are activated.21,26,27  
 
Figure 1.1. Canonical signaling of the Hedgehog pathway in the a) active and b) 
inactive state. 
 
The first small-molecule inhibitor of the pathway to be discovered was 
cyclopamine, a natural product found in Veratrum Californicum and a Smo inhibitor 
(Scheme 1).28 More Smo inhibitors were subsequently identified, the most notable of 
which is vismodegib, an FDA-approved treatment for BCC.29,30 Additionally, small-
molecule activators of the pathway have been found, such as SAG and purmorphamine 
which also act on Smo.31,32 As an example of a targeted screen, a small-molecule 
microarray setup has led to an antagonist of Shh, robotnikinin.33 In cell-based assays, 
A B
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on the other hand, inhibitors of the Gli/DNA interaction have been found (e.g. GANT-61) 
and small molecules which later proved to inhibit the pathway by modulating the motor 
protein dynein (ciliobrevin A).34,35 Recently, a small molecule inhibiting Hh signaling was 
discovered which was found to target GPR39, a G protein-coupled receptor with 
previously no known connection to the Hh pathway.36 Elucidation of these compounds’ 
mechanism of action therefore has furthered the understanding of the pathway’s 
signaling steps.  
 
Scheme 1.1. Structures of Hedgehog pathway modulators. 
 
In addition to the ‘canonical’ Hh signaling, more recent evidence has shown that 
the pathway also promotes ‘noncanonical’ signaling.37 Examples of this signaling 
include Gli-independent activation of Rho small GTPases through Smo and pro-
apoptotic signaling through Shh and Ptch, independent of Smo.38-40 Further complexity 
is added by the observation that small-molecule modulators of the pathway can act on 
the same protein and have different cellular outcomes. For example, cyclopamine 
promotes Smo accumulation in the primary cilium while this is prevented by 
vismodegib.41,42 Even more strikingly, purmorphamine and cyclopamine bind in the 
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same Smo binding pocket, but purmorphamine activates the pathway while 
cyclopamine inhibits it.28,32  
 
Cancer dependencies  
The development of vismodegib as a treatment for BCC was based on the fact 
that nearly 100% of patients with sporadic BCC have mutations causing faulty activation 
of the Hh pathway43-45 and the premise that cancer cells become “dependent” on their 
activated growth signals. Cancers are the result of a series of somatic mutations of 
oncogenes, leading to uncontrolled growth. Some of these mutations are required to 
continue growing; removing the signal from these mutations causes the cancer cells to 
arrest their growth or die. As healthy cells generally do not depend on signals such as 
the Hh signal, they would not be as strongly affected by removal or inhibition of this 
oncogene (Figure 1.2a).46 This concept, known as oncogene dependency, is a relatively 
recent concept and has been used to create targeted chemotherapies with limited 
toxicity profiles. Examples of therapies targeting such oncogene dependencies that 
exist in the clinic are vemurafenib, an inhibitor of V600E-mutated BRAF approved for 
metastatic melanoma, or imatinib, an inhibitor of the BCR/ABL fusion protein and c-kit 
kinases approved for chronic myelogenous leukemia and gastrointestinal tumors.47,48 In 
addition to oncogene dependencies, it appears that there are also non-oncogene 
dependencies where cancer cells have become dependent on certain housekeeping or 
signaling genes as a result of their genetic mutations (Figure 1.2b). Examples of this 
type of dependency are breast cancer cell lines with mutations in BRCA1 or BRCA2 
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Figure 1.2. Mutations in cancer cells cause these cells to rewire their signaling around 
the overactivated or damaged protein. As a result of this, cancer cells can become 
dependent on the mutated protein/pathway (a), or another, compensating pathway (b). 
Small-molecule inhibition of this dependency can then be exploited to selectively kill 
cancer cells.  
 
(both DNA-repair proteins) which are sensitive to poly (ADP-ribose) polymerase (PARP) 
inhibition. This dependency appears to be due to these cell lines having an already 
damaged DNA repair apparatus and thus relying on PARP for their DNA repair. 
A
B
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Inhibition of PARP thus leads to these cells losing all DNA repair functions and 
ultimately causes death.48 In line with this, the PARP inhibitor olaparib has shown 
promise in clinical trials of BRCA1/BRCA2-mutated patients with breast cancer.49,50 
 
Cancer cell-line profiling 
One problem with targeted cancer therapies is that currently only few patients 
actually benefit from them. Additionally, resistance is a commonly occurring problem.51 
In order to increase the number of patient-matched cancer therapies and to accelerate 
their discovery, cancer cell-line profiling has been used to identify novel dependencies. 
In these efforts, increasingly large numbers of cancer cell lines (CCLs) are tested for 
their sensitivity to small-molecule inhibition or inhibition of gene expression through 
RNA interference (RNAi). The sensitivities are then related to CCL features such as 
lineage, genetic, or epigenetic markers (Figure 1.3).52-54 This approach has successfully 
confirmed the identification and subsequent targeting of dependencies on oncogenic 
 
Figure 1.3. Cell-line profiling can help generate new hypotheses about cancer 
dependencies. Genetically and epigenetically characterized CCLs are tested for their 
sensitivity against a set of annotated small molecules. If many sensitive or non-
responsive cell-lines share a feature, this might lead to a new hypothesis. 
   10 
 
BRAF and EGFR alleles.55 However, these studies are often limited by numbers of 
CCLs, compounds, or features characterized within the CCLs. New technologies and 
larger datasets allow more hypotheses to be generated and developed into therapies. 
 
Roadmap 
This thesis describes an effort to develop novel small-molecule probes and their 
application to cancer biology. In a pathway-targeted effort, a high-throughput screen for 
novel Hh pathway inhibitors and the classification of several known probes with 
additional activity as Smo inhibitors is described in Chapter Two. Chapter Three 
describes the identification of a group of molecules arising from the same screen as 
novel pathway inhibitors and the characterization of their distinct structure-activity 
relationships (SAR). Their mechanism of action is further elucidated in Chapter Four. In 
an unbiased approach, Chapter Five describes the generation of a large dataset of 
CCLs and their sensitivity to an annotated small-molecule informer set. Hypotheses 
generated from this approach, and follow-up experiments to one hypothesis, are then 
described in Chapter Six. Finally, Chapter Seven gives an outlook at future possibilities 
of small-molecule probe development in cancer biology. 
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Chapter Two 
 
Effects of known small-molecule probes on the Hedgehog 
signaling pathway 
 
 
Dr. Jose Perez and Dr. Benjamin Stanton developed and performed the cell-based 
Hedgehog screen and collected the conditioned medium used. Dr. Perez confirmed the 
hits in dose. I tested the hits’ toxicity in Shh Light II cells, retested their effect in 
C3H10T1/2 cells, and prioritized candidates to further follow-up. I characterized these 
compounds’ mechanisms of action in the SAG activation, Ptch-/-, and BODIPY-
cyclopamine assays. 
 
 
 
 
 
 
 
 
 
In part adapted from Schaefer, G.I.; Perez, J.R.; Duvall, J.R.; Stanton, B.Z.; Shamji, 
A.F.; Schreiber, S.L. “Discovery of Small-Molecule Modulators of the Sonic Hedgehog 
Pathway” J. Am. Chem. Soc. 2013, 135, 9675-9680.1 
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Screen for inhibitors of Hedgehog pathway 
In an effort to develop novel small-molecule probes for applications in cancer 
research, a pathway-targeted effort (Chapters 2 – 4) as well as an unbiased approach 
(Chapter 5 & 6) was employed. While inhibitors of the Hedgehog (Hh) pathway exist in 
the clinic, resistance is an issue and inhibitors with novel mechanisms of actions can 
help develop more potent therapies.2 To enhance our molecular understanding of the 
Hh pathway, we aimed to discover novel small-molecule probes of Hh signaling. We first 
performed a cell-based high-throughput screen for novel inhibitors of Gli-induced 
transcription. 21,753 compounds were screened in a cell-based assay using Shh Light II 
cells. These cells are derived from NIH/3T3 cells by co-transfection with a Gli-
responsive Firefly luciferase reporter.3,4 All compounds were screened in duplicate at a 
single concentration. Screening positives (mean inhibition ≥ 65%) were re-tested in 
dose and their toxicity was assessed using CellTiter-Glo to measure cellular ATP levels 
as a surrogate for viability. 390 hits were identified and 180 were advanced for further 
investigation after toxicity measurements (Suppl. Figure S2.1, Suppl. Figure  S2.2). 
 The compounds’ activity on the Hh pathway was further verified using a second 
biological assay that measures alkaline phosphatase expression as a surrogate for Hh-
induced differentiation of C3H10T1/2 cells into osteoblasts.5 160 compounds were 
confirmed in this assay and advanced as candidates for further investigation. 
Interestingly, when studying the confirmed hits, it was found that several of the 
compounds were annotated in the literature as having a mechanism of action other than 
inhibition of Hh signaling and the behavior of 11 of these compounds in pathway-
relevant assays was further analyzed (Figure 2.1, Table 2.1).1 
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Figure 2.1. Inhibition of Shh-conditioned medium-induced differentiation of C3H10T1/2 
cells by previously-annotated compounds, and cyclopamine as a control after 48h. All 
values are shown and generated from three (BRL 15572, colchicine, phorbol 12-
myristate 13-acetate, pifithrin-a, SDZ-201106, tyrphostin 9, vinblastine, cyclopamine) or 
two (cytochalasin D, L-741,742, MY-5445, ZM336372) independent experiments run in 
duplicate (values are calculated average ± SD). 
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Table 2.1. list of candidates with previously annotated mechanisms of action 
compound 
name 
structure 
selected annotated 
mechanism of action* 
BRL 15572 
 
selective h5-HT1D antagonist
6 
colchicine 
 
inhibitor of microtubule 
formation, binds tubulin7 
cytochalasin D 
 
inhibitor of actin polymerization8 
L-741,742 
 
antagonist of dopamine D4 
receptor9 
MY-5445 
 
inhibitor of cGMP 
phosphodiesterase10 
phorbol 12-
myristate 13-
acetate 
 
activator of protein kinase C11 
pifithrin- 
 
inhibitor of p53 induced 
apoptosis12 
SDZ-201106 
 
partial inhibitor of Na+ pump, 
positive inotropic and calcium 
sensitizing agent13,14 
tyrphostin 9 
 
inhibitor of platelet-derived 
growth factor receptor tyrosine 
kinase15 
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Table 2.1. (Continued) 
compound 
name 
structure 
selected annotated 
mechanism of action* 
vinblastine 
 
inhibitor of microtubule 
assembly16 
ZM336372 
 
in vitro inhibitor but in vivo 
activator of Raf-117 
*for compounds with several annotated mechanisms-of-action, representative examples were selected in 
this table.  
 
Characterization of compounds’ mechanism of action 
The compounds’ activity on the pathway could stem from different origins. It 
could be from on-target effects with their annotated target, resulting in cross-signaling or 
other perturbations of the Hh pathway. Alternatively, the compounds could have more 
than one cellular target and thus act on the Hh pathway directly. To gain more insight 
into the origins of the compounds’ activity within the Hh pathway, additional experiments 
were conducted. The compounds were tested in Ptch-/- cells, mouse embryonic 
fibroblasts that contain a -galactosidase reporter gene instead of the Ptch gene 
downstream of the Ptch promoter (Figure 2.2).3 The pathway in these cells is 
constitutively activated through the loss of Ptch, and compounds only retain activity in 
this assay if they act at a step downstream or at Ptch, but not upstream of it. 
Additionally, the compounds were assayed in C3H10T1/2 cells where the pathway is 
activated with SAG (a small-molecule activator of Smo) rather than Shh-conditioned 
media (Figure 2.3).4 Activity of compounds in this assay suggests that the compounds 
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act at or below of Smo in the pathway. The compounds were active in both assays, 
suggesting that they act at a step at or below Smo in the pathway. Some compounds 
show toxicity in these assays, but less than inhibition at the respective concentrations. 
 
 Figure 2.2. β-galactosidase expression (black dots) and viability (white dots) 
(measured using ATP levels as a surrogate) response of Ptch−/− cells to 48 h treatment 
with previously annotated compounds and cyclopamine as a control. All values are 
shown and generated from three independent experiments run in duplicate (values are 
calculated average ± SD). 
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Figure 2.3. Inhibition of SAG-induced differentiation (black dots) and viability (white dots) 
(measured using ATP levels as a surrogate) of C3H10T1/2 cells by previously 
annotated compounds and cyclopamine as a control after 48h. All values are shown 
and generated from three independent experiments run in duplicate (values are 
calculated average ± SD). 
 
To directly test the compounds’ ability to bind Smo, a protein known to interact 
with many molecules, the compounds were tested in a competition assay. In this cellular 
assay, it is determined whether compounds displace BODIPY-cyclopamine, a 
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fluorescent cyclopamine-derivative. The HEK293T cells are transfected with a smo-
myc-his construct, which can also be probed for using an anti-myc antibody. Loss of 
BODIPY-cyclopamine signal in transfected cells thus suggests that molecules bind Smo 
in the cyclopamine-binding site (Figure 2.4).18  
 
Figure 2.4. Effects of DMSO, cyclopamine, and the compounds (10 M) on BODIPY-
cyclopamine (5-10 nM) binding to exogenously expressed Smo. blue (Hoechst 33342), 
red (anti-myc), green (BODIPY-cyclopamine). 
BRL15572
colchicine
cyclopamineDMSO
L-741,742
MY-5445
phorbol
12-myristate 
13-acetate
pifithrin-
SDZ-201106
tyrphostin 9
vinblastine
ZM336372
cytochalasin D
= 25 m
BODIPY-
cyclopamine
anti-myc
BODIPY-
cyclopamine
anti-myc
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Several annotated probes appear to interact with Smo 
BRL 15572, L-741,742, MY-5445, pifithrin-, SDZ-201106, tyrphostin 9, and 
ZM336372 displaced BODIPY-cyclopamine in this assay, leading to the conclusion that 
Smo is one of their cellular targets. For these compounds, the activity on the Hh 
pathway most likely stems from Smo inhibition. These compounds have previously been 
annotated to interact with different cellular targets, some of them selectively over other 
targets. While cross-signaling with the proteins from these annotated interactions might 
be partially responsible for the Hh pathway perturbation, the displacement of BODIPY-
cyclopamine suggests an interaction of the compounds with Smo and thus a potential 
additional target for these compounds (Figure 2.4).  
For the compounds that did not displace BODIPY-cyclopamine (colchicine, 
cytochalasin D, vinblastine, and phorbol 12-myristate 13-acetate), the action on the 
pathway cannot be clearly classified as being due to cross-signaling with their 
annotated target or as being an off-target effect from their original annotation. 
Colchicine and vinblastine are anti-microtubule agents and cytochalasin D is a disruptor 
of actin filament formation. Both processes have been shown to affect the Hh pathway 
by influencing the primary cilium and protein trafficking.19-21 Activation of protein kinase 
c using phorbol 12-myristate 13-acetate has also been shown to negatively regulate the 
Hh pathway.22 The mechanism of action of these compounds is thus most likely on-
target cross-signaling into the pathway.  
The data presented above thus suggests that caution should be exercised with 
some of the previously reported probes. Their bioactivity might not only stem from their 
annotated mechanisms of action, which makes it harder to interpret their activity in 
 26 
 
different bio-assays. When designing an experiment, the concentrations at which these 
compounds display activity with their originally annotated targets should be taken into 
account (Table 2.2).  
 
Table 2.2. Concentrations at which previously annotated compounds display activity 
compound 
concen-
tration 
activity at concentration 
% Hh 
inhibitiona 
BRL 15572 0.008 M 
EC50 of h5-HT1D receptor expressed in 
CHO cells (0.75 intrinsic activity)6 
21.8 
L-741,742 1 M 
antagonizes inhibition mediated by 1M 
dopamine of 10 M forskolin-induced 
elevation of cAMP levels in HEK293 cells9 
14.2 
MY-5445 0.6 M 
IC50 of purified cyclic GMP 
phosphodiesterase (FI)10 
27.9 
pifithrin- 10 M 
inhibits apoptotic cell death induced by 
doxorubicin, etoposide, taxol, or cytosine 
arabinose in C8 cells12 
60.2 
SDZ-201106 1 M 
IC50 of 
22Na+ uptake by chicken cardiac 
cells14 
85.3 
tyrphostin 9 0.04 M 
IC50 of PDGF induced DNA synthesis in 
RVMSC cells15 
-5.7 
ZM336372 0.07 M 
IC50 of c-Raf in cell lysates from v-Ras and 
Lck-transfected Sf9 cells17 
1.8 
a% inhibition of CM-induced osteoblast differentiation at dose point closest to 
concentration reported in literature  
 
The concentration of some compounds’ interaction with their target is significantly 
below that of the interactions with the Hh pathway and does not cause significant % 
inhibition of osteoblast differentiation. One example of this is BRL15572, which was 
annotated as an inhibitor of the h5-HT1D receptor with more than 100 fold selectivity 
over h5-HT1B.
6 Therefore, if this compound is used at low concentrations, and the main 
reason for its use is to distinguish between the two receptors, using it in a study should 
minimize influences from the Smo off-target effect. 
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The relevant concentration for MY-5445 lies significantly below that at which it 
shows activity in the Hh pathway. However, that activity was not measured in cells and 
its cellular activity might be at higher concentrations. For L-741,742 and SDZ-201106, 
the concentrations that were used in their original studies are significantly closer to its 
active concentration in the Hh pathway. For studies using these compounds, caution 
must be exercised when interpreting their biological effects. In order to confirm findings 
made using these compounds, different probes that hit the desired target, ideally with 
distinct structural features, can be used.  
While the IC50 from the literature for ZM336372 is also significantly below the 
concentration that the Hh inhibition is seen at, this compound has given an interesting 
response. In vitro, it has been shown to inhibit c-Raf, while its in vivo activity, contrary to 
that, actually activates c-Raf. This could be due to a feed-back loop, or due to off-target 
effects. One off-target that has been identified is SAPK/p38.17 Therefore, this compound 
has a confusing profile, with Smo targeting being an additional factor and interpretations 
of its activity should be made carefully. 
The actual target for pifithrin- has not yet been identified, but it is used as an 
inhibitor of p53-mediated apoptosis.12 It has been shown that a feedback loop exists 
between the Hh signaling pathway and p53.23,24 Inhibition of Smo could thus be involved 
in pifithrin-’s mechanism of action. Further experiments would be needed to confirm 
this hypothesis. 
 
 
 
 28 
 
Conclusion 
In conclusion, the screen found several compounds that had previously 
annotated as modulators to other biological pathways. I show that the compounds also 
inhibit the Hh pathway, and appear to target Smo. When using these compounds in 
experiments, caution should be exercised in interpreting the data based on just the 
annotated target, as Smo inhibition might also be a factor. In some cases, this can be 
avoided by using the compounds at lower concentrations. However, the large number of 
alternately-annotated compounds that target Smo found in this screen suggests that 
many more compounds have multiple mechanisms of action. If looking at other 
compounds or receptors, one might find more off-target effects of many different probes. 
Therefore, having structurally distinct, selective probes targeting the same protein and 
probes which target different proteins of a pathway, is an advantage when using tool 
molecules to dissect biological findings and pathways. The goal of the chemical biology 
community should be to fill in the gaps in targets with structurally diverse small-molecule 
probes. 
 
Experimental Section 
Materials and Methods 
Screening: Compounds screened were taken from the commercial, natural 
products, bioactives, and diversity-oriented synthesis (DOS) libraries available at the 
Broad Institute (Cambridge, MA, USA). 
Cell Lines and Reagents: HEK293T, C3H10T1/2, and Shh Light II cells were 
purchased from ATCC (Manassas, VA, USA). Ptch-/- cells were kindly provided by Dr. 
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James Chen (Stanford University, CA, USA). Shh Light II cells were grown at 37°C/5% 
CO2 in DMEM supplemented with 10% bovine calf serum (BCS) (ATCC, VA, USA), 1% 
penicillin/streptomicyn (Cellgro, VA, USA), 2 mM L-glutamine (Life Technologies, 
Carlsbad, CA, USA), 0.4 mg/ml G-418 (EMD Millipore Chemicals, Billerica, MA, USA), 
and 0.15 mg/ml Zeocin (Invitrogen, Carlsbad, CA, USA). All other cell lines were 
maintained at 37°C/5% CO2 in DMEM supplemented with 10% fetal bovine serum 
(FBS) (Invitrogen, Carlsbad, CA, USA), and 1% penicillin/streptomicyn. Shh Light II cells 
were activated using a 1:25 dilution of Shh-conditioned medium in LCCM (phenol red-
free DMEM (Cellgro, Manassan, VA, USA) with 0.5% bovine calf serum, 1% 
penicillin/streptomycin, and 800 M L-Gln prepared the same day). The differentiation of 
C3H10T1/2 cells was induced by 4-5% Shh conditioned medium or 25-30 nM SAG in 
DMEM (depending on EC80 of induction determined in a pilot experiment for each 
freshly thawed batch of cells) supplemented with 0.5% FBS and 1% 
penicillin/streptomycin. Shh conditioned medium was previously collected from Shh-N 
overexpressing HEK 293T cells (kindly provided by Dr. James Chen (Stanford 
University, USA)) as reported before.4  
Assay Treatments and Readouts: Small-molecule controls were purchased from 
Sigma-Aldrich (St Louis, MO, USA), Alfa-Aesar (Ward Hill, MA, USA), Enzo Life 
Sciences (Farmingdale, NY, USA), Toronto Research Chemicals (North York, ON, 
Canada), and EMD Millipore Chemicals (Billerica, MA, USA). Alkaline-Phosphatase 
buffer was purchased from Boston Bioproducts (Ashland, MA, USA), and CDP-Star® 
Western Blot Chemiluminescence Reagent was purchased from Perkin Elmer (Waltham, 
MA, USA). Bright-Glo, Beta-Glo, and CellTiter-Glo reagents were purchased from 
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Promega (Madison, WI, USA). Antibodies were purchased from Life Technologies 
(Carlsbad, CA, USA), and Roche Diagnostics (Indianapolis, IN, USA). BODIPY-
cyclopamine was purchased from Medical Isotopes (Pelham, NH, USA) and Toronto 
Research Chemicals (North York, ON, Canada). Smo-Myc-His construct was kindly 
provided by Dr. James Chen (Stanford University, CA, USA). Plate Reader settings 
used were: luminescence settings: Perkin Elmer (Waltham, MA, USA) Envision 2104 
Multilabel Plate Reader, luminescence mirror, luminescence 700 emission filter, 0.1 s 
measurement time, 6.5 mm measurement height; US luminescence settings: Perkin 
Elmer Envision 2102 or 2104 Multilabel Plate Reader, 384 plate US luminescence 
aperture, 0.5 mm distance between plate and detector, 0.5 s measurement time, 0% 
Glow (CT2) correction factor. High-content microscope images were taken on a 
Molecular Devices ImageXpress High-Content Microscope (Sunnyvale, CA, USA) using 
DAPI settings for nuclear staining (10-80 ms exposure), GFP settings for BODIPY-
cyclopamine (160 ms-1 s exposure), and Texas Red settings for Alexa Fluor 568 
antibody (80-160 ms exposure), or on a Molecular Devices ImageXpress 5000 High-
Content Microscope using DAPI settings for nuclear staining (3 ms exposure), FITC 
settings for BODIPY-cyclopamine (80 ms exposure), and Rhodamine settings for Alexa 
Fluor 568 antibody (10 ms exposure).  
 
Assay Protocols 
Shh Light II screen/assay: To measure Hh activity in high-throuput, a luciferase-
based assay was performed using Shh Light II cells with a Bright-Glo luciferase reagent 
readout. Shh Light II cells were seeded in clear bottom, white 384 well plates at 3,500 
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cells/well density in 50 L/well DMEM supplemented with 10% BCS, 2 mM L-glutamine, 
1% penicillin/streptomicyn, 0.4 mg/ml G-418, and 0.15 mg/ml zeocin. Plates were 
covered with rayon plate covers and incubated for 4 days at 37°C/5% CO2. After 
removal of the covers, the medium was removed from the plates and they were washed 
with 50 L/well PBS. The PBS was removed and 40 L/well of a 1:25 dilution of Shh-
conditioned medium in LCCM (phenol red-free DMEM with 0.5% bovine calf serum, 1% 
penicillin/streptomycin, and 800 M L-Gln prepared the same day) was added. The 
compounds were pinned with 100 nL/well, new rayon plate covers were applied, and the 
plates were incubated for 26-30 hours. The plate covers were removed and the medium 
aspirated. The plates were covered with a foil seal and frozen at -80°C for 1 hour. 
Afterwards, the plates were thawed at room temperature for 10 min, at 37°C for 15 min 
and at room temperature for another 10 min to equilibrate. 50 L/well Bright-Glo 
luciferase reagent was added. The plates were shaken at room temperature for 2 min, 
and if there were bubbles, they were carefully blown with a heat gun to pop the bubbles 
(but not to heat the liquid). The plates were read out using US luminescence settings. 
Shh Light II CellTiter-Glo Viability assay: To control for toxicity leading to the 
effects seen, a viability assay was performed in the Shh Light II cells. Shh Light II cells 
were seeded in clear bottom, white 384 well plates at 2,500 cells/well density in 50 
L/well DMEM supplemented with 10% BCS, 2 mM L-glutamine, 1% 
penicillin/streptomicyn, 0.4 mg/ml G-418, and 0.15 mg/ml zeocin. The cells were 
incubated at room temperature for 1 h and subsequently for 1 day at 37°C/5% CO2. The 
cells were treated as in the Shh Light II assay above, but after pinning of the 
compounds, the plates were pinned again with a staurosporine control plate containing 
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1 mM staurosporine and DMSO. The plates were subsequently incubated at 37°C/5% 
CO2 for 30 hours. After the incubation period, the plates were removed from the 
incubator and allowed to come to room temperature. The plate covers were removed, 
and the medium aspirated. Subsequently, 20 L of phenol-red free DMEM was added to 
each well, followed by 20 L of a 1:3 dilution of CellTiter-Glo reagent in PBS and the 
plates were shaken at room temperature for two minutes. The plates were then 
incubated at room temperature for at least 10 min and read out using luminescence 
settings. 
C3H10T1/2 differentiation assay: To validate the compounds in a different 
biological readout, the C3H10T1/2 differentiation assay was performed. C3H10T1/2 
cells were seeded in solid bottom, white 384 well plates at 3000 cells/well density in 50 
L/well DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were 
incubated at 37°C/5% CO2 until confluent (approximately 36 hours). The medium was 
removed and each well was washed with 40 L PBS. 40 L of DMEM supplemented 
with 0.5% FBS, 1% penicillin/streptomycin, and either 4-5% Shh conditioned medium, or 
25-30 nM SAG was added to each well. Subsequently, the compounds were pinned at 
their respective concentrations with 100 nL/well. The plates were incubated at 37°C/5% 
CO2 for 48 hours. After the incubation period was over, the medium was removed and 
20 L of lysis buffer (Alkaline-Phosphatase-1 buffer with 1% Triton-X 100) was added to 
each well. The plates were shaken for 45 min at room temperature. Subsequently, 50 
L of CDP-Star® Western Blot Chemiluminescence Reagent (for the detection of 
alkaline phosphatase) was added to each well and the plates were incubated for 30 min 
before being read out using US luminescence settings.  
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Ptch-/- -galactosidase assay: To test the compounds’ mechanism of action, they 
were tested in Ptch-/- mouse embryonic fibroblasts. Ptch-/- cells were seeded in solid 
bottom, white 384 well plates at 1000 cells/well density in 50 L/well DMEM 
supplemented with 10% FBS and 1% penicillin/streptomycin. Cells were incubated at 
37°C/5% CO2 for 48 hours. The medium was removed and each well was washed with 
40 L PBS. 40 L of DMEM supplemented with 0.5% FBS, 1% penicillin/streptomycin 
was added to each well. Subsequently, the compounds were pinned at their respective 
concentrations with 100 nL/well. The plates were incubated at 37°C/5% CO2 for 48 
hours. After the incubation period was over, the plates were removed from the incubator 
and allowed to equilibrate to room temperature. Subsequently, 20 L of Beta-Glo 
luminescence reagent was added to each well and the plates were shaken at room 
temperature for 30 min before being read out using luminescence settings. 
C3H10T1/2 and Ptch-/- CellTiter-Glo Viability assay: The cells were plated as in 
the C3H10T1/2 differentiation assay or the Ptch-/- beta-galactosidase assay above. The 
cells were then incubated as in the assays above. The cells were treated as in the 
C3H10T1/2 differentiation assay or the Ptch-/- beta-galactosidase assay above, but after 
pinning of the compounds, the plates were pinned again with a staurosporine control 
plate containing 1 mM staurosporine and DMSO. The plates were subsequently 
incubated at 37°C/5% CO2 for 48 hours. After the incubation period was over, the plates 
were removed from the incubator and allowed to come to room temperature. 
Subsequently, 20 L of a 1:1 dilution of CellTiter-Glo reagent in PBS was added to each 
well and the plates were shaken at room temperature for a few seconds. The plates 
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were then incubated at room temperature for at least 10 min and read out using 
luminescence settings. 
BODIPY-cyclopamine competition assay: To test the compounds’ ability to 
compete with BODIPY-cyclopamine binding, they were tested in a BODIPY-
cyclopamine imaging assay. HEK293T cells were plated in clear-bottom, black 96-well 
plates, 10,000 cells/well, 100 L/well in DMEM supplemented with 10% FBS and 1% 
penicillin/streptomycin pre-coated with poly-D-lysine. The cells were incubated at 
37°C/5% CO2 for 48 hours. The cells were then transfected with a Smo-Myc-His 
construct (kindly provided by Dr. James Chen (Stanford University, USA)) using Fugene 
6 transfection reagent. The plates were incubated for another 24 hours after which they 
were carefully washed with PBS, and 100 L DMEM supplemented with 0.5% FBS and 
1% penicillin/streptomycin preincubated with the compounds (10 M) and BODIPY-
cyclopamine (10 nM) was added to each well. The plates were then incubated for 30 
min at 37°C/5% CO2. Afterwards, each well was washed twice with 100 L PBS, and 
100 L formaldehyde (diluted 1:10 in PBS) was added to each well to fix the cells. After 
30 min of incubation at room temperature, each well was washed three times with 100 
L PBS, and 100 L of 1% FBS in PBS was added to block the cells. After another 60 
min of incubation at room temperature, the FBS solution was removed and 100 L 1° 
antibody (anti-c-myc from mouse IgG, 9E10, 1:1000 dilution in PBS) was added to each 
well. The plates were subsequently incubated for 4 hours at room temperature. 
Afterwards, each well was washed twice with 100 L PBS, and 2° antibody (Alexa Fluor 
568 donkey anti-mouse, 1:1000 in PBS) was added to each well. After 60 min of 
incubation at room temperature, each well was washed twice with 100 L PBS, and 100 
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L of 10 M Hoechst 33342 in PBS was added to each well and the plates were 
incubated for 10-15 min at room temperature. Finally, the plates were washed twice with 
100 L/well PBS, and 100 L PBS were added to each well before the plates were 
imaged. Keeping the plates in the dark during the incubation periods improves the 
quality of the images. 
 
Data Analysis 
Primary screening, dose response, and viability data (Shh Light II cells): Primary 
screening and dose response data was normalized to neutral (NC; n = 36) and positive 
control (PC; n = 36) wells present on each plate using the Genedata Assay Analyzer 
(v7.3). Active compounds in the primary screen were identified as compounds that 
inhibited the Gli1 luciferase reporter expression by >65% relative to the positive control 
cyclopamine at 12.5 M. For EC50 determinations of screening positives in the same 
assay data points were also normalized to neutral (0%) and positive control (-100%) 
wells and curve fits were performed using the fitting models in the Genedata Screener 
Condoseo package (7.0.3). Viability data was normalized to neutral (0%) and positive 
control (-100%, staurosporine) wells. 
Dose response curves (C310T1/2 and Ptch-/- cells): Mock treatments for each 
plate were averaged and used to calculate a percent response for each compound 
treatment on the corresponding plate. Percent responses were averaged for each dose 
point (every assay was performed two or three times in duplicate on separate days). 
Error bars are based on the standard deviation of the percent responses of each 
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concentration. % inhibitory data was calculated by subtracting the corresponding activity 
value from 100% 
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Chapter Three 
 
Discovery and optimization of small-molecule modulators 
of the Sonic Hedgehog pathway 
 
 
Dr. Jose Perez and Dr. Benjamin Stanton developed and performed the cell-based 
hedgehog screen presented in this chapter and collected the conditioned medium used. 
Dr. Perez confirmed the hits in dose. I tested the hits’ toxicity in Shh Light II cells and 
retested the effect of all stereoisomers and analogs in C3H10T1/2 cells. I synthesized 
all additional analogs, characterized them, and measured their response in cells. The 
analytical platform at the Broad Institute measured the solubility of the compounds. 
 
 
 
 
 
 
 
 
 
In part adapted from Schaefer, G.I.; Perez, J.R.; Duvall, J.R.; Stanton, B.Z.; Shamji, 
A.F.; Schreiber, S.L. “Discovery of Small-Molecule Modulators of the Sonic Hedgehog 
Pathway” J. Am. Chem. Soc. 2013, 135, 9675-9680.1 
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Confirmation of additional screening hits 
The screen presented in the previous chapter had additional results of great 
interest. Both the primary screen data and multiple dose-retest data revealed a striking 
correlation between activity and stereochemistry of members of a library of the 
screening collection. These compounds were initially synthesized using the 
build/couple/pair strategy of diversity-oriented synthesis (DOS).2,3 As a consequence, all 
possible stereoisomers of each structural type are included in the collection. The 
compounds in the library screened include approximately 6,700 compounds with 
varying eight-membered rings that are formed by nucleophilic aromatic substitution 
reactions. Based on the primary screening data, two of the eight stereoisomers of 
several compounds having the same eight-membered ring skeleton were active, the 
RSR and the SSR isomer, with the sole difference being the configuration of the extra-
annular methyl group (Figure 3.1). These initial findings were confirmed in the second 
biological assay using Hh-induced differentiation of C3H10T1/2 cells. Re-testing all 
eight stereoisomers of several hit compounds in dose using Shh-conditioned medium-
induced C3H10T1/2 cells confirmed that BRD50837, the RSR isomer, selectively blocks 
the Hh pathway in cells (Figure 3.1b, Suppl. Figure S3.1).  
All hits were tested in the secondary differentiation assay using C3H10T1/2 cells 
to substantiate their on-pathway activity (Table 3.1, Suppl. Table S3.1). Additionally, to 
rule out gross toxicity as source of signal, all compounds were tested in a viability assay 
using CellTiter-Glo as a means to estimate cellular levels of ATP (Suppl. Table S3.1). 
BRD50837 displayed high potency with an EC50 of 0.09 M. A PubChem search of 
other assays wherein BRD50837 (CID 44499307) was screened revealed that, as of 
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May 27, 2013, BRD50837 had been tested in 31 different assays, but only scored in our 
initial screen, suggesting that it is not broadly active. Compared to other similarly potent 
compounds, BRD50837 showed good PBS solubility (64.3 M), and was thus chosen 
as a starting point for further experimentation (Table 3.1).  
 
Figure 3.1. a) Primary screening data are displayed as percent luciferase activity in Shh 
Light II cells. Each small block displays a heat map associated with eight stereoisomeric 
compounds having the same skeleton and appendages. The overall panel A displays a 
near-complete matrix of multiple skeletons (only one shown in C) and building blocks 
used for R2 and R3 (displayed on the left (y-axis) and bottom (x-axis)). In the heat maps, 
blue represents inhibition (-100), yellow represents no activity (0), and red represents 
activation (100) normalized to DMSO control. Empty cells represent compounds not 
tested. Values shown are from testing compounds twice in single dose. b) The 
highlighted block represents the dose response data of eight stereoisomers of a primary 
subject of this report (BRD50837). c) Dose-response curve of BRD50837 in C3H10T1/2 
cell differentiation assay and structure of BRD50837 highlighting positions of building 
block attachment. All values shown are generated from three independent experiments 
run in duplicate (values are calculated average ± SD). 
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Table 3.1. EC50 in C3H10T1/2 cells and PBS solubility of analogs of BRD50837 
                      
compound scaffold Rx Ry Rz 
EC50  
(M)b 
solubility 
(M)a 
7 
(BRD50837) 
A 
 
 
 0.09 64.3 
8 “ 
 
“ “ 0.22 - 
9 “ 
 
“ “ 0.29 - 
10 “ 
 
“ “ 0.91 - 
11 “ 
 
“ “ 2.03 - 
12 “ 
 
“ “ 0.08 1.1 
19 “  “ “ - - 
20 “ 
 
“ “ 0.03 5.5 
21 “ 
 
“ “ 0.08 3.9 
25 “ 
 
“ “ 0.18 - 
26 “ 
 
“ “ 0.22 0.7 
18 “ 
 
“  4.03 - 
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Table 3.1. (Continued) 
compound scaffold Rx Ry Rz 
EC50  
(M)b 
solubility 
(M)a 
13 “ “ 
 
 0.95 - 
14 “ “ 
 
“ 1.45 - 
15 
(BRD9526) 
“ “ 
 
“ 0.06 57.4 
16 “ “ 
 
“ 0.76 - 
17 “ “ 
 
“ 3.37 - 
22 “ “ 
 
“ 0.58 - 
23 “ “ 
 
“ 0.45 - 
24 “ “ 
 
“ 2.86 - 
27 “ “ 
 
“ 2.32 - 
28 “ “ 
 
“ - - 
29 B “ 
 
 - - 
30 C “ “ “ - - 
 
a) solubility was measured for compounds that were considered for subsequent experimentation based 
on their EC50; b) dose-response curve did not pass EC50, so an EC50 value was not calculated. 
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Building block-based structure–activity relationships 
To elucidate additional building block-based structure–activity relationships 
(SAR), I synthesized novel analogs, varying the attachments on the aniline and the 
extra-annular amine, as well as removing the extra-annular alcohol. BRD50837 (7) and 
additional novel analogs 8-19 were synthesized using an abbreviated synthetic pathway 
relative to the previously reported solid-phase synthesis (Scheme 3.1, Suppl. Scheme 
S3.1). For the synthesis of 7-16, intermediate 4a was synthesized from 1 and 2a as 
previously reported.2,3  Subsequently, the nitrobenzene was reduced to an aniline that  
 
Scheme 3.1. Synthesis of analogsa 
 
a
Reagents and conditions: (a) PyBOP, DIPEA, DCM, rt, 52-83%. (b) borane dimethyl sulfide complex, 
THF, 65°C, 88-89%. (c) 2-fluoro-3-nitrobenzoic acid chloride, NEt3, DCM, rt, 92-100%. (d) CsF, DMF, 
85°C, 100%. (e) 10% Pd/C, H2, EtOH, 35°C, 100%. (f) R2Cl, 2,6-lutidine, DCM, rt.  (g) NaNO2, NaHSO3, 
EtOH/AcOH, rt, 48%. (h) TBSOTf, 2,6-lutidine, DCM, rt, then HF/pyridine, THF, rt. (i) R3Cl, 2,6-lutidine, 
DCM, 0°C, 68% over 3 steps (18). (j) DDQ, pH 7 buffer/DCM, rt, 6-59% over 4 steps (7-16), 49% over 4 
steps (19). (k) TFA, DCM, rt. (l) 4-chlorobenzaldehyde, sodium triacetoxy-borohydride, DMF/2% AcOH, rt, 
10% over 4 steps (17). 
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was acylated with acyl chlorides to yield anilides 5. After deprotection of the extra-
annular nitrogen with HF/pyridine and addition of a sulfonyl chloride, the PMB group 
was removed with DDQ, resulting in the final compounds. 
To synthesize analog 18, 2b was used instead of 2a as a starting material and 
the final PMB deprotection step was omitted. Analog 17 was synthesized by preparing 
intermediate 5a as before, removing the PMB group with DDQ, deprotecting the Boc 
group with trifluoroacetic acid (TFA) and forming the tertiary amine 17 by reductive 
amination with para-chlorobenzaldehyde. Compound 19 was prepared by treating 
intermediate 4a with sodium nitrate and sodium bisulfate, which resulted in the 
deaminated product 6. Subsequent deprotection of the Boc group with HF/pyridine, 
addition of the sulfonyl chloride and removal of the PMB group with DDQ yielded 19. All 
compounds were purified by column chromatography (30 min, 0-100% ethyl acetate in 
hexanes) and if necessary by HPLC purification (Synthetic Procedures).  
Both new and previously synthesized analogs were tested in C3H10T1/2 cells 
using Shh-conditioned medium-induced differentiation as readout of Hh signaling (Table 
3.1, Suppl. Table S3.1). Viability for all compounds was tested in this system as well, 
using CellTiter-Glo as a measure of ATP levels (Suppl. Table S3.1). Changes on the 
aniline moiety of the compound were tolerated, but activity was optimal for saturated 
ring systems (BRD50837, 12, 20). The cyclopropyl derivative (BRD50837) proved to 
have better solubility in PBS than the cyclohexyl derivative (12, 20), making it the more 
favorable candidate. Complete removal of the aniline moiety (19) resulted in a loss of 
activity. Ureas instead of amides also showed activity, but were less soluble (21, 25, 
26).  
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Changing the sulfonamide building block from para-chlorobenzene sulfonyl 
chloride to ortho- or meta- chlorobenzene sulfonyl chloride (13, 14) resulted in reduced 
activity. An additional chlorine in the ortho position of the sulfonamide building block 
(BRD9526 (15)) did not impact the activity, suggesting that the chlorine in the para-
position is interacting with a putative cellular target, while that in the ortho-position is 
not. This conclusion was reinforced by the previous observation that the compound 
lacking the chlorine entirely had reduced activity (24). When testing the previously 
synthesized compounds, it was found that the chlorine derivative is more active as 
compared to the fluorine and methyl derivatives (22, 23). Having an additional 
methylene in the sulfonyl chloride also resulted in a decrease of activity (16). Preparing 
the tertiary amine (17) rather than the sulfonamide resulted in a decrease of activity, 
demonstrating a possible electronic or spatial requirement for the sulfonamide 
connector. This notion was also reflected by additional tertiary amines tested in previous 
SAR studies (27, 28). 
Removing the extra-annular alcohol (18) resulted in a loss of activity, showing 
that the alcohol, which originally was used as a point of attachment in solid-phase 
synthesis, is necessary.  
The original DOS pathway also yielded compounds having eight-membered rings 
where the aniline moiety is in the para instead of the ortho position, and nine-membered 
rings where the aniline moiety is also in the para position.2 BRD50837s analogs having 
these structural elements were not active (29, 30). 
I prioritized BRD50837 and BRD9526 (15) for further experimentation, as both 
displayed good EC50 values (Figure 3.3a) and similar PBS solubility (Table 3.1). Neither 
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showed significant toxicity based on measuring ATP levels as a surrogate for growth or 
viability (Figure 3.3b). Reduction of Gli1 expression in C3H10T1/2 cells by 1 M 
treatments of these two compounds was confirmed (Suppl. Figure S3.2). 
Figure 3.3. All values are shown and generated from three independent experiments 
run in duplicate (values are calculated average ± SD). (a) Inhibition of Shh-conditioned 
medium (CM) induced differentiation of C3H10T1/2 cells by BRD50837, BRD9526, and 
cyclopamine after 48 h. (b) Viability of CM-induced C3H10T1/2 cells in response to 48 h 
treatment by BRD50837, BRD9526, and cyclopamine.  
 
Conclusion 
In conclusion, the Hh pathway inhibitor screen identified a group of compounds 
with striking correlation between stereochemistry and activity in Hh pathway assays. 
The stereochemistry-based SAR was confirmed, and further building block-based SAR 
was conducted. Based on their activity and solubility, two compounds, BRD50837 and 
BRD9526, were prioritized for further mechanism of action studies. 
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Experimental Section 
Materials and Methods 
Screening, Cell Lines and Reagents:  as described in Chapter 2. 
Organic Synthesis & Compound Characterization: All chemicals and solvents 
were purchased from Sigma-Aldrich (St Louis, MO, USA), Maybridge (Cornwall, UK), 
ArkPharm (Libertyville, IL, USA), AstaTech (Bristol, PA, USA), and Aurora (San Diego, 
CA, USA). Chemicals were used without further purification. Small molecules previously 
synthesized at the Broad Institute of Harvard and MIT used in SAR studies were purified 
using HPLC purification. Compound quality (purity and identity) was determined prior to 
each assay by UPLC-MS (Waters, Milford, MA, USA). Purity was measured by UV 
absorbance at 210 nm and identity was determined on a SQ mass spectrometer by 
positive electrospray ionization. Mobile phase A consisted of either 0.01% ammonium 
hydroxide or 0.01% formic acid in water, while mobile phase B consisted of the same 
additives in acetonitrile. The gradient ran from 5% to 95% mobile phase B over 0.8 min 
at 0.45 mL/min. An Acquity BEH C18, 1.7 um, 1.0x50 mm column was used with 
column temperature maintained at 65°C. Compounds were dissolved in DMSO at a 
nominal concentration of 1 mg/mL, and 0.25 mL of this solution was injected. Reactions 
were monitored by thin-layer chromatography (TLC) using E. Merck silica gel 60 F254 
precoated plates (0.25 mm) or by tandem liquid chromatography/mass spectroscopy 
(LCMS) using a Waters 2795 separations module and 3100 mass detector. 
Visualization for TLC was achieved with UV light and aqueous potassium 
permanganate (KMnO4) staining followed by heating. NMR spectra were measured on a 
Bruker Ultrashield 300 (300 MHz 1H, 75 MHz 13C) (Billerica, MA, USA) or Varian Unity 
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INova 500 (500 MHz 1H) (Palo Alto, CA, USA). Proton chemical shifts are reported in 
ppm () referenced to the NMR solvent.4 Data are reported as follows: chemical shifts, 
multiplicity (br = broad, s = singlet, d = doublet, t = triplet, dd = doublet of doublets, m = 
multiplet; coupling constant(s) in Hz; integration). All NMR data was collected at 25°C. 
Infrared spectra were obtained on a Thermo Scientific Nicolet Avatar 370 DTGS IR 
spectrometer (Waltham, MA, USA) and are reported in cm-1. Optical rotation was 
measured on a Rudolph Research Analytical Autopol IV automatic polarimeter 
(Hackettstown, NJ, USA). Flash chromatography purifications were performed using a 
CombiFlash Rf system (Teledyne ISCO, Inc., Lincoln, NE, USA) with pre-packed 40-60 
μm Silica Gel (60 Å mesh) silica gel columns. High resolution LCMS (HRMS) was on an 
Agilent 1290 Infinity separations module and 6230 time-of-flight (TOF) mass detector 
operating in ESI+ mode. For HPLC purification, compounds were purified by mass-
directed purification on a Waters Autopurification system (Milford, MA, USA). Collection 
was triggered on the (M+H)+ and (M+Na)+ ions on a ZQ mass spectrometer using 
positive electrospray ionization. Mobile phase A consisted of 0.2% ammonium 
hydroxide in water, while mobile phase B consisted of the 0.2% ammonium hydrocide in 
acetonitrile. An initial hold at 0% mobile phase B for 1.0 min was followed by a gradient 
from 0% to 100% mobile phase B over 11.0 min at 24 mL/min. A 2.0 mL/min at-column 
dilution was present using 100% acetonitrile as well as a 2.0 mL/min make-up flow 
using 90/10/0.1 methanol/water/formic acid. An XBridge OBD Prep C18, 5 um, 19x100 
mm column was used at room temperature. Solubility was determined in phosphate 
buffered saline (PBS) pH 7.4 with 1% DMSO.  Each compound was prepared in 
duplicate at 100 uM in both 100% DMSO and PBS with 1% DMSO.  Compounds were 
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allowed to equilibrate at room temperature with a 250 rpm orbital shake for 24 
hours.  After equilibration, samples were analyzed by UPLC-MS (Waters, Milford, MA) 
with compounds detected by SIR detection on a single quadrupole mass 
spectrometer.  The DMSO samples were used to create a two-point calibration curve to 
which the response in PBS was fit. Synthetic intermediates were characterized by 1H 
NMR and LCMS. Final compounds were characterized by 1H NMR and high resolution 
LCMS, and BRD50837 and BRD9526 were also characterized by 13C NMR, IR, and 
optical rotation. 
Assay Treatments and Readouts: as described in Chapter 2. In addition: RNA 
extraction reagents, cDNA reverse transcription reagents, and SYBR-Green reagent 
were purchased from Life Technologies/Applied Biosystems (Carlsbad, CA, USA); 
primers for qPCR were purchased from Qiagen (Valencia, CA, USA). RNA 
concentrations were measured using a Thermo Scientific Nanodrop 2000 
spectrophotometer (Waltham, MA, USA). qPCR readouts were taken on an ABI Prism 
7900 HT qPCR (Carlsbad, CA, USA), using standard curve assay settings (384 wells 
clear plate) with Sequence Detection Systems Software Version 2.3.  
 
Assay Protocols 
Shh Light II screen/assay, Shh Light II CellTiter-Glo Viability assay, C3H10T1/2 
differentiation assay, C3H10T1/2 CellTiter-Glo Viability assay: as described in Chapter 
2. 
C3H10T1/2 cell treatment for gene expression: To confirm that the compounds 
lower Gli expression in C3H10T1/2 cells, gene expression experiments were performed 
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in these cells. The C3H10T1/2 cells were seeded with 200,000 cells/well into 6 well 
plates in DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. The cells 
were incubated at 37°C/5% CO2 until confluent (about 36 hours). Afterwards the wells 
were washed and DMEM supplemented with 0.5% FBS and 1% penicillin/streptomycin 
was added to the wells, either with 5% Shh conditioned medium (to those wells induced 
to differentiate), or without (to those used as non-induced control).  The 
compounds/DMSO were added in the respective concentrations to the Shh conditioned 
medium induced wells and the respective DMSO amount was added to the non-induced 
wells. The cells were then incubated for 48 hours at 37°C/5% CO2. The cells were 
subsequently harvested by washing them once with PBS, scraping each well and 
collecting them in 1.7 mL Eppendorf tubes. The tubes were centrifuged at 14,000 rpm 
for 5 min and the supernatant was carefully aspirated. The pellets were either used right 
away for RNA extraction or frozen at -20°C until needed. 
RNA extraction: If the cell pellets were frozen, they were allowed to thaw for 30 
min before starting the RNA extraction. The pellets were resuspended in 1 mL TRIZOL 
reagent and 200 L chloroform was added to each sample. The samples were shaken, 
incubated for 5 min at room temperature and afterwards centrifuged for 15 min at 
14,000 rpm. The top, clear phase was carefully extracted and added into a clean 1.7 mL 
Eppendorf tube. 500 L isopropanol was added to each sample as well as 5 L 
glycogen to precipitate the RNA. The samples were shaken and incubated for 15 min at 
room temperature and subsequently centrifuged for 15 min at 14,000 rpm. The 
supernatant was carefully aspirated and the pellet was washed with 1 mL of 70% 
ethanol in millipore water. The samples were again centrifuged at 14,000 rpm for 10 min 
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and the supernatant was carefully aspirated. The pellets were air-dried for 30 min and 
20 L TE-buffer or EB-buffer was added. The samples were allowed to resuspend 
overnight at 4°C or for 30 min at room temperature before the RNA concentrations were 
measured. 
cDNA Reverse Transcription: cDNA Reverse Transcription was done using the 
High Capacity cDNA Reverse Transcription Kit (ABI) according to manufacturer’s 
instructions with 1 g RNA per sample. After the reverse transcription was done, the 
samples were either used right away for the qPCR, or frozen at -20°C until being used 
for the qPCR. 
qPCR: The reverse transcribed samples were diluted with RNAse free water to 
55 L/sample. 11 L of the respective primer (Gapdh-3 and Gli-1), 22 L of SYBR 
Green PCR Master Mix, and 11 L cDNA of the respective sample were mixed and 10 
L of the mix was pipetted into a 384 well qPCR plate (in quadruplicate). The plates 
were sealed with optical adhesion film and the qPCR was read out. CT values were 
calculated using the instrument’s software. 
 
Data Analysis 
Primary screening, dose response, and viability data (Shh Light II cells), Dose 
response curves (C310T1/2): as described in Chapter 2. 
EC50 dose fits: EC50 dose response curves were fitted using a smart fit strategy 
with initial values of S0 = 100 and Sinf = 10 (C3H10T1/2 differentiation assays), or 0 
(viability assays) using Condoseo (Genedata Screener 10.0.2). Sinf was chosen based 
 53 
 
on inhibition of control (12.5 M cyclopamine for C3H10T1/2 differentiation, and 2.5 M 
staurosporine for viability assays). 
Gene expression data: For each sample, four technical replicates were 
measured and CT values for each replicate were calculated using the instrument’s 
analysis feature. CT values were subsequently averaged for each sample and the fold 
expression changes normalized within each experiment to non-induced C3H10T1/2 
cells was calculated using the 2-CT method.
5 Experiments were done three times in 
triplicate on separate days. 
 
Synthetic Procedures 
Intermediate 4a was synthesized as previously described.2,3 
Protocol to Intermediate 4b: 
 
4-(tert-butoxycarbonyl(methyl)amino)-3-(tert-butyldimethylsilyloxy)-2-methylbutanoic 
acid 1 (1.8 g, 1.0 eq) was dissolved in DCM (20 mL, final concentration = 0.2 M) under 
N2 and PyBOP (2.64 g, 1.0 eq), and diisopropyl ethylamine (DIPEA) (2.6 mL, 3.0 eq) 
was added. The mixture was cooled to 0°C before isopropylamine (0.32 g, 1.1 eq) in 
DCM (4.9 mL) was added. The mixture was allowed to come to room temperature and 
stirred for 15 h before being quenched with water and extracted with DCM. The 
combined organic extracts were dried over MgSO4, filtered, and concentrated. The 
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crude product was purified by flash chromatography on silica gel (20-30% EtOAc in 
hexanes) to give the product Ib1 with 52% yield. 
tert-butyl-((2R,3R)-2-((tert-butyldimethylsilyl)oxy)-4-(isopropylamino)-3-methyl-4-
oxobutyl)(methyl)carbamate  Ib1: 1H NMR (300 MHz, CDCl3, room temperature)  6.50 
(br dd, J = 61.8, 7.1 Hz, 1H), 4.21 – 3.99 (m, 2H), 3.51 (d, J = 14.3 Hz , 1H), 3.10 – 2.95 
(m, 1H), 2.91 (s, 3H), 2.52 – 2.34 (m, 1H), 1.48 (s, 9H), 1.23 – 1.07 (m, 9H), 0.96 (s, 
9H), 0.11 (d, J = 10.6 Hz, 6H). LRMS-ES+ m/z: 403.35 (M+). 
___________________________________________________________ 
 
tert-butyl-((2R,3R)-2-((tert-butyldimethylsilyl)oxy)-4-(isopropylamino)-3-methyl-4-
oxobutyl)(methyl)carbamate  I1b (1.05 g, 1.0 eq) was dissolved in THF (26.1 mL, final 
concentration 0.1 M) under N2 and  borane dimethylsulfide complex (BH3
.DMS) (1.24 
mL, 5.0 eq) was added dropwise. The mixture was heated to 65°C. After 5 h, it was 
cooled to room temperature and excess hydride was quenched by carefully adding 
MeOH. The mixture was concentrated under reduced pressure and, to remove excess 
B(OMe)3, co-evaporated with MeOH three times. The resulting, clear oil was re-
dissolved in a 2:3 ratio of MeOH (15.6 mL) and 10% aqueous potassium sodium tartrate 
(23.3 mL, final concentration 0.067 M) and heated at reflux for 12 h. The product was 
concentrated under reduced pressure and the aqueous layer extracted three times with 
EtOAc. The combined organic layers were washed once with brine, dried over MgSO4, 
filtered, and concentrated to give amine 3b with 88% yield. 
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tert-butyl-((2R,3S)-2-((tert-butyldimethylsilyl)oxy)-4-(isopropylamino)-3-
methylbutyl)(methyl)carbamate 3b: 1H NMR (300 MHz, CDCl3, room temperature)  
3.98 – 3.83 (m, 1H), 3.47 – 3.28 (m, 1H), 3.02 – 2.90 (m, 1H), 2.86 (s, 3H), 2.77 – 2.65 
(m, 1H), 2.65 – 2.50 (m, 1H), 2.42 (dd, J = 11.3, 7.4 Hz, 1H), 1.75 – 1.58 (m, 1H), 1.43 
(s, 9H), 1.02 (d, J = 4.9 Hz, 6H), 0.96 – 0.73 (m, 12H), 0.02 (d, J = 5.1 Hz, 6H). LRMS-
ES+ m/z: 389.40 (M+). 
___________________________________________________________ 
 
2-fluoro-3-benzoic acid I2 (7.23 g, 1.0 eq) was dissolved in thionyl chloride (SOCl2) 
(17.1 mL, 6.0 eq) and heated under reflux under N2 to 85°C for 2 h. The mixture was 
then concentrated and the resulting product I3 immediately used for the next step. 
___________________________________________________________ 
 
tert-butyl-((2R,3S)-2-((tert-butyldimethylsilyl)oxy)-4-(isopropylamino)-3-
methylbutyl)(methyl)carbamate 3b (0.89 g, 1.0 eq) was dissolved in DCM (11.5 mL, 0.2 
M) under N2 and 2-fluoro-3-benzoic acid chloride I3 (1.17 g, 2.5 eq) was added at 0°C . 
Triethyl amine (1.6 mL, 5.0 eq) was added and the reaction was brought to room 
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temperature. The reaction was stirred until complete consumption of 3b was observed 
(1-2 h) and subsequently quenched with saturated NH4Cl solution. The resulting mixture 
was extracted with DCM and the combined organic extracts were dried over MgSO4, 
filtered, and concentrated. Flash chromatography on silica gel (10-30 % EtOAc in 
hexanes) produced the product I4b with 92% yield. 
tert-butyl-((2R,3S)-2-((tert-butyldimethylsilyl)oxy)-4-(2-fluoro-N-isopropyl-3-
nitrobenzamido)-3-methylbutyl)(methyl)carbamate I4b: 1H NMR (300 MHz, CDCl3, room 
temperature8.13 – 7.98 (m, 1H), 7.70 – 7.53 (m, 1H), 7.41 – 7.29 (m, 1H), 4.04 – 3.91 
(m, 1H), 3.83 – 3.41 (m, 3H), 3.41 – 3.00 (m, 3H), 2.95 – 2.68 (m, 3H), 2.49 – 2.27 (m, 
1H), 2.27 – 2.08 (m, 1H), 1.91 – 1.78 (m, 1H), 1.69 – 1.54 (m, 1H), 1.50 – 1.31 (m, 
9H),1.15 – 1.04 (m, 2H), 1.04 – 0.94 (m, 2H), 0.94 – 0.87 (m, 6H), 0.82 – 0.73 (m, 1H) 
0.64 (s, 3H), 0.10 (d, J = 10.9 Hz, 4H), -0.03 (s, 1H), -0.15 (s, 1H). LRMS-ES+ m/z: 
578.33 (M+Na)+. 
___________________________________________________________ 
 
tert-butyl-((2R,3S)-2-((tert-butyldimethylsilyl)oxy)-4-(2-fluoro-N-isopropyl-3-
nitrobenzamido)-3-methylbutyl)(methyl)carbamate I4b (1.17 g, 1.0 eq) was dissolved in 
DMF (21.1 mL, 0.1 M) at room temperature  under N2 and cesium fluoride (0.96 g, 3 eq) 
was added. The reaction was stirred and heated to 85°C. After complete consumption 
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of starting material was observed (~5h), the reaction was cooled and concentrated 
under reduced pressure. The resulting oil was taken up in EtOAc, washed with 
saturated NH4Cl solution, dried with MgSO4, filtered, and concentrated to yield 4b. The 
product was used without further purification. 
tert-butyl-(((2R,3S)-5-isopropyl-3-methyl-10-nitro-6-oxo-3,4,5,6-tetrahydro-2H-
benzo[b][1,5]oxazocin-2-yl)methyl)(methyl)carbamate 4b: 1H NMR (300 MHz, CDCl3, 
room temperature) 7.76 – 7.57 (m, 2H), 7.03 (t, J = 7.9 Hz, 1H),  4.95 – 4.67 (m, 2H), 
3.90 – 3.57 (m, 1H), 3.40 – 3.01 (m, 3H), 2.88 (s, 3H), 2.20 – 1.97 (m, 1H), 1.44 (s, 9H), 
1.36 – 1.19 (m, 6H), 1.09 – 0.96 (m, 3H). LRMS-ES+ m/z: 444.31 (M+Na)+. 
___________________________________________________________ 
General Protocol to Intermediate 5: 
 
4 (1.0 eq) in EtOH (0.05 M) was stirred with palladium (10% on activated carbon, 0.10 
eq) at 35°C under H2. After the starting material was completely consumed (as 
monitored by LC-MS, 1-2 h), the mixture was cooled, filtered through celite, and 
concentrated. The crude material was dissolved in DCM (final concentration 0.02 M) 
and the desired acyl chloride (1.1 eq, see Suppl. Scheme S3.1 for acyl chlorides used) 
was added. The mixture was cooled to 0°C and 2,6-lutidine (5.0 eq) was added. The 
reaction was stirred overnight and subsequently quenched with saturated NH4Cl 
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solution. The resulting mixture was extracted with DCM and the combined organic 
extracts were dried over MgSO4, filtered, and concentrated. The product was 
immediately used for the next step without further purification.  
___________________________________________________________ 
General Protocol from 5a to 7-16: 
 
5a (1.0 eq) was dissolved in DCM (0.1 M) and 2,6-lutidine (4.0 eq) and TBSOTf (3.0 eq) 
were added at room temperature. The reaction was stirred for 2h and subsequently 
quenched with saturated NH4Cl solution. The mixture was extracted with EtOAc and the 
combined organic extracts were dried over MgSO4, filtered, and concentrated to 
produce the crude silyl carbamate which was dissolved again in THF (0.1 M). 
HF/pyridine (70%, 1.0 eq) was added and the mixture was stirred for 40 min at room 
temperature. The reaction was then quenched with saturated NH4Cl solution and 
extracted with EtOAc. The combined organic extracts were dried over MgSO4, filtered, 
and concentrated. The crude material was dissolved in DCM (0.03 M) and 2,6-lutidine 
(6.0 eq) was added and the mixture was cooled to 0°C. The desired sulfonyl chloride 
(3.0 eq, see Suppl. Scheme S3.1 for sulfonyl chlorides used) was added in minimal 
DCM. The reaction was stirred at 0°C overnight and subsequently quenched with water. 
The mixture was extracted with DCM, dried over MgSO4, filtered, and concentrated. The 
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product was filtered through a short silica plug (0-100 % EtOAc in Hexanes) to remove 
polar by-products. The product was then dissolved in a 4:1 DCM and pH 7 buffer 
solution (final concentration ranging from 0.03 M to 0.04 M). The mixture was cooled to 
0°C and DDQ (1.5 eq) was added. The reaction was stirred at 0°C for another 10 mins 
and then brought to room temperature and stirred overnight. The reaction was 
quenched with water and extracted with DCM. The combined organic extracts were 
washed with saturated NaHCO3 solution and subsequently, activated carbon was added. 
The mixture was filtered through celite and the filtrand was washed with hot DCM 
several times. The filtrate was concentrated and the product was purified by flash 
chromatography on silica gel (0-100% EtOAc in hexanes). If the compound was not 
pure by LCMS, it was further purified as mentioned. 
 
BRD50837, (7) 
Following the general protocol, 1.46 g of 4a was reacted with 0.28 g palladium (10% on 
activated carbon) in 52.4 mL EtOH. 1 g of the resulting product was reacted with 0.19 
mL AC1 and 1.1 mL 2,6-lutidine in 95 mL DCM. 0.7 g of the product was deprotected 
using 0.81 mL TBSOTf, 0.55 mL 2,6-lutidine in 11.8 mL DCM, and 0.11 mL HF/pyridine 
in 11.8 mL THF. 0.15 g of the product was reacted with 0.19 g SC1 and 0.21 mL 2,6-
lutidine in 12.1 mL DCM and the product was deprotected using 0.05 g DDQ in 4 mL 
DCM and 1 mL pH 7 buffer solution (final concentration: 0.03 M) to give 7 in 24% overall 
yield. 
BRD50837 (7): []D
20 57.8 (c 1.0, CHCl3). IR (cm
-1) 3365 (br, w), 2925 (w), 1680 (m), 
1610 (s), 1578 (m), 1529 (s), 1434 (s), 1337 (s), 1159 (s), 1093 (m), 975 (s), 767 (s), 
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752 (s), 609 (m), 558 (m). 1H NMR (300 MHz, CDCl3, room temperature) 8.81 (s, 1H), 
8.38 (d, J = 7.8 Hz, 1H),  7.70 (d, J = 8.4 Hz, 2H), 7.48 (d, J = 8.5 Hz, 2H), 7.10 (d, J = 
7.9 Hz, 1H), 6.92 (t, J = 8.0 Hz, 1H), 5.07 – 4.85 (m, 2H), 4.17 – 3.97 (m, 1H), 3.87 (dd, 
J = 11.7, 3.5 Hz, 1H), 3.56 – 3.40 (m, 1H), 3.36 – 3.11 (m, 3H), 2.74 – 2.55 (m, 4H), 
2.06 – 1.92 (m, 1H), 1.92 – 1.80 (m, 1H), 1.18 (d, J = 6.9 Hz, 3H), 1.08 – 0.94 (m, 5H), 
0.84 – 0.74 (m, 2H). 13C NMR (75 MHz, CDCl3, room temperature)  173.1, 172.1, 
144.3, 139.4, 136.7, 129.6, 128.6, 128.5, 126.0, 122.6, 121.0, 120.7, 72.8, 66.5, 53.0, 
52.4, 47.6, 35.4, 35.1, 15.4, 14.2, 11.2, 8.2, 8.1. HRMS (ESI) calcd for C26H33ClN3O6S 
[M+H]+: 550.1779. Found: 550.1783. 
 
8 
Following the general protocol, 1.46 g of 4a was reacted with 0.28 g palladium (10% on 
activated carbon) in 52.4 mL EtOH. 0.1 g of the resulting product was reacted with 
0.015 mL AC2 and 0.11 mL 2,6-lutidine in 9.5 mL DCM. The product was deprotected 
using 0.13 mL TBSOTf, 0.09 mL 2,6-lutidine in 1.9 mL DCM, and 0.017 mL HF/pyridine 
in 1.9 mL THF. The product was reacted with 0.12 g SC1 and 0.13 mL 2,6-lutidine in 7.7 
mL DCM and the product was deprotected using 0.05 g DDQ in 4 mL DCM and 1 mL 
pH 7 buffer solution (final concentration: 0.03 M) to give 8 in 36% overall yield. 
8: 1H NMR (300 MHz, CDCl3, room temperature) 8.64 (s, 1H), 8.41 (d, J = 6.9 Hz, 1H), 
7.71 (d, J = 8.6 Hz, 2H), 7.49 (d, J = 8.6 Hz, 2H), 7.13 (d, J = 8.0 Hz, 1H), 6.95 (t, J = 
8.0 Hz, 1H), 5.05 – 4.85 (m, 2H), 4.04 (dd, J = 14.2, 10.1 Hz, 1H), 3.88 (dd, J = 11.5, 
2.0 Hz, 1H), 3.55 – 3.40 (m, 1H), 3.36 – 3.23 (m, 1H), 3.03 (d, J = 8.6 Hz, 1H), 2.70 (s, 
3H), 2.62 (d, J = 14.1 Hz, 1H), 2.23 (s, 3H), 2.06 – 1.90 (m, 1H), 1.78 (s, 1H), 1.19 (d, J 
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= 7.0 Hz, 3H), 0.99 (d, J = 6.7 Hz, 3H). HRMS (ESI) calcd for C24H31ClN3O6S [M+H]
+: 
524.1622. Found: 524.1624. 
 
9 
Following the general protocol, 1.46 g of 4a was reacted with 0.28 g palladium (10% on 
activated carbon) in 52.4 mL EtOH. 0.1 g of the resulting product was reacted with 
0.022 mL AC3 and 0.11 mL 2,6-lutidine in 9.5 mL DCM. The product was deprotected 
using 0.13 mL TBSOTf, 0.09 mL 2,6-lutidine in 1.9 mL DCM, and 0.017 mL HF/pyridine 
in 1.9 mL THF. The product was reacted with 0.12 g SC1 and 0.13 mL 2,6-lutidine in 7.5 
mL DCM and the product was deprotected using 0.06 g DDQ in 4 mL DCM and 1 mL 
pH 7 buffer solution (final concentration: 0.04 M) to give 9 in 36% overall yield. 
9: 1H NMR (300 MHz, CDCl3, room temperature) 8.87 (s, 1H), 8.46 (d, J = 7.9 Hz, 1H), 
8.02 (d, J = 6.8 Hz, 2H), 7.63 (d, J = 8.5 Hz, 2H), 7.57 – 7.34 (m, 5H), 7.20 (d, J = 8.0 
Hz, 1H), 7.02 (t, J = 8.0 Hz, 1H),  5.09 – 4.86  (m, 2H), 3.95 – 3.79 (m, 2H), 3.55 – 3.40 
(m, 1H), 3.34 – 3.22 (m, 1H), 3.17 (d, J = 8.5 Hz, 1H), 2.75 (d, J = 14.1 Hz, 1H), 2.69 (s, 
3H), 2.09 – 1.93 (m, 1H), 1.89 (s, 1H) , 1.18 (d, J = 6.9 Hz, 3H), 0.96 (d, J = 6.6 Hz, 3H). 
HRMS (ESI) calcd for C29H33ClN3O6S [M+H]
+: 586.1779. Found: 586.1784. 
 
10 
Following the general protocol, 3.58 g of 4a was reacted with 0.68 g palladium (10% on 
activated carbon) in 128 mL EtOH. 0.1 g of the resulting product was reacted with 0.03 
g AC4 and 0.11 mL 2,6-lutidine in 9.5 mL DCM. The product was deprotected using 
0.15 mL TBSOTf, 0.10 mL 2,6-lutidine in 2.2 mL DCM, and 0.020 mL HF/pyridine in 2.2 
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mL THF. The product was reacted with 0.13 g SC1 and 0.15 mL 2,6-lutidine in 8.8 mL 
DCM and the product was deprotected using 0.07 g DDQ in 4 mL DCM and 1 mL pH 7 
buffer solution (final concentration: 0.04 M)  to give 10 in 23% overall yield. 
10: 1H NMR (300 MHz, CDCl3, room temperature, 2 diastereomers)  9.03 (d, J = 4.3 
Hz, 1H), 8.42 (t, J = 7.5 Hz, 1H), 7.67 (dd, J = 8.5, 2.8 Hz, 2H), 7.44 (d, J = 8.5 Hz, 2H), 
7.17 (d, J = 7.9 Hz, 1H), 6.95 (t, J = 8.0 Hz, 1H), 5.07 – 4.92 (m, 1H), 4.86 – 4.68 (m, 
1H), 4.17 – 4.00 (m, 1H), 3.90 (d, J = 10.9 Hz, 2H), 3.64 – 3.47 (m, 2H), 3.42 (dd, J = 
14.1, 4.0 Hz, 1H), 3.31 – 3.18 (m, 2H), 3.12 (d, J = 6.0 Hz, 1H), 2.78 (d, J = 6.6 Hz, 3H), 
2.26 – 2.08 (m, 2H), 1.98 – 1.88 (m, 1H), 1.86 – 1.78 (s, 1H), 1.63 – 1.50 (m, 4H), 1.29 
– 1.14 (m, 3H), 1.02 – 0.94 (m, 3H). HRMS (ESI) calcd for C28H37ClN3O7S [M+H]
+: 
594.2041. Found: 594.2048. 
 
11 
Following the general protocol, 1.46 g of 4a was reacted with 0.28 g palladium (10% on 
activated carbon) in 52.4 mL EtOH. 0.1 g of the resulting product was reacted with 0.03 
mL AC5 and 0.10 mL 2,6-lutidine in 9.5 mL DCM. The product was deprotected using 
0.14 mL TBSOTf, 0.09 mL 2,6-lutidine in 2.0 mL DCM, and 0.018 mL HF/pyridine in 2.0 
mL THF. The product was reacted with 0.13 g SC1 and 0.14 mL 2,6-lutidine in 8.0 mL 
DCM and the product was deprotected using 0.05 g DDQ in 4 mL DCM and 1 mL pH 7 
buffer solution (final concentration: 0.03 M)  to give 11 in 24% overall yield. 
11: 1H NMR (500 MHz, DMSO-d6, room temperature)  8.73 (s, 1H), 8.10 (d, J = 7.8 Hz, 
1H), 7.84 (d, J = 8.6 Hz, 2H), 7.70 (d, J = 8.6 Hz, 2H), 7.05 (d, J = 7.9 Hz, 1H), 6.90 (t, J 
= 7.9 Hz, 1H), 4.91 (t, J = 5.1 Hz, 1H), 4.83 (d, J = 8.6 Hz, 1H), 4.68 – 4.58 (m, 1H), 
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3.80 (t, J = 10.5 Hz, 2H), 3.75 – 3.64 (m, 1H), 3.59 – 3.44 (m, 2H), 3.30 – 3.22 (m, 2H), 
3.06 (d, J = 14.1 Hz, 1H), 2.97 (dd, J = 15.0, 12.7 Hz, 1H), 2.69 (s, 3H), 2.33 (d, J = 6.8 
Hz, 2H), 2.12 – 2.03 (m, 1H), 2.02 – 1.95 (m, 1H), 1.57 (dd, J = 27.2, 12.6 Hz, 2H), 1.29 
– 1.17 (m, 3H), 1.10 (d, J = 6.9 Hz, 3H), 0.89 (d, J = 6.6 Hz, 3H). HRMS (ESI) calcd for 
C29H39ClN3O7S [M+H]
+: 608.2197. Found: 608.2204. 
 
12 
Following the general protocol, 0.51 g of 4a was reacted with 0.10 g palladium (10% on 
activated carbon) in 18.4 mL EtOH. 0.12 g of the resulting product was reacted with 
0.04 mL AC6 and 0.13 mL 2,6-lutidine in 11.4 mL DCM. The product was deprotected 
using 0.16 mL TBSOTf, 0.11 mL 2,6-lutidine in 2.3 mL DCM, and 0.021 mL HF/pyridine 
in 2.3 mL THF. The product was reacted with 0.15 g SC1 and 0.17 mL 2,6-lutidine in 9.4 
mL DCM and the product was deprotected using 0.05 g DDQ in 4 mL DCM and 1 mL 
pH 7 buffer solution (final concentration: 0.03 M). The final product was additionally 
purified by preparative thin layer chromatography using E. Merck silica gel 60 F254 
precoated plates (2 mm) and 100% EtOAc to give 12 in 6% overall yield. 
12: 1H NMR (500 MHz, DMSO-d6, room temperature)  8.68 (s, 1H), 8.08 (d, J = 7.7 Hz, 
1H), 7.83 (d, J = 8.5 Hz, 2H), 7.70 (d, J = 8.5 Hz, 2H), 7.04 (d, J = 7.9 Hz, 1H), 6.90 (t, J 
= 7.9 Hz, 1H), 4.91 (t, J = 5.0 Hz, 1H), 4.83 (d, J = 8.3 Hz, 1H), 4.67 – 4.59 (m, 1H), 
3.65 (dd, J = 14.1, 9.2 Hz, 1H), 3.56 – 3.47 (m, 2H), 3.42 – 3.35 (m, 1H), 3.05 (d, J = 
14.0 Hz, 1H), 3.00 – 2.92 (m, 1H), 2.69 (s, 3H), 2.29 – 2.20 (m, 2H), 2.12 – 2.04 (m, 
1H), 1.75 – 1.68 (m, 2H), 1.66 – 1.59 (m, 3H), 1.24 – 1.12 (m, 4H), 1.09 (d, J = 6.8 Hz, 
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3H), 0.99 – 0.92 (m, 2H), 0.88 (d, J = 6.4 Hz, 3H). HRMS (ESI) calcd for C30H41ClN3O6S 
[M+H]+: 606.2405. Found: 606.2410. 
 
13 
Following the general protocol, 1.46 g of 4a was reacted with 0.28 g palladium (10% on 
activated carbon) in 52.4 mL EtOH. 1 g of the resulting product was reacted with 0.19 
mL AC1 and 1.1 mL 2,6-lutidine in 9.5 mL DCM. The product was deprotected using 
0.81 mL TBSOTf, 0.55 mL 2,6-lutidine in 11.8 mL DCM, and 0.11 mL HF/pyridine in 
11.8 mL THF. 0.15 g of the product was reacted with 0.13 mL SC2 and 0.21 mL 2,6-
lutidine in 12.1 mL DCM and the product was deprotected using 0.05 g DDQ in 4 mL 
DCM and 1 mL pH 7 buffer solution (final concentration: 0.03 M)  to give 13 in 19% 
overall yield. 
13: 1H NMR (300 MHz, CDCl3, room temperature) 8.81 (s, 1H), 8.39 (d, J = 7.9 Hz, 
1H), 7.76 (s, 1H), 7.65 (d, J = 7.7 Hz, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.45 (t, J = 7.9 Hz, 
1H), 7.10 (d, J = 8.0 Hz, 1H), 6.93 (t, J = 8.0 Hz, 1H), 5.05 – 4.85 (m, 2H), 4.16 – 4.00 
(m, 1H), 3.88 (dd, J = 11.6, 3.7 Hz, 1H), 3.54 – 3.40 (m, 1H), 3.36 – 3.18 (m, 2H), 3.11 
(d, J = 8.7 Hz, 1H), 2.74 – 2.61 (m, 4H), 2.05 – 1.93 (m, 1H), 1.93 – 1.77 (m, 1H),  1.19 
(d, J = 6.9 Hz, 3H), 1.08 – 0.93 (m, 5H), 0.85 – 0.72 (m, 2H). HRMS (ESI) calcd for 
C26H33ClN3O6S [M+H]
+: 550.1779. Found: 550.1782. 
 
14 
Following the general protocol, 1.46 g of 4a was reacted with 0.28 g palladium (10% on 
activated carbon) in 52.4 mL EtOH. 1 g of the resulting product was reacted with 0.19 
 65 
 
mL AC1 and 1.1 mL 2,6-lutidine in 9.5 mL DCM. The product was deprotected using 
0.81 mL TBSOTf, 0.55 mL 2,6-lutidine in 11.8 mL DCM, and 0.11 mL HF/pyridine in 
11.8 mL THF. 0.15 g of the product was reacted with 0.12 mL SC3 and 0.21 mL 2,6-
lutidine in 12.1 mL DCM and the product was deprotected using 0.05 g DDQ in 4 mL 
DCM and 1 mL pH 7 buffer solution (final concentration: 0.03 M)  to give 14 in 35% 
overall yield. 
14: 1H NMR (300 MHz, CDCl3, room temperature) 8.83 (s, 1H), 8.34 (d, J = 7.9 Hz, 
1H), 7.99 (d, J = 7.9 Hz, 1H), 7.54 – 7.40 (m, 2H), 7.34 (t, J = 7.3 Hz, 1H), 7.06 (d, J = 
8.0 Hz, 1H), 6.88 (t, J = 8.0 Hz, 1H), 5.10 (d, J = 9.9 Hz, 1H), 5.03 – 4.85 (m,  1H), 4.51 
– 4.33 (m, 1H), 3.87 (dd, J = 11.6, 3.5 Hz, 1H), 3.58 – 3.10 (m, 1H), 3.40 – 3.12 (m, 3H), 
2.96 (d, J = 14.7 Hz, 1H), 2.66 (s, 3H), 2.15 – 1.93 (m, 1H), 1.93 – 1.78 (m, 1H), 1.18 (d, 
J = 6.9 Hz, 3H), 1.06 – 0.91 (m, 5H), 0.84 – 0.67 (m, 2H). HRMS (ESI) calcd for 
C26H33ClN3O6S [M+H]
+: 550.1779. Found: 550.1781. 
 
BRD9526 (15) 
Following the general protocol, 1.46 g of 4a was reacted with 0.28 g palladium (10% on 
activated carbon) in 52.4 mL EtOH. 1 g of the resulting product was reacted with 0.19 
mL AC1 and 1.1 mL 2,6-lutidine in 9.5 mL DCM. The product was deprotected using 
0.81 mL TBSOTf, 0.55 mL 2,6-lutidine in 11.8 mL DCM, and 0.11 mL HF/pyridine in 
11.8 mL THF. 0.15 g of the product was reacted with 0.23g SC4 and 0.21 mL 2,6-
lutidine in 12.1 mL DCM and the product was deprotected using 0.05 g DDQ in 4 mL 
DCM and 1 mL pH 7 buffer solution (final concentration: 0.03 M)  to give 15 in 20% 
overall yield. 
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BRD9526 (15):  []D
20 8.2 (c 1.0, CHCl3). IR (cm
-1) 3366 (br, w), 2929 (w), 1680 (m), 
1610 (s), 1576 (m), 1530 (s), 1434 (s), 1334 (s), 1158 (s), 1038 (m), 978 (s), 821 (s), 
750 (s), 612 (s) 492 (m).  1H NMR (300 MHz, CDCl3, room temperature) 8.77 (s, 1H), 
8.34 (d, J = 7.8 Hz, 1H),  7.92 (d, J = 8.5 Hz, 1H), 7.50 (s, 1H), 7.32 (d, J = 8.5 Hz, 1H), 
7.05 (d, J = 7.8 Hz, 1H), 6.88 (t, J = 7.9 Hz, 1H), 5.11 (d, J = 9.9 Hz, 1H), 5.05 – 4.90 (m, 
1H), 4.39 (dd, J = 14.6, 10.4 Hz, 1H), 3.87 (dd, J = 11.0, 3.4 Hz, 1H), 3.56 – 3.35 (m, 
2H), 3.28 (d, J = 9.1 Hz, 2H), 2.96 (d, J = 14.6 Hz, 1H), 2.63 (s, 3H) 2.11 – 1.94 (m, 1H), 
1.94 – 1.77 (m, 1H), 1.17 (d, J = 6.8 Hz, 3H), 1.07 – 0.91 (m, 5H), 0.84 – 0.70 (m, 2H). 
13C NMR (75 MHz, CDCl3, room temperature)  173.2, 172.6, 144.1, 139.7, 135.4, 
133.0, 132.9, 131.9, 128.5, 127.5, 125.6, 122.6, 121.1, 120.6, 71.9, 66.5, 53.4, 52.0, 
47.4, 35.4, 34.0, 15.5, 14.3, 11.3, 8.2, 8.2. HRMS (ESI) calcd for C26H32Cl2N3O6S 
[M+H]+: 584.1389. Found: 584.1396. 
 
16 
Following the general protocol, 1.46 g of 4a was reacted with 0.28 g palladium (10% on 
activated carbon) in 52.4 mL EtOH. 1 g of the resulting product was reacted with 0.19 
mL AC1 and 1.1 mL 2,6-lutidine in 9.5 mL DCM. The product was deprotected using 
0.81 mL TBSOTf, 0.55 mL 2,6-lutidine in 11.8 mL DCM, and 0.11 mL HF/pyridine in 
11.8 mL THF. 0.15 g of the product was reacted with 0.20 g SC5 and 0.21 mL 2,6-
lutidine in 12.1 mL DCM and the product was deprotected using 0.05 g DDQ in 4 mL 
DCM and 1 mL pH 7 buffer solution (final concentration: 0.03 M) to give 16 in 26% 
overall yield. 
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16: 1H NMR (300 MHz, CDCl3, room temperature) 8.78 (s, 1H), 8.40 (d, J = 7.0 Hz, 
1H), 7.34 (d, J = 8.3 Hz, 2H), 7.26 (d, J = 1.1 Hz, 2H), 7.05 (d, J = 7.9 Hz, 1H), 6.91 (t, J 
= 8.0 Hz, 1H), 5.05 – 4.86 (m, 2H), 4.16 (s, 2H), 3.93 – 3.73 (m, 2H), 3.56 – 3.38 (m, 
1H), 3.35 – 3.14 (m, 3H), 2.68 – 2.51 (m, 4H), 2.07 – 1.88 (m, 1H), 1.88 – 1.77 (m, 1H), 
1.16 (d, J = 6.9 Hz, 3H), 1.06 – 0.96 (m, 2H), 0.91 – 0.76 (m, 5H). HRMS (ESI) calcd for 
C27H35ClN3O6S [M+H]
+: 564.1935. Found: 564.1939. 
___________________________________________________________ 
General Protocol from 5a to 17: 
 
5a (1.0 eq) was dissolved in a 4:1 DCM and pH 7 buffer solution (final concentration: 
0.04 M). The mixture was cooled to 0°C and DDQ (1.5 eq) was added. The reaction 
was stirred at 0°C for another 10 mins and then brought to room temperature and stirred 
for 4 h. The reaction was quenched with water and extracted with DCM. The combined 
organic extracts were washed with saturated NaHCO3 solution and subsequently, 
activated carbon was added. The mixture was filtered through celite and the filtrand was 
washed with hot DCM several times. The product was filtered through a short silica plug 
(0-100 % EtOAc in Hexanes) to remove polar by-products. The product was then 
dissolved in DCM (1.0 M) and TFA (0.1 eq to 1.0 eq DCM) was added. The reaction 
was stirred for 1 h at room temperature. The mixture was concentrated and saturated 
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NaHCO3 solution was added. The mixture was extracted with DCM, and the combined 
organic extracts were dried with MgSO4, filtered, and concentrated. The product was 
dissolved in DMF with 2% acetic acid (0.03 M) and the aldehyde AH1 (3.0 eq) was 
added. The mixture was stirred for 45 mins before sodium triacetoxyborohydride (STAB, 
3.0 eq) was added. The reaction was stirred overnight and in the morning, another 2.0 
eq of AH1 and STAB were added and the reaction was allowed to stir for another 2 h. 
The reaction was diluted with EtOAc and NaHCO3 and extracted with EtOAc. The 
mixture was washed with water and brine and the combined organic extracts were dried 
with Na2SO4, filtered, and concentrated. The product was purified by flash 
chromatography on silica gel (0-100% EtOAc in hexanes). 
 
17 
Following the general protocol, 0.51 g of 4a was reacted with 0.10 g palladium (10% on 
activated carbon) in 18.4 mL EtOH. 0.11 g of the resulting product was reacted with 
0.02 mL AC1 and 0.12 mL 2,6-lutidine in 10.4 mL DCM. The product was reacted with 
0.07 g DDQ in 4 mL DCM and 1 mL pH 7 buffer solution before 0.06 g of the product 
was deprotected in a 1:10 dilution of 0.12 mL TFA in 1.15 mL DCM. The product was 
then reacted with 0.09 g STAB and 0.6 g AH1, giving 17 after purification in 10% overall 
yield (91% purity). 
17: 1H NMR (500 MHz, DMSO-d6, room temperature, 91% purity)  9.02 (s, 1H), 7.90 
(d, J = 7.3 Hz, 1H), 7.33 (d, J = 8.3 Hz, 2H), 7.26 (d, J = 8.3 Hz, 2H), 7.10 (d, J = 7.8 
Hz, 1H), 6.85 (t, J = 8.0 Hz, 1H), 4.88 (t, J = 5.0 Hz, 1H), 4.74 – 4.67 (m, 1H), 4.50 (dd, 
J = 13.2, 6.8 Hz, 1H), 3.60 – 3.55 (m, 1H), 3.55 – 3.50 (m, 2H), 3.50 – 3.45 (m, 1H), 
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3.31 – 3.26 (m, 1H), 3.02 – 2.90 (m, 2H), 2.62 (dd, J = 13.3, 3.2 Hz, 1H), 2.11 (s, 3H), 
2.02 – 1.93 (m, 1H), 1.11 (d, J = 6.9 Hz, 3H), 0.85 (d, J = 6.6 Hz, 3H), 0.82 – 0.65 (m, 
5H).HRMS (ESI) calcd for C27H35ClN3O4 [M+H]
+: 500.2316. Found: 500.2317. 
___________________________________________________________ 
Protocol from 5b to 18: 
 
5b (1.0 eq) was dissolved in DCM (0.1 M) and 2,6-lutidine (4.0 eq) and TBSOTf (3.0 eq) 
were added at room temperature. The reaction was stirred for 2h and subsequently 
quenched with saturated NH4Cl solution. The mixture was extracted with EtOAc and the 
combined organic extracts were dried over MgSO4, filtered, and concentrated to 
produce the crude silyl carbamate which was dissolved again in THF (0.1 M). 
HF/pyridine (70%, 1.0 eq) was added and the mixture was stirred for 40 min at room 
temperature. The reaction was then quenched with saturated NH4Cl solution and 
extracted with EtOAc. The combined organic extracts were dried over MgSO4, filtered, 
and concentrated. The crude material was dissolved in DCM (0.03 M) and 2,6-lutidine 
(6.0 eq) was added and the mixture was cooled to 0°C. The desired sulfonyl chloride 
(3.0 eq) was added in minimal DCM. The reaction was stirred at 0°C overnight and 
subsequently quenched with water. The mixture was extracted with DCM, dried over 
MgSO4, filtered, and concentrated. The compound was purified by HPLC. 
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18 
Following the general protocol, 0.96 g of 4b was reacted with 0.24 g palladium (10% on 
activated carbon) 46 mL EtOH. The resulting product was reacted with 0.23 mL AC1 
and 1.3 mL 2,6-lutidine in 114 mL DCM. 0.45 g of the resulting product was deprotected 
using 0.66 mL TBSOTf, 0.47 mL 2,6-lutidine in 9.8 mL DCM, and 0.10 mL HF/pyridine 
in 9.8 mL THF. The product was reacted with 0.62 g SC1 and 0.68 mL 2,6-lutidine in 
38.9 mL DCM to give 18 in 68%  overall yield. 
18: 1H NMR (300 MHz, CDCl3, room temperature)  8.78 (s, 1H), 8.36 (d, J = 7.8 Hz, 
1H), 7.69 (d, J = 8.4 Hz, 2H), 7.46 (d, J = 8.3 Hz, 2H), 7.13 (d, J = 7.6 Hz, 1H), 6.90 (t, J 
= 7.9 Hz, 1H), 4.85 – 4.70 (m, 1H), 4.64 (d, J = 9.5 Hz, 1H), 4.13 – 3.96 (m, 1H), 3.23 (d, 
J = 8.7 Hz, 2H), 2.72 (s, 3H), 2.65 (d, J = 14.2 Hz, 1H), 1.96 – 1.76 (m, 2H), 1.26 – 1.15 
(m, 6H), 1.05 – 0.91 (m, 5H), 0.81 – 0.69 (m, 2H). HRMS (ESI) calcd for C26H33ClN3O5S 
[M+H]+: 534.1829. Found: 534.1836. 
___________________________________________________________ 
General Protocol from 4a to 19: 
 
4a (1.0 eq) in EtOH (0.05 M) was stirred with palladium (10% on activated carbon, 0.10 
eq) at 35°C under H2. After the starting material was completely consumed (as 
monitored by LC-MS, 1-2 h), the mixture was cooled, filtered through celite, and 
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concentrated. The product was dissolved in a 7:1 mixture of EtOH and acetic acid (final 
concentration 0.007 M). Aqueous solutions of sodium nitrite (14.0 eq) and sodium 
bisulfite (10.0 eq) were added. The reaction was stirred at room temperature and 
monitored by LCMS. After 20 h, an additional 7.0 eq of sodium nitrite and 5.0 eq of 
acetic acid were added and the reaction was stirred at room temperature overnight. The 
reaction was quenched with water, extracted with chloroform, and concentrated. The 
product was purified using flash chromatography on silica gel (10-30% EtOAc in 
hexanes).  
6: Following the general protocol, 1.06 g of 4a was reacted with 0.20 g palladium (10% 
on activated carbon) in 38 mL EtOH. 0.13 g of the resulting product was reacted with 
0.24 g (14 eq) NaNO2 and 0.26 g (10 eq) NaHSO3 and later again with 0.12 g (7 eq) 
NaNO2 and 0.13 (5 eq) NaHSO3 in 31 mL EtOH and 4.4 mL AcOH (7:1 mixture) to give 
6 48% yield.  
tert-butyl-(((2R,3S)-5-((R)-1-((4-methoxybenzyl)oxy)propan-2-yl)-3-methyl-6-oxo-
3,4,5,6-tetrahydro-2H-benzo[b][1,5]oxazocin-2-yl)methyl)(methyl)carbamate 6: 1H NMR 
(300 MHz, CDCl3, room temperature)  7.51 (d, J = 6.5 Hz, 1H), 7.29 – 7.18 (m, 3H), 
6.96 – 6.79 (m, 4H), 4.71 – 4.57 (m, 2H), 4.52 – 4.42 (m, 2H), 3.79 (s, 3H), 3.76 – 3.66 
(m, 1H), 3.58 – 3.49 (m, 1H), 3.46 – 3.33 (m, 2H), 3.28 – 3.17 (m, 2H), 2.79 (s, 1.5H), 
2.73 (s, 1.5H), 1.40 (s, 9H), 1.32 – 1.22 (m, 3H), 0.94 (d, J = 6.6 Hz, 3H), 0.89 – 0.81 (m, 
1H). LRMS-ES+ m/z: 513.31 (M +). 
___________________________________________________________ 
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tert-butyl-(((2R,3S)-5-((R)-1-((4-methoxybenzyl)oxy)propan-2-yl)-3-methyl-6-oxo-
3,4,5,6-tetrahydro-2H-benzo[b][1,5]oxazocin-2-yl)methyl)(methyl)carbamate 6 (1.0 eq) 
was dissolved in DCM (0.1 M) and 2,6-lutidine (4.0 eq) and TBSOTf (3.0 eq) were 
added at room temperature. The reaction was stirred for 2h and subsequently quenched 
with saturated NH4Cl solution. The mixture was extracted with EtOAc and the combined 
organic extracts were dried over MgSO4, filtered, and concentrated to produce the 
crude silyl carbamate which was dissolved again in THF (0.1 M). HF/pyridine (70%, 1.0 
eq) was added and the mixture was stirred for 40 min at room temperature. The 
reaction was then quenched with saturated NH4Cl solution and extracted with EtOAc. 
The combined organic extracts were dried over MgSO4, filtered, and concentrated. The 
crude material was dissolved in DCM (0.03 M), and 2,6-lutidine (6.0 eq) was added and 
the mixture was cooled to 0°C. The desired sulfonyl chloride (3.0 eq) was added in 
minimal DCM. The reaction was stirred at 0°C overnight and subsequently quenched 
with water. The mixture was extracted with DCM, dried over MgSO4, filtered, and 
concentrated. The crude product was then dissolved in a 4:1 DCM and pH 7 buffer 
solution (final concentration: 0.08 M). The mixture was cooled to 0°C and DDQ (1.5 eq) 
was added. The reaction was stirred at 0° for another 10 mins and then brought to room 
temperature and stirred overnight. The reaction was quenched with water and extracted 
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with DCM. The combined organic extracts were washed with saturated NaHCO3 
solution and subsequently, activated carbon was added. The mixture was filtered 
through celite and the filtrand was washed with hot DCM several times. The filtrate was 
concentrated and the product was purified by flash chromatography on silica gel (0-  
100% EtOAc in hexanes).  
 
19 
Following the general protocol, 0.06 g of 6 was reacted with 0.08 mL TBSOTf and 0.06 
mL 2,6-lutidine in 1.2 mL DCM, and later with 11 L HF/pyridine in 1.2 mL THF. The 
product was reacted with 0.7 g SC1 and 0.08 mL 2,6-lutidine in 4.7 mL DCM. The 
resulting product was reacted with 0.04 g DDQ in 4 mL DCM and 1 mL pH 7 buffer 
solution to give 19 in 49% overall yield. 
19: 1H NMR (300 MHz, CDCl3, room temperature) 7.70 (d, J = 8.5 Hz, 2H), 7.56 – 
7.34 (m, 3H), 7.32 – 7.16 (m, 1H), 6.95 (t, J = 7.5 Hz, 1H), 6.76 (d, J = 8.3 Hz, 1H), 4.88 
– 4.76 (m, 1H), 4.74 – 4.56 (m, 1H), 3.90 (d, J = 11.4 Hz, 1H), 3.73 – 3.58 (m, 1H), 3.53 
(dd, J = 13.9, 5.2 Hz, 1H), 3.36 – 3.23 (m, 2H), 3.08 (dd, J = 13.9, 7.4 Hz, 1H), 2.81 (s, 
3H), 2.28 – 2.15 (m, 1H), 1.97 – 1.85 (m, 1H), 1.29 (d, J = 7.0 Hz, 3H), 1.01 (d, J = 6.6 
Hz, 3H). HRMS (ESI) calcd for C22H28ClN2O5S [M+H]
+: 467.1407. Found: 467.1409. 
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Spectra 
I1b 1H NMR: 
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3b 1H NMR: 
 
 
I4b 1H NMR:  
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4b 1H NMR:  
 
 
6 1H NMR:  
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BRD50837 (7) 1H NMR: 
 
 
BRD50837 (7) 13C NMR:  
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BRD50837 (7) IR:  
 
 
8 1H NMR:  
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9 1H NMR: 
 
 
10 1H NMR: 
 
 
 
 80 
 
11 1H NMR: 
 
 
12 1H NMR: 
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13 1H NMR:  
 
 
14 1H NMR:  
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BRD9526 (15) 1H NMR: 
 
 
BRD9526 (15) 13C NMR: 
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BRD9526 (15) IR: 
 
 
16 1H NMR:  
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17 1H NMR:  
 
 
18 1H NMR:  
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19 1H NMR:  
 
 
 
 
References 
(1) Reprinted (adapted) with permission from Schaefer, G. I. et al. "Discovery of 
Small-Molecule Modulators of the Sonic Hedgehog Pathway." J. Am. Chem. Soc., 
135, 9675-9680. Copyright (2013) American Chemical Society. 
 
(2) Marcaurelle, L. A. et al. "An aldol-based build/couple/pair strategy for the 
synthesis of medium- and large-sized rings: discovery of macrocyclic histone 
deacetylase inhibitors." J. Am. Chem. Soc. 2010, 132, 16962-16976. 
 
(3) Chou, D. H. et al. "Synthesis of a novel suppressor of beta-cell apoptosis via 
diversity-oriented synthesis." ACS Med. Chem. Lett. 2011, 2, 698-702. 
 
(4) Gottlieb, H. E., Kotlyar, V. & Nudelman, A. "NMR Chemical Shifts of Common 
Laboratory Solvents as Trace Impurities." J. Org. Chem. 1997, 62, 7512-7515. 
 
 86 
 
(5) Livak, K. J. & Schmittgen, T. D. "Analysis of relative gene expression data using 
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method." Methods 2001, 
25, 402-408. 
 
 
 
  
 
 
 
 
Chapter Four 
 
Mechanism-of-action studies on small-molecule 
modulators of the Sonic Hedgehog pathway 
 
 
I assayed the compounds’ mechanism of action in SAG-induced C3H10T1/2 cells,  
Ptch-/- cells, and Sufu-/- cells. I prepared and characterized the immobilized analog and 
its intermediates. I prepared the samples used for iTRAQ analysis together with Steven 
Poynter. Dr. Monica Schenone and Emily Hartmann processed the samples and ran the 
iTRAQ Mass-Spectrometry and analysis. 
 
 
 
 
 
 
 
 
 
 
In part adapted from Schaefer, G.I.; Perez, J.R.; Duvall, J.R.; Stanton, B.Z.; Shamji, 
A.F.; Schreiber, S.L. “Discovery of Small-Molecule Modulators of the Sonic Hedgehog 
Pathway” J. Am. Chem. Soc. 2013, 135, 9675-9680.1 
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BRD50837’s and BRD9526’s level of activity in the Hedgehog pathway 
To understand the mechanisms of action of the compounds discovered in 
Chapter 3, I tested the response to BRD50837 and BRD9526 in several epistasis 
experiments and in a competition assay in comparison to cyclopamine, a commonly 
used Smo inhibitor. I first tested the compounds in C3H10T1/2 cells that were treated 
with SAG (a small-molecule activator of Smo), rather than Shh-conditioned medium, to 
activate the Hh pathway (Figure 4.1a).2 Like cyclopamine, the compounds suppressed 
SAG-induced differentiation, suggesting a mechanism of action involving modulation of 
a step in the signaling cascade at or following Smo signaling. In parallel, I tested the 
compounds in Ptch-/- cells, mouse embryonic fibroblasts that contain a -galactosidase 
reporter gene instead of the Ptch gene downstream of the Ptch promoter.3 Lacking the 
repressor Ptch, the Hh pathway is constitutively active in these cells. In this assay, 
cyclopamine maintained its inhibition of the pathway, but BRD50837 and BRD9526 had 
no effect (Figure 4.1b). When viewing the overall pathway as a linear set of response 
nodes, these results are apparently in contrast to the previous observation – they 
suggest that the compounds act at the level of Ptch or a step upstream of Ptch 
signaling. However, I also identified compounds from the original screen with responses 
similar to cyclopamine in Ptch-/- cell-based, SAG/C3H10T1/2 cell-based, and BODIPY-
cyclopamine displacement assays (Chapter 2), which gave me confidence that the 
assays accurately measure compound/activity profiles. 
With these puzzling results in hand, I performed two addtitional assays to 
characterize the compounds. I first tested the compounds in a competition assay to 
determine whether they displace BODIPY-cyclopamine in a cellular assay, thus
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Figure 4.1. All values are shown and generated from three independent experiments 
run in duplicate (values are calculated average ± SD). a) Inhibition of SAG-induced 
differentiation of C3H10T1/2 cells by BRD50837, BRD9526, and cyclopamine after 48 
h. b) -galactosidase expression response of Ptch-/- cells to 48 h treatment with 
BRD50837, BRD9526, and cyclopamine.  
 
suggesting that they bind Smo in the cyclopamine-binding site.4 Unlike cyclopamine, 
both BRD50837 and BRD9526 did not lead to a reduction of BODIPY-cyclopamine 
binding (Figure 4.2a), suggesting that BRD50837 and BRD9526 do not interfere with 
cyclopamine binding. 
I next tested the activity of BRD50837 and BRD9526 in SuFu-/- cells. These 
mouse embryonic fibroblasts lack the pathway repressor SuFu, which leads to 
constitutively active Hh signaling.5 It has been reported that Smo antagonists do not 
inhibit this signaling while the pathway inhibitor GANT-61 does.6 In our experiments, 
cyclopamine partially inhibited downstream Gli1 expression (Figure 4.2b), perhaps due 
to an off-target activity observed at high concentrations.7,8 However, another more 
potent Smo inhibitor (vismodegib)9 showed no suppression of Gli1 expression, 
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Figure 4.2. a) Effects of cyclopamine, BRD50837, and BRD9526 on BODIPY-
cyclopamine (10 nM) binding to exogenously expressed Smo. blue (Hoechst 33342), 
red (anti-myc), green (BODIPY-cyclopamine). b) Gli1 expression in  Sufu-/- cells treated 
with GANT61, cyclopamine, BRD50837, and BRD9526. All values are shown and 
generated from three independent experiments run in duplicate (values are calculated 
average + SD). 
 
consistent with the existing model of SuFu being downstream of Smo (Figure 4.2b). 
BRD50837 and BRD9526, like cyclopamine, partially lowered Gli1 expression at 
concentrations of 2 M and 10 M (Figure 4.2b). This partial inhibition may reflect an 
off-target effect at high concentrations, but it is also possible that these compounds act 
in a way that influences the pathway at the level of or downstream of SuFu signaling. 
The compounds therefore act similarly to cyclopamine, a well-characterized 
pathway inhibitor, in some aspects (SAG/C3H10T1/2 cell-based and SuFu-/- cell-based 
assays), but seem to have a different mechanism of action in other aspects (Ptch-/- cell-
based and BODIPY-cyclopamine displacement assays). These data suggest that 
BRD50837 and BRD9526 may function by mechanisms of action that are distinct from 
cyclopamine and not easily described by traditional linear models of the pathway. 
Consistent with this notion, BRD50837/BRD9526 repressed Gli1 expression of 
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C3H10T1/2 cells to a lesser extent than cyclopamine when the compounds were tested 
at concentrations that yield similar responses in Shh-conditioned medium-induced 
differentiation of C3H10T1/2 cells (1 M, and 10 M, respectively, Suppl. Figure S3.2). 
 
Identifying possible targets - iTRAQ 
 To find more definite answers about the compounds’ mechanism of action, 
identification of protein binding partner(s) would be optimal. Different methods for target 
identification such as biochemical, genomic interactions, or computational methods 
have been developed.10,11 I decided to employ a quantitative proteomics approach using 
the isobaric tags for relative and absolute quantification (iTRAQ) technology to gain 
more insight into a possible target of BRD50837 and BRD9526. 
 To identify targets using quantitative proteomics, the small molecule is 
immobilized to a solid support. In a biochemical affinity purification, the immobilized 
compound is then incubated with lysate and either soluble active molecule, or, as 
negative control, inactive molecule or vehicle. Subsequently, the solid support is 
washed, proteins purified in the pull-down are digested, and each sample is tagged 
using a different iTRAQ tag (Figure 4.3). These tags are designed to be isobaric, but 
fragment into different reporter ions when using mass spectrometry (MS). The relative 
abundance of each tag for a peptide can be used to quantify the ratio of the 
corresponding protein between the different samples.12 Non-specific binders of the solid 
support or linker employed will have a ratio between vehicle and soluble active molecule 
samples that is approximately 1. Specific binders of the immobilized molecule however, 
will also bind the soluble active molecule, which competes with the immobilized 
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Figure 4.3. Workflow for an iTRAQ experiment. The active small molecule is 
immobilized on solid support and incubated with cell lysates (solid square, circle, star = 
proteins). Additionally, the samples will be incubated with either DMSO, soluble 
competitor (BRD50837), or soluble inactive compound (enantiomer of BRD50837). After 
washing off any proteins that did not bind the immobilized molecule, the proteins are 
digested and tagged with iTRAQ tags (triangles). MS/MS quantifies the abundance of 
each tag for each peptide. Non-specific binders (square) will have similar relative 
abundance while specific binders (star) will be downregulated in the soluble competitor 
sample. 
 
molecule. They will get washed off with the soluble competitor, and thus be enriched in 
the vehicle sample (Figure 4.3). 
To prepare the iTRAQ experiment, I first synthesized a derivative of BRD50837 
that contained a linker to attach it to the solid support. Because the SAR showed that 
variations of attachments at the aniline are more easily tolerated, I decided to 
incorporate a linker at that position. Starting after hydrogenation of scaffold 4a, the 
polyethylene glycol linker 92 was added to give 93 (Scheme 4.1). Subsequent 
deprotection of the Boc group using HF/pyridine, addition of sulfonyl chloride SC1, and 
removal of the PMB with DDQ resulted in compound 94. This compound was tested for 
activity in Shh-conditioned medium-induced differentiation of C3H10T1/2. Incorporation 
of the linker did lead to a loss in activity, but the compound was still very active, but not 
due to toxicity (Figure 4.4a, 4.4b). Saponification of the ethyl ester (95) and activation of  
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Scheme 4.1. Synthesis of immobilized analoga 
 
a
Reagents and conditions: (a) 10% Pd/C, H2, EtOH, 35°C. (b) 92, PyBOP, DIPEA, DCM, rt, 78% over 2 
steps. (c) TBSOTf, 2,6-lutidine, DCM, rt, then HF/pyridine, THF, rt. (d) SC1, 2,6-lutidine, DCM, 0°C (e) 
DDQ, pH 7 buffer/DCM, rt, 32% over 3 steps (f) LiOH, 1:1 THF/H2O, rt, 73%. (g) EDC, NHS, DMF, 40°C. 
(h) Affigel 102, TEA, DMSO, rt. 
 
the carboxylic acid using EDC and NHS then allowed coupling to the solid support 
(Scheme 4.1). 
For my experiment, I prepared three samples: one using DMSO as a vehicle, one 
using BRD50837 as a soluble competitor, and one using BRD50837’s inactive 
enantiomer (IE) as a soluble competitor. Specific targets of BRD50837 should be 
enriched in both the DMSO and the IE samples, but not in the BRD50837 sample 
(Figure 4.3). The data was analyzed in three groups: group 1 being DMSO/BRD50837, 
group 2 being IE/DMSO, and group 3 being IE/BRD50837. The two independent 
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Figure 4.4. a) Inhibition of Shh-conditioned medium (CM)-induced differentiation of 
C3H10T1/2 cells by BRD50837, 94, and cyclopamine after 48 h. All values are shown 
and generated from two independent experiments run in duplicate (values are 
calculated average ± SD). b) Viability of SAG-induced C3H10T1/2 cells in response to 
48 h treatment with BRD50837, 94, and cyclopamine. All values are shown and 
generated from one experiment run in duplicate. c) number of proteins identified and 
quantitated in each replicate of the iTRAQ experiment. 
 
experiments run on different days with different iTRAQ tags showed good correlation for 
overall amount of proteins and peptides purified (Figure 4.4c). However, the histograms 
of the two replicates show very different distributions of ratios (Figure 4.5 a-c), meaning 
that the ratios did not replicate well between the two runs and further replicates might be 
required. 
-9 -8 -7 -6 -5 -4
0
50
100
150
log10(concentration/M)
A
T
P
 l
e
v
e
l/
%
94 BRD50837 cyclopamine
viability in C3H10T1/2 cells
(CM activation)
-9 -8 -7 -6 -5 -4
0
50
100
150
log10(concentration/M)
a
lk
a
li
n
e
 p
h
o
s
p
h
a
ta
s
e
 e
x
p
re
s
s
io
n
/%
BRD50837 cyclopamine94
Osteoblast differentiation
(CM activation)
Replicate Proteins
1 1268
2 1298
2+ peptides; 3+ ratios per replicate
A B
C
 95 
 
 
Figure 4.5. a-c) log2 ratios and frequency histograms for replicate 1 vs. replicate 2 of 
DMSO/BRD50837 (a), inactive enantiomer (IE)/DMSO (b), IE/BRD50837 (c). Proteins 
circled in red are isoforms of GSTM. d) western blot analysis for GSTM1 of protein 
affinity purification. Competition used in lanes: 1 = none (DMSO only), 2 = BRD50837, 3 
= BRD50837s inactive enantiomer. Ponceau S stain shows overall protein content in the 
lanes. 
 
Despite these insufficiencies, there is a group of four proteins that demand 
attention. These proteins are outliers with a higher signal ratio in Group 2 and Group 3. 
All four are different proteins from the same family, glutathione S-transferase  (GSTM1, 
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GSTM2, GSTM4, GSTM5) (Figure 4.5b, 4.5c). GSTMs are not a protein subfamily 
frequently detected as targets in other iTRAQ experiments run in different systems,13 
making these outliers of interest. Glutathione S-transferases (GSTs) are involved in drug 
metabolism. In cells, foreign compounds, such as drugs or probes, are tagged by GSTs 
through transfer of an abundant cofactor, glutathione. This transfer marks the agents for 
export from the cells and subsequent excretion.14,15  
Comparing the IE and BRD50837 samples is the most direct comparison for the 
competition experiment, as in both cases a small-molecule competitor is in solution, with 
the difference being the competitor’s stereochemistry. Curiously, the GSTMs are not 
enriched in the DMSO vs. BRD50837 sample (Figure 4.5a). While this could be due to 
the different environment created by lack of any small-molecule, it might also mean that 
the enrichment of GSTMs is due to a bias within the experiment. However, a preliminary 
repetition of the pull-down with subsequent gel electrophoresis and western blot 
detection of GSTM1, confirms the results from the iTRAQ experiment (Figure 4.5d). In 
addition, it is striking that four different proteins from the same subfamily, and only that 
subfamily, showed enriched ratios. GSTs share about 60% sequence identity within a 
class, but less than 30% between classes, suggesting specificity in binding interactions 
in the affinity purification.16 Therefore, these experiments suggest an interaction of 
BRD50837 and GSTMs in cell lysates, but more experiments are needed to determine 
the nature of the interaction and possible impacts on the Hh pathway. These could 
include orthogonal measures of direct binding such as isothermal calorimetry or surface 
plasma resonance, in vitro assessment of enzyme inhibition/activation, and proof of 
phenotype using RNAi or overexpression of the candidate target. 
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One other caveat that should be considered with biochemical affinity purifications 
is the difficulty in identifying membrane proteins or proteins with low cellular abundance 
as targets.10,17,18 Additionally, immobilization of the small molecule to the beads can 
potentially destroy the interactions with the target, even if the compound with linker was 
still active. Therefore, while GSTMs potentially interact with the compounds in cells and 
this interaction can be further investigated, additional experiments directed at identifying 
a target might be necessary. These could include using affinity purification, but 
performing the pull-down in live cells with covalent capture18 or immobilization of 
compounds at different points of attachment. Gene expression profiles could 
furthermore enhance the understanding of pathways modulated by the compounds. 
 
Conclusion 
I report here the discovery of BRD50837 and BRD9526, two selective small-
molecule inhibitors of the Shh pathway. Though similar in some respects to traditional 
pathway inhibitors, the compounds show a distinct pattern of activity in cells perturbed 
for components of the pathway. The basis for these differences is not yet known, but it 
hints at the complexity of the pathway. Studies to identify cellular targets have 
generated GSTMs as potential interacting proteins. Further experiments will be 
necessary to confirm these interactions with BRD50837 and BRD9526 and effects on 
the pathway. Elucidating the compounds’ mechanism of action will help to realize their 
full potential as probes and enable the study of this enigmatic pathway. 
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Experimental Section 
Materials and Methods 
Organic Synthesis & Compound Characterization: as described in Chapter 3. In 
addition: Affigel 102 gel as solid support was purchased from Biorad (Hercules, CA, 
USA). NMR spectra were measured on a Bruker Ultrashield 400 (400 MHz 1H, 100 MHz 
13C) (Billerica, MA, USA).  
Assay Treatments and Readouts: as described in Chapter 2 & 3. In addition: 
SuFu-/- and SuFu+/+ cells were kindly provided by Dr. Rune Toftgård and Dr. Stephan 
Teglund (both Karolinska Institutet, Sweden). SuFu-/- and SuFu +/+ cells were grown at 
37°C/5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) (Cellgro, Manassan, VA, 
USA) supplemented with 10 % fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, 
USA), 2 mM L-glutamine, 1 mM sodium pyruvate (both Life Technologies, Carlsbad, CA, 
USA), and 10 g/ml gentamicin. Cells were lysed for iTRAQ using a ModRIPA (50 mM 
Tris-HCl, pH 7.8, 150 mM NaCl, 0.1% sodium deoxycholate, 1 mM EDTA) buffer with    
1% NP-40. Protein concentrations were measured using a Pierce BCA Protein Assay 
Kit from Thermo Scientific (Waltham, MA, USA) on a Molecular Devices SpectraMax M5 
microplate reader (Sunnyvale, CA, USA). iTRAQ reagents were purchased from AB 
Sciex (Framingham, MA, USA). Samples were read out using a Thermo Scientific Q 
Exactive Mass Spectrometer. Gels, protein ladder, buffers (loading and running) for gel 
electrophoresis, and western blotting membranes were purchased from Life 
Technologies (Carlsbad, CA, USA). Ponceau S solution to visualize protein content in 
membranes was purchased from Sigma-Aldrich (St Louis, MO, USA). Proteins were 
transferred from gels to membranes using an Invitrogen iBlot transfer device (Carlsbad, 
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CA, USA). Milk and 2° antibody for western blotting (anti-rabbit IgG) were purchased 
from Cell Signaling Technology (Beverly, MA, USA).  1° antibody for western blotting 
(Rabbit IgG, anti-GSTM1) was purchased from EMD Millipore (Darmstadt, Germany). 
SuperSignal West Femto Substrate kit was purchased from Thermo Scientific (Waltham, 
MA, USA). Developed membranes were visualized using a Kodak Carestream Image 
Station 4000MM Pro (Bruker, Billerica, MA, USA) with chemiluminescence settings for 2 
minutes. 
 
Assay Protocols 
C3H10T1/2 differentiation assay, Ptch-/- -galactosidase assay, C3H10T1/2 & 
Ptch-/- CellTiter-Glo Viability assay, BODIPY-cyclopamine competition assay, RNA 
extraction, cDNA Reverse Transcription, qPCR: as described in Chapter 2 & 3. 
Sufu-/- cell treatment for gene expression: To test the compounds’ mechanism of 
action, they were tested in SuFu-/- mouse embryonic fibroblasts. The SuFu-/- cells and 
the SuFu+/+ cells were seeded with 130,000 cells/well into 6 well plates in DMEM 
supplemented with 10% FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, and 10 g/mL 
gentamicin. The cells were incubated at 37°C/5% CO2 for 24 hours. Afterwards the 
wells were washed and DMEM supplemented with 0.5% FBS and 1% 
penicillin/streptomycin was added. The compounds/DMSO were added in the respective 
concentrations to the Sufu-/- cells and the respective DMSO amount was added to the 
SuFu+/+ cells. The cells were then incubated for 72 hours at 37°C/5% CO2. The cells 
were subsequently harvested by washing them once with PBS, scraping each well and 
collecting them in a 1.7 mL Eppendorf tube. The tubes were centrifuged at 14,000 rpm 
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for 5 min and the supernatant was carefully aspirated. The pellets were either used right 
away for RNA extraction or frozen at -20°C until needed. 
C3H10T1/2 sample preparation for iTRAQ & gel separation: To determine the 
compounds possible targets, affinity purification was performed. C3H10T1/2 cells were 
grown in T175 flasks in DMEM supplemented with 10% FBS and 1% 
penicillin/streptomycin at 37°C/5% CO2 until confluent. Subsequently, the media was 
removed and the cells were washed once with PBS before 25 mL/flask DMEM 
supplemented with 0.5% FBS, 1% penicillin/streptomycin, and 5% Shh-conditioned 
medium was added. The cells were then incubated for 48 hours at 37°C/5% CO2. 
Subsequently, the cells were harvested by washing them once with PBS, trypsinizing 
and counting. They were centrifuged at 1000 rpm for 5 minutes, the media removed, 
placed on ice, and the pellets washed once with PBS. The PBS was then removed, and 
1 mL lysis buffer (ModRipa with 1% NP-40) per 50 million cells was added to the pellet. 
The pellets were homogenized by vortexing and incubated on ice for 15 minutes. 
Subsequently, the mixture was centrifuged at 14,000 rpm for 10 minutes at 4°C. The 
protein concentration was assessed and 1500 mg (700 mg for gel electrophoresis) 
protein were brought to 1 mL with lysis buffer and incubated with 6 L (200x) 
BRD50837, inactive enantiomer (both 10 mM solution in DMSO), or DMSO for 1 hour 
on ice. The mixture was then added to a slurry of 45 L beads with immobilized active 
compound for each sample and incubated overnight at 4°C under rotation. 
Subsequently, the beads were centrifuged at 3000 rpm for 5 minutes at 4°C and 
washed once with 1 mL lysis buffer and twice with 1 mL cold PBS. For each washing 
step, they were incubated under rotation for 10 minutes and subsequently centrifuged 
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again. For iTRAQ, the PBS was removed and the beads were stored frozen at -80°C in 
about 10 L of PBS. For gel electrophoresis, the PBS was removed and 40 L of 2X 
NuPage LDS Sample buffer was added to each sample. The samples were 
subsequently boiled for 10 min at 95°C and moved forward to gel separation. 
iTRAQ sample tagging and mass spectrometry: 90 L digestion buffer (2M urea, 
50 mM Tris HCl) was added to thawed beads. Proteins bound to beads were reduced 
with 2 L 500 mM DTT for 30 minutes and alkylated with 4 L of 500 mM 
Iodoacetamide for 45 minutes in the dark. 2 g of sequencing grade trypsin was 
incubated overnight at room temperature. Mixture was quenched with 20 L 10% FA, 
and supernatant and two 50 L washes with digestion buffer were collected into a fresh 
tube. Acetonitrile was added to mixture to a final concentration of 3%, and samples 
were desalted on Oasis cartridges. Concentrated peptide eluents were dried and iTRAQ 
labeled using Sciex iTRAQ kits (standard manufacturer protocols were followed). 
Peptides were analyzed for labeling efficiency, labeled peptides were quenched, 
combined, and dried. Combined peptides were fractionated using strong cation 
exchange and desalted prior to mass spectrometry analysis. Samples were run on a Q 
Exactive with a 110 minute UPLC gradient. 
Gel electrophoresis and western blotting: the samples were loaded on a Bolt 4-
12% Bis-Tris Plus gel and run in MES SDS running buffer at 175V for 30 minutes. 
Proteins were transferred to nitrocellulose membranes (0.2 m pore size) using the iBlot 
system for 7.5 min. After transfer, total protein load was visualized using Ponceau S 
solution according to manufacturer’s protocol. Membranes were destained using a 0.1 
M solution of NaOH and washed briefly using TBST (tris-buffered saline and tween 20) 
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buffer. Membranes were blocked in 5% milk in TBST buffer at 4°C overnight. 
Subsequently, membranes were washed three times for ten minutes with TBST buffer 
and incubated with 1° antibody (rabbit IgG, anti-GSTM1) at 4°C overnight. Membranes 
were again washed three times for ten minutes with TBST buffer and incubated with 2° 
antibody (anti-rabbit IgG) for one hour at room temperature. Finally, membranes were 
washed three times for ten minutes with TBST buffer, developed using a Thermo 
Scientific SuperSignal West Femto Substrate kit and visualized using 
chemiluminescence settings. 
 
Data Analysis 
Dose response curves (C3H10T1/2 and Ptch-/- cells): As described in Chapter 2.  
Gene expression data SuFu-/- cells: For each sample, four technical replicates 
were measured and CT values for each replicate were calculated using the instrument’s 
analysis feature. CT values were subsequently averaged for each sample and the fold 
expression changes normalized within each experiment to SuFu+/+ cells was calculated 
using the 2-CT method.
19 Experiments were done three times in duplicate on separate 
days. 
iTRAQ: Raw MS files were extracted, searched against a Uniprot mouse 
database, and validated using Agilent Spectrum Mill MS Proteomics Workbench. iTRAQ 
mix (N-term, K) was selected as a fixed modification in extraction and MS/MS search. 
Following export, non-mouse proteins and proteins with one peptide were removed, and 
remaining proteins were median normalized. A moderated T test was performed to 
identify significant protein interactors. A protein was deemed significant if its p value 
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was higher than 0.02 and its average ratio was in the 95th percentile or higher. All 
proteins and their enrichments are listed in Suppl. Table S4.1 (digital). 
 
Synthetic Procedures 
Protocol analog linker 94 
 
4a (0.2 g, 1.0 eq) in EtOH (7.2 mL, 0.05 M) was stirred with palladium (10% on 
activated carbon, 3.8 mg, 0.10 eq) at 35°C under H2. After the starting material was 
completely consumed (as monitored by LC-MS, 1-2 h), the mixture was cooled, filtered 
through celite, and concentrated. The crude material was dissolved in DCM (3.6 mL, 0.1 
M) under N2 and PyBOP (0.28 g, 1.5 eq), and diisopropyl ethylamine (DIPEA) (0.19 mL, 
3.0 eq) was added. The mixture was cooled to 0°C before 3-(2-(3-ethoxy-3-
oxopropoxy)ethoxy)propanoic acid (92) was added. The mixture was allowed to come to 
room temperature and stirred for 15 h before being quenched with water and extracted 
with DCM. The combined organic extracts were dried over MgSO4, filtered, and 
concentrated. The crude product was purified by flash chromatography on silica gel (0-
100% EtOAc in hexanes) to give the product 93 with 78% yield. 
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93: 1H NMR (400 MHz, CDCl3, room temperature) δ 8.92 (s, 1H), 8.31 (d, J = 7.4 Hz, 
1H), 7.22 (d, J = 8.0 Hz, 2H), 7.12 (d, J = 7.5 Hz, 1H), 6.90 - 6.79 (m, 3H), 5.10 – 4.95 
(m, 1H), 4.72 – 4.60 (m, 1H), 4.56 – 4.46 (m, 1H), 4.46 – 4.37 (m, 1H), 4.31 – 4.17 (m, 
1H), 4.15 – 4.04 (m, 2H), 3.89 – 3.80 (m, 2H), 3.76 (s, 3H), 3.73 – 3.65 (m, 2H), 3.65 – 
3.50 (m, 6H), 3.24 – 3.15 (m, 2H), 2.93 – 2.80 (m, 1H), 2.79 – 2.68 (m, 1H), 2.56 2.48 (t, 
J = 6.1 Hz, 2H), 2.45 (s, 3H), 2.43 – 2.35 (m, 1H), 2.02 – 1.90 (m, 1H), 1.33 (s, 9H), 
1.21 (t, J = 6.9 Hz, 3H), 1.16 (d, J = 6.5 Hz, 3H), 0.90 (d, J = 6.2 Hz, 3H). ).13C NMR 
(101 MHz, CDCl3, room temperature) δ 171.76, 170.45, 170.20, 159.41, 156.78, 
144.81, 129.90, 129.49, 128.05, 126.33, 122.56, 120.77, 120.63, 113.88, 79.91, 74.15, 
72.76, 71.65, 70.29, 70.18, 67.44, 66.64, 60.53, 55.33, 51.36, 49.60, 47.55, 37.80, 
35.09, 35.05, 34.36, 28.37, 14.82, 14.22, 10.94. LRMS-ES+ m/z: 744.46 (M+). 
___________________________________________________________ 
 
93 (135 mg, 1.0 eq) was dissolved in DCM (1.8 mL, 0.1 M) and 2,6-lutidine (0.09 mL, 
4.0 eq) and TBSOTf (0.125 mL, 3.0 eq) were added at room temperature. The reaction 
was stirred for 2h and subsequently quenched with saturated NH4Cl solution. The 
mixture was extracted with EtOAc and the combined organic extracts were dried over 
MgSO4, filtered, and concentrated to produce the crude silyl carbamate which was 
dissolved again in THF (1.8 mL, 0.1 M). HF/pyridine (70%, 85 L, 1.0 eq) was added 
and the mixture was stirred for 40 min at room temperature. The reaction was then 
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quenched with saturated NH4Cl solution and extracted with EtOAc. The combined 
organic extracts were dried over MgSO4, filtered, and concentrated. The crude material 
was dissolved in DCM (7.3 mL, 0.025 M) and 2,6-lutidine (0.13 mL, 6.0 eq) was added 
and the mixture was cooled to 0°C. The sulfonyl chloride SC1 (0.12 g, 3.0 eq) was 
added in minimal DCM. The reaction was stirred at 0°C overnight and subsequently 
quenched with water. The mixture was extracted with DCM, dried over MgSO4, filtered, 
and concentrated. The product was filtered through a short silica plug (0-100 % EtOAc 
in Hexanes) to remove polar by-products. The product was then dissolved in a 7:1 DCM 
and pH 7 buffer solution (8 mL, 0.02 M). The mixture was cooled to 0°C and DDQ (0.06 
g, 1.5 eq) was added. The reaction was stirred at 0°C for another 10 mins and then 
brought to room temperature and stirred overnight. The reaction was quenched with 
water and extracted with DCM. The combined organic extracts were washed with 
saturated NaHCO3 solution and subsequently, activated carbon was added. The 
mixture was filtered through celite and the filtrand was washed with hot DCM several 
times. The filtrate was concentrated and the product was purified by flash 
chromatography on silica gel (0-100% EtOAc in hexanes) to give the product 94 in 32% 
yield.  
94: 1H NMR (400 MHz, CDCl3, room temperature) δ 8.65 (s, 1H), 8.40 (d, J = 7.2 Hz, 
1H), 7.69 (d, J = 8.2 Hz, 2H), 7.48 (d, J = 8.3 Hz, 2H), 7.13 (d, J = 7.0 Hz, 1H), 6.93 (t, J 
= 7.9 Hz, 1H), 5.00 – 4.87 (m, 2H), 4.16 – 4.06 (m, 2H), 3.95 – 3.78 (m, 4H), 3.76 – 3.67 
(m, 2H), 3.66 – 3.54 (m, 4H), 3.54 – 3.42 (m, 1H), 3.36 – 3.20 (m, 2H), 2.79 – 2.69 (m, 
3H), 2.68 (s, 3H), 2.56 – 2.49 (m, 2H), 2.05 – 1.96 (m, 1H), 1.26 – 1.15 (m, 6H), 0.98 (d, 
J = 6.2 Hz, 3H). 13C NMR (101 MHz, CDCl3, room temperature) δ 172.14, 171.67, 
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170.15, 144.57, 139.46, 136.62, 129.68, 128.61, 128.16, 126.39, 122.80, 121.12, 
120.65, 73.03, 70.38, 70.25, 67.30, 66.84, 66.72, 60.56, 52.89, 52.60, 47.70, 38.00, 
35.46, 35.28, 35.20, 14.31, 14.17, 11.11. LRMS-ES+ m/z: 698.40 (M+). 
___________________________________________________________ 
Protocol compound activation and bead loading 
 
94 (18.5 mg, 1.0 eq) was dissolved in a 1:1 mixture of THF/water (800 L, 0.03 M) and 
LiOH (3.2 mg, 5.0 eq) was added. The mixture was stirred at room temperature 
overnight. The mixture was quenched with saturated NaHCO3, and the aqueous phase 
was acidified with 1M HCl to pH1. The mixture was extracted with EtOAc and combined 
organic extracts were dried over MgSO4, filtered, and concentrated. The concentrate 
was purified by flash chromatography on silica gel (0-10% MeOH in DCM) to give the 
product 95 in 73% yield. 
95: 1H NMR (400 MHz, CDCl3, room temperature) δ 8.69 (s, 1H), 8.41 (d, J = 7.3 Hz, 
1H), 7.72 (d, J = 8.1 Hz, 2H), 7.49 (d, J = 8.2 Hz, 2H), 7.13 (d, J = 7.4 Hz, 1H), 6.94 (t, J 
= 7.8 Hz, 1H), 5.04 – 4.87 (m, 2H), 3.99 – 3.75 (m, 4H), 3.74 – 3.66 (m, 2H), 3.65 – 3.54 
(m, 4H), 3.54 – 3.44 (m, 1H), 3.33 – 3.20 (m, 2H), 2.82 – 2.73 (m, 3H), 2.72 (s, 3H), 
2.57 – 2.46 (m, 2H), 2.10 – 1.95 (m, 1H), 1.19 (d, J = 6.4 Hz, 3H), 0.98 (d, J = 6.1 Hz, 
3H). 13C NMR (101 MHz, CDCl3, room temperature) δ 174.14, 172.44, 170.47, 144.67, 
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139.50, 136.55, 129.72, 128.68, 128.07, 126.52, 122.97, 121.10, 120.57, 73.01, 70.42, 
70.07, 67.34, 66.73, 66.55, 52.90, 52.73, 47.82, 38.03, 35.42, 35.35, 34.91, 14.19, 
11.10. LRMS-ES+ m/z: 767.34 (M+). 
___________________________________________________________ 
 
95 (5.9 mg, 1.0 eq) was dissolved in DMF (400 L, 0.02 M) and N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 3.4 mg, 2.0 eq) and N-
hydroxy succinimide (NHS, 2.0 mg, 2.0 eq) was added. The reaction was heated to 
40°C and stirred for 3 h. After 3 h, the mixture was 90% activated by LCMS and did not 
react further. The mixture was directly used for the next step. 
1 vial of Affigel 102 beads (1 mL, 12 mol) was washed twice with DMSO and three 
times with anhydrous DMSO. The beads were resuspended in DMSO (500 L) and 
activated compound 95 in DMF from above (72 L, 12.5% loading) was added. 
Triethylamine (17 L, 10 eq) was added and the vials were shaken gently at room 
temperature. After 90 min, no starting material was detectable by LCMS. The beads 
were washed 4 times with DMSO, resuspended in PBS (500 L), and stored at 4°C. 
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Spectra 
93 1H NMR: 
 
 
93 13C NMR: 
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94 1H NMR: 
 
 
94 13C NMR: 
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95 1H NMR: 
 
 
95 13C NMR: 
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Chapter Five 
 
Cancer cell-line profiling to identify cancer genetic and 
lineage dependencies targeted by small molecules 
 
 
I mined the literature to decide which compounds could be part of the informer set 
together with Dr. Jordi Barretina, Dr. Marcin Imielinski, Dr. Stefan Kubicek, Dr. Ben 
Munoz, Josh Paulk, Dr. Gopal Ramachandran, Dr. Arvind Ramanathan, Dr. Aly Shamji, 
Dr. Andrew Stern, Dr. Bridget Wagner, and Dr. Stuart Schreiber. Dr. Jaime Cheah, 
Edmund Price, Dr. Ke Liu, Richard Ebright, Dr. Daisuke Ito, Stephanie Wang, Dr. 
Abigail Bracha, and I carried out the assay development and profiling runs of the CCLs. 
Dr. Amrita Basu, Nicole Bodycombe, Dr. Mathias Wawer, Dr. Josh Gilbert, and Dr. Paul 
Clemons processed and analyzed the data. Dr. Andrew Wilson and Dr. Dineo Khabele 
confirmed the response of ML210 and ML162. Ted Liefeld implemented the CTRP 
portal. 
 
 
 
 
In part adapted from Basu, A.; Bodycombe, N.E.; Cheah, J.H.; Price, E.V.; Liu, K. 
Schaefer, G.I.; Ebright, R.Y.; Stewart, M.L.; Ito, D.; Wang, S.; Bracha, A.L.; Liefeld, T.; 
Wawer, M.; Gilbert, J.C.; Wilson, A.J.; Stransky, N.; Kryukov, G.V.; Dancik, V.; Barretina, 
J.; Garraway, L.A.; Hon, C.S-Y.; Munoz, B.; Bittker, J.A.; Stockwell, B.R.; Khabele, D.; 
Stern, A.M.; Clemons, P.A.; Shamji, A.F.; Schreiber, S.L. “An interactive resource to 
identify cancer genetic and lineage dependencies targeted by small molecules”, Cell, 
2013, 154, 1151–1161.1 
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Profiling cancer cell lines against small molecules 
In contrast to the directed approach of finding small-molecule probes for a pre-
defined pathway presented in the previous chapters, unbiased approaches can uncover 
novel hypotheses about all areas of cellular biology. Cancer cell-line (CCL) profiling has 
been employed previously to determine patterns of cancer dependencies. In order to 
identify cancer dependencies and small molecules that can target these dependencies 
directly, we profiled the sensitivity of 242 CCLs against an Informer Set consisting of 
354 small molecules with annotated targets and activities. The results are provided in 
the Cancer Therapeutics Response Portal (CTRP; http://www.broadinstitute.org/ctrp) 
which enables researchers to analyze relationships between features of the CCLs and 
small-molecule sensitivity. 
 In order to profile the CCLs’ sensitivity to small molecules, we first assembled an 
Informer Set of compounds. These molecules targeted several distinct cellular proteins 
and/or had high selectivity for their annotated targets (e.g., rapamycin targeting mTOR2). 
In order to validate possible correlations between genetic features and sensitivity, 
compounds having different structures but the same target protein (e.g., cyclosporin A 
and tacrolimus targeting calcineurin3), and compounds targeting the same family of 
proteins, but with differential selectivity (e.g., histone deacetylase inhibitors4) were 
included. If several compounds with similar target profiles were available, priority was 
given to those in clinical development, strong selectivity data, or with pharmacokinetic 
data, so that drug development based on the discovered dependencies could be 
accelerated. The Informer Set consisted of 36 FDA-approved drugs, 54 clinical 
candidates, and 264 probes (Suppl. Table S5.1 (digital)). 
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 The Cancer Cell Line Encyclopedia collection comprises ~1,000 genetically 
characterized CCLs. This characterization includes gene expression, 
amplifications/deletions, somatic mutations in >1,600 cancer genes, and 
lineage/histological subtypes and is freely available (http://www.broadinstitute.org/ccle). 
We chose subsets of lineages that overlap with The Cancer Genome Atlas and in 
published genome-wide RNAi screens.5 We plated each CCL in its established media at 
a density optimized during assay development (Suppl. Table S5.2j-l (digital)) and 
treated with compounds for 72h at eight concentrations. CellTiter-Glo was used to 
measure cellular ATP levels as a surrogate for viability. The area under percent-viability 
curves (AUC), which is a function of both relative potency and total level of inhibition for 
a compound across CCLs, was computed as a metric of sensitivity (Suppl. Table S5.2 
(digital), Suppl. Figure S5.1).  
 To analyze the sensitivity data, we first looked at the distributions of AUCs across 
all compounds to determine if trends among subpopulations were present (Figure 5.1a). 
Most CCLs show a differential spread of responses across the Informer Set. However, 
CCLs within the hematopoietic and lymphoid lineage and suspension CCLs were often 
more sensitive to compounds tested than other CCLs (Figure 5.1b). To control for 
potential confounding factors arising from this observation, the analyses of AUC 
distributions was divided into sets that included all CCLs, as well as sets that excluded 
specific context-dependent subsets of CCLs (Figure 5.1c, Suppl. Figure S5.1). 
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Figure 5.1. Response of CCLs to Informer Set. Sensitivity of 242 CCLs to small-
molecule probes/drugs was assessed at dose (CellTiter-Glo) and areas under the 
concentration-response curve (AUC) were computed. Data are shown as box plots 
indicating distributions of AUC values for each compound (A) and a heatmap of AUC 
values (scale represents AUC values ranging between 1 (sensitive; red) and 6 
(unresponsive; blue)) (B) for single CCLs (columns) treated with single compounds 
(rows). Missing numerical values in heatmap were imputed using a k-nearest neighbors 
approach. AUC distributions were analyzed by incorporating context-dependent 
exclusions (C) of cell lines (grey bars represent excluded cell lines).  
 
 For each compound across all CCLs and relevant subsets, statistics-based 
enrichment analyses were performed. These analyses combined rank-based and 
parametric tests to identify genetic alterations and cellular features that are significantly 
enriched among sensitive or unresponsive CCLs. All correlations are available as a 
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table (Suppl. Table S5.2 (digital)) and those with statistical significance can also be 
visualized online in the CTRP. 
 
Cancer cell-line profiling identifies known cancer dependencies 
 In order to properly predict novel, clinically relevant cancer dependencies using 
CCL profiling, CCLs have to be a good model of tumor responses. This can only be 
confirmed using patient-derived data under the same treatments. Several known 
relationships between mutations and sensitivity were identified during our effort. Cell 
lines with a BRAF V600E mutation showed increased sensitivity to P-0850, an analog of 
the FDA-approved BRAF-V600E inhibitor vemurafenib (Figure 5.2a).6 Additionally, upon 
inspection of the unresponsive V600E CCLs, the unresponsiveness could be attributed 
to previously identified mechanisms of resistance to vemurafenib: 1) enhanced EGFR 
signaling has been reported to lead to resistance in vemurafenib-treated colon cancers,7 
and the CCL SKMEL28 contains an activating mutation in EGFR; and 2) RKO, a 
colorectal CCL, has been shown to circumvent dependence on BRAF by producing high 
levels of hepatocyte growth factor (HGF), which activates CRAF via MET in an 
autocrine fashion. It has been shown that blocking HGF signaling using a MET inhibitor 
can resensitize the cells to BRAF-V600E inhibition.8,9 Thus, studying nonresponsive 
outliers of other compounds can offer insight into resistance mechanisms. 
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Figure 5.2. Genetic dependencies targeted by small molecules. The distribution of CCL 
response (AUC values) to compound treatment is represented as a heatmap denoting 
sensitivity (red) or unresponsiveness (blue) aligned with genomic alterations for 
corresponding CCLs (gray bars). The CCL profiling identified known clinically drug-
targeted genetic dependencies (A) and known drug-resistance mechanisms (BRAF 
V600E outlier cell lines: *RKO; #SKMEL28). It also suggests dependencies with both 
mutation and copy number variation in MYC (B). Global analysis of the profiled data 
showed EGFR-mutated CCLs are unresponsive to NAMPT inhibitors (C). CNV-H: high-
copy number (>8 copies), TES: all targeted-exome sequencing mutant calls, TES-A: 
targeted-exome sequencing, non-neutral missense mutations; Onco: Oncomap mutant 
calls, MUT: any mutation call.  
 
 Another known dependence is that of NRAS- and KRAS-mutant CCLs to 
selumetinib, a MEK1/2 inhibitor. This compound has shown preliminary moderate 
activity in KRAS-mutant patients during clinical trials (Figure 5.2a).10-12 However, several 
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mutant CCLs are not sensitive to selumetinib, which suggests that factors other than 
KRAS/NRAS might also influence the response. As with P-0850, analysis of 
unresponsive outliers could lead to identification of other biomarkers for selumetinib 
response. 
 When looking at genetic features within specific lineages, more correlations were 
found. For example, neratinib, a dual ERBB2/EGFR inhibitor currently in clinical trials for 
advanced non-small cell lung cancer,13 shows increased potency in EGFR-mutant lung 
CCLs (Figure 5.2a). Therefore, our CCL profiling effort can identify known 
dependencies, but also detect already-known resistance mechanisms. It is thus 
reasonable to expect to discover new insights as well.  
 
Novel hypotheses generated by CCL profiling 
 Several oncogenes are known that have been shown to drive cancers but do not 
yet have targeted therapies. The profiling effort suggests small molecules that could be 
used to exploit the dependencies created by these oncogenes. For example, 
(-)-gallocatechin-3-monogallate (GCG) shows a strong response in CCLs with MYC 
mutations, including those interfering with MYC protein degradation (Figure 5.2b).14 A 
GCG analog, epigallocatechin-3-monogallate, has been shown to decrease MYC 
expression in digestive tract-derive CCLs and mouse tumor models.15,16 Additionally, 
mutations in MYC and amplifications of MYC show sensitivity to an inhibitor of the 
chemokine receptor CXCR2, SB-225002 (Figure 5.2b). This receptor is implicated in 
promoting oncogene-induced senescence.17 Its relationship to MYC biology is not yet 
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well understood, but the correlation of two kinds of genomic alterations to SB-225002 
suggests that further investigations into this connection might be warranted. 
 While the discovery of novel cancer dependencies with sensitivities to small 
molecules is of high interest, attention should also be paid to those molecules where 
mutated genes correlate with unresponsiveness. Several genes showed 
unresponsiveness to many compounds. For example, EGFR-mutated CCLs correlated 
with unresponsiveness to different inhibitors of NAMPT (Figure 5.2c). Additionally, in a 
murine model of KRAS-mutant lung cancer, STK11 has been implicated in resistance to 
docetaxel.18 Similarly, patients with BRAF-mutant metastatic colon cancers show little 
response to EGFR-targeted therapy.19 CCL profiling shows that many cell lines with 
mutations in these genes are unresponsive to a wide variety of compounds. These 
results suggest that mutations, such as those listed above, might cause resistance to a 
wide range of small molecules, and could lead to a more guided approach when treating 
patients with mutations in these genes. 
 
Lineage dependencies of CCLs 
 Apart from genetic features, lineage features also correlated with sensitivity to 
different small molecules. For example, ovarian CCLs were very sensitive to ML210 and 
RSL3, two probes that selectively kill engineered HRAS-mutant CCLs (Figure 5.3a). 
These probes were originally found to selectively kill transformed cell lines BJeLR 
(HRasG12V, SV40 large T and small T antigens) and DRD (HRasG12V, hTERT, SV40 
small T oncoprotein, dominant negative p53, cyclin D1, and mutant CDK4), relative to 
untransformed controls.20 However, mutations in HRAS did not correlate with sensitivity 
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to the compounds. The potency of ML210 against five ovarian CCLs was confirmed, 
using sulforhodamine B to measure cellular protein content as a surrogate for 
cytotoxicity (Figure 5.3b).21 This confirmation included three previously untested CCLs.  
 
Figure 5.3. Lineage dependencies targeted by small molecules. (a) Ovarian CCLs are 
highly sensitive to ML210 and RSL3. (b) An expanded panel of ovarian CCLs showed 
sensivity to ML210 (IC50 ~10 nM) independent of the BRCA1 status of the CCLs. All 
values are shown and generated from three independent experiments run in 
sextuplicate (values are percent-viability score (Experimental Section)).  
  
RSL3 and related compounds kill cells via a mechanism called ferroptosis.22 
They do, however, also appear to promote markers of apoptosis within this context. 
CCLs that are sensitive to these compounds might possibly have features also present 
in the engineered cells described above, which cause this sensitivity to ferroptosis 
modulators. However, in order to test this hypothesis and find these features, more 
CCLs will need to be profiled. Multi-feature correlation analyses may also aid in 
determining features that drive sensitivity. 
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The same oncogene often creates different dependencies in different lineage 
contexts (e.g., BRAF in melanoma vs. colorectal) and the CTRP allows us to identify 
dependencies in all CCLs as well as single lineages. One example is KRAS-mutant 
CCLs, which show significant correlation with navitoclax in colorectal, but not all 
lineages (Suppl. Table S5.2 (digital)). It has been shown that navitoclax synergizes with 
selumetinib to kill KRAS-mutant CCLs, but while some effect can be seen in all lineages, 
the synergy is most pronounced in colorectal CCLs.23 In this study, the authors 
concluded that selumetinib alone in KRAS-mutant CCLs is largely cytostatic rather than 
cytotoxic, explaining the lack of efficacy. Navitoclax however, activates apoptosis and 
induces cell death in combination with selumetinib. In the assay we conducted CCLs 
were treated for 72h and viability was measured in ATP levels, a surrogate for cell 
growth or proliferation. Therefore, relationships between sensitivity and genes involving 
cytostasis may be identified. While they are very sensitive to selumetinib, KRAS-mutant 
CCLs in our study often only show partial inhibition of ATP levels, a sign of cell growth 
inhibition. Thus, combining specific cancer genotype-selective cytostatic compounds 
with other molecules might result in greater efficacy. Corcoran et al. describe a 
screening approach for detecting such combinations. This approach also demonstrates 
that the level of inhibition is important in analyses of existing data and motivates future 
incorporation of assays for cell death into data collection.23 
While our approach mostly associates sensitivity to small molecules with single 
features, multiple features can be influencing a CCLs response to a compound. This 
fact can cause challenges in interpreting whether a factor is causal. For instance, many 
hematopoietic/lymphoid CCLs show more sensitivity to many compounds than other 
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lineages. One example is MYC-mutant CCLs which are very sensitive to the BRD4 
inhibitor JQ-1, but many of which are also hematopoietic/lymphoid CCLs. It is unclear 
whether the genetic or the lineage feature determines sensitivity more. A larger set of 
mutant CCLs will be necessary to study the mutations separately within 
hematopoietic/lymphoid and solid tumor CCLs. In general, the CTRP allows for this kind 
of analysis. One example is SB-225002, which shows good potency in MYC-amplified 
CCLs, no matter if all lineages or only those from solid tumors are analyzed. 
 
Global clustering of compounds 
 As we had included structurally different compounds with similar mechanisms of 
action, we wanted to see in a global analysis what insights about dependencies we 
could gather studying connections between genes and sets of compounds. To ensure 
that these clustering experiments were not dominated by relatively weaker connections, 
we limited the analyses to those with false discovery rates (FDR) of q<0.025. We used 
hierarchical clustering of compounds based on connections to genetic features profiles 
(Suppl Table S5.3 (digital)). Several compounds with similar mechanism of action 
clustered together, such as: PRIMA-1 and PRIMA-1-Met (re-activators of mutant p53 
signaling), FK866 and GMX-1778 (NAMPT inhibitors), neopeltolide and 
leucascandrolide A (modulators of respiration), and teniposide and etoposide 
(topoisomerase inhibitors) (Suppl. Figure S5.2). The fact that small molecules with 
similar mechanism of action result in similar CCL responses also shows that the data is 
consistent and repeatable.  
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Other CCL profiling efforts 
CCLs have been used as model systems for human cancer for several decades, 
but CCL profiling is a more recent development. Several large-scale efforts have been 
implemented, often with different selection of CCLs, growth conditions, data collection 
(e.g., readouts), data filtering (e.g., for potentially confounding CCLs) and analysis, and 
formulation of questions in controlled computational experiments. This may lead to 
different results and interpretations. It is encouraging that using our approach, known 
connections (e.g., KRAS-NRAS/selumetinib, BRAF/V600E inhibitors) can be identified. 
While not all correlations with sensitivity overlap between ours and others’ studies, there 
is a significant overlap in the results. For example, Garnett et al. also identified novel 
connections between GW-843682X, a PLK1 inhibitor and CDKN2A (sensitivity) and 
nutlin-3 and TP53 (unresponsiveness),24 showing that results are reproducible. 
Connections that differ between studies (e.g., NOTCH1/navitoclax (Garnett et al.) vs 
CTNNB1/navitoclax (CTRP)) demonstrate that care should be used when interpreting 
the data, putting emphasis on interpretation within the given parameters and confirming 
conclusions with well-designed follow-up studies. 
 
Conclusion 
CCL profiling enables us to identify novel cancer dependencies, small molecules 
to target them, and insights into unresponsiveness or resistance to certain compounds. 
Known dependencies were detected, and many other can be discovered. This profiling 
effort employed an Informer Set of small molecules that not only targeted mutations 
directly, but also non-altered proteins that CCLs have developed dependencies on. This 
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approach of targeting cancer differs from a related targeting of ‘non-oncogene 
addictions’, or “hallmarks” of cancers,25 which does not pay attention to specific 
genomic alterations.26  
With more CCLs and compounds being profiled, the predictions that can be 
made from the data will grow stronger. New probes and drugs, as well as combinations 
of compounds, across a larger set of CCLs will expand the number of hypotheses 
generated. Additionally, new analyses of the existing data can also uncover novel 
hypotheses, especially when including other cellular features such as gene expression, 
metabolic, proteomic, and epigenetic profiles.  
 
Experimental Section 
Materials and Methods  
Cell Lines and Reagents: cells were purchased from the Broad Institute 
Biological Samples Platform or ATCC (Manassas, VA, USA). All CCLs were grown at 
37°C/5% CO2 in their specified medium (Suppl. Table S5.2 (digital)). All CCLs were 
tested for mycoplasma using a Takara PCR Mycoplasma Detection Kit (Otsu, Japan). 
Media components and supplements were purchased from ATCC (VA, USA), Cellgro 
(VA, USA), Life Technologies (Carlsbad, CA, USA), EMD Millipore Chemicals (Billerica, 
MA, USA), or Invitrogen (Carlsbad, CA, USA).  
Assay Treatments and Readouts: 354 small molecules were assembled for the 
Informer Set after careful evaluation of probe-development literature (seminars, journals, 
NIH Molecular Libraries Initiative Probe Reports, and patents). These molecules perturb 
targets and processes on which cancer cells may become dependent. They were 
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purchased from Active Biochem (Maplewook, NJ, USA), AnalytiCon (Potsdam, 
Germany), Asinex (Winston-Salem, NC, USA), Avanti (Alabaster, AL, USA), Axon 
MedChem (Reston, VA, USA), BioVision (Milpitas, CA, USA), Cayman Chemicals (Ann 
Arbor, MI, USA), Cellagen (San Diego, CA, USA), ChemBridge (San Diego, CA, USA), 
ChemDiv (San Diego, CA, USA), Chemietek (Indianapolis, IN, USA), EMD Millipore 
Chemicals (Billerica, MA, USA), Enamine (Monmouth Jct, NJ, USA), Enzo Lifesciences 
(Farmingdale, NY, USA), Fermentek (Jerusalem, Israel), InterBioScreen (Moscow, 
Russia), LC Laboratories (Woburn, MA, USA), Maybridge (Trevillet, UK), Medkoo 
(Chapel Hill, NC, USA), MicroSource (Gaylordsville, CT, USA), Princeton Biomolecular 
Research (Princeton, NJ, USA), Selleck (Houston, TX, USA), Sigma-Aldrich (St Louis, 
MO, USA), Specs (Delft, Netherlands), Symansis (Timaru, New Zealand), Tocris (Bristol, 
UK), Toronto Research Chemicals (North York, ON, Canada), Vitas-M (Moscow, 
Russia), WuXi AppTec (Shanghai, China), synthesized by Broad internal chemists, or 
provided directly by external collaborators. A list of all compounds, with annotated 
targets and structures, is provided (Suppl. Table S5.1 (digital)). CellTiter-Glo reagent 
was purchased from Promega (Madison, WI, USA). Plate Reader instruments and 
settings used were: luminscence settings (384-well): Perkin Elmer (Waltham, MA, USA) 
Envision 2104 Multilabel Plate Reader, luminescence mirror, luminescence 700 
emission filter, 0.1 s measurement time, 6.5 mm measurement height. Absorbance (510 
nm) settings: Molecular Devices Spectramax M5 spectrophotometer (Sunnyvale, CA, 
USA), absorbance wavelength: 510 nm. Compounds were pin-transferred using a 
CyBio (Jena, Germany) Cy-Bi Well Vario. 
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Assay Protocols 
Assay development: To determine the optimal plating density for profiling, 
treatment of each CCL with staurosporine at various densities was measured using 
CellTiter-Glo. CCLs were plated at 500-2,000 cells/well (adherent) or 500-5,000 
cells/well (suspension) in opaque, white 384 well plates at 30 L/well in their specified 
medium (Suppl. Table S5.2 (digital)). Cells were incubated for 24 h at 37°C/5% CO2 and 
pinned with various concentrations of 100 nL/well staurosporine (16-pt, 1.67-fold dilution 
series, 16 replicates/concentration). The plates were subsequently incubated at 37°C/   
5% CO2 for 72 hours. After the incubation period was over, the plates were removed 
from the incubator and allowed to come to room temperature. Subsequently, 30 L of a 
1:2 dilution of CellTiter-Glo reagent in PBS was added to each well and the plates were 
shaken at room temperature for a few seconds. The plates were then incubated at room 
temperature for at least 10 min and read out using luminescence settings (384-well).  
Cancer Cell-Line (CCL) Profiling: CCLs were plated at the density optimized 
during assay development in opaque, white 384 well plates at 30 L/well in their 
specified medium (Suppl. Table S5.2 (digital)). Cells were incubated for 24 h at 37°C/   
5% CO2 and pinned with compound plates (8-pt, 2-fold concentration ranges as defined 
by literature review, each compound plate was pinned against two assay plates) at 100 
nL/well. The plates were subsequently incubated at 37°C/5% CO2 for 72 hours. After 
the incubation period was over, the plates were removed from the incubator and 
allowed to come to room temperature. Subsequently, 30 L of a 1:2 dilution of CellTiter-
Glo reagent in PBS was added to each well and the plates were shaken at room 
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temperature for a few seconds. The plates were incubated at room temperature for at 
least 10 min and read out using luminescence settings (384-well).  
Confirming sensitivity of ovarian CCLs to ML210: Five ovarian CCLs, SKOV3, 
OVCAR8, NCI/ADR-RES, UWB1.289 (BRCA1 null), and UWB1.289+BRCA (stably 
expressed BRCA1-WT) CCLs were plated at 2,000 cells/well in opaque, white 384 well 
plates in their specified medium (Suppl. Table S5.2 (digital)). Cells were incubated for 
24 h at 37°C/5% CO2 and pinned with compound plates (four concentrations of ML210) 
at 100 nL/well. The plates were subsequently incubated at 37°C/5% CO2 for 72 hours. 
After the incubation period was over, cell viability was assayed using a sulforhodamine 
B assay as previously described21 with minor modifications for seeding at the chosen 
density. The plates were read out using absorbance (510 nm) settings. Three 
independent runs were performed with six replicates at each compound dose for each 
run. 
 
Data Analysis 
Assay development: Mock treatments for each plate were averaged and used to 
calculate a percent response for each staurosporine treatment concentration on the 
corresponding plate. Percent responses were averaged for each concentration point at 
each cellular density and standard deviation was measured. Z’ factors were calculated 
at each concentration point and compared between the cellular densities. Densities with 
the largest dynamic detection window (percent inhibition minimized when Z’ = 0; if 
several densities were similar, lower confluency was the deciding factor) were taken as 
optimized seeding density. 
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AUCs were used to calculate sensitivity summary scores (as described below). 
Variability in the AUC potentially stemming from using different cell densities across 
CCLs was calculated to be of the same magnitude as day-to-day variability in AUCs. 
Thus, performing the assays at densities with robust signal detection was favored. 
Data processing: A compound-performance score (D-score) was computed for 
each concentration of compound.27 This score expresses effect size as a weighted 
average of differences between control and treatment, and, by estimating how likely it is 
that an observed effect size is different from effects expected for mock-treatment 
(DMSO) in the assay, statistical significance. Using any number of replicates of a 
compound treatment across plates and days, the method of maximum likelihood 
combines these into the weighted average and its uncertainty. The D-score is the ratio 
of difference to the uncertainty, a normalized value for each compound in an assay. 
This weighted average was computed on log-transformed small-molecule sensitivity 
data and an appropriately weighted average of ratios (i.e., weighted fold-change) of 
compound-treated to mock-treated wells was obtained. After re-exponentiation, this 
number was used as percent-viability score. Dose-response curves of percent-viability 
scores were fit using the MATLAB curve-fitting tool box (smooth cubic splines for 
multivariate data). Areas-under-curve (AUCs) for each compound were used as a 
measure of sensitivity in subsequent enrichment and regression analyses. 
Genetic data: Annotations of CCLs are publicly available 
(http://www.broadinstitute.org/ccle). This includes gene expression (Affymetrix 
GeneChip Human Genome U133 Plus 2.0 Array), copy number (Affymetrix Genome-
Wide Human SNP Array 6.0), and mutation status from hybrid capture followed by 
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massively parallel sequencing of >1,600 genes and from mass spectrometric 
genotyping (OncoMap) for 492 mutations in 33 oncogenes/tumor suppressors.28 
Genetic diversity was illustrated by analyzing frequency distributions of number of 
genes across all CCLs and the number of unique lesions for each gene (Suppl. Figure 
S5.1) 
Enrichment analysis: p-values that quantify the enrichment of genetic alterations 
relative to ranked sensitivities measured for a single compound across many CCLs 
were calculated using a sorting-based enrichment-scoring algorithm.29 The p-value for 
each compound and each genetic feature corresponds to the likelihood of seeing that 
pattern of alterations (or a stronger one) enriched among the ranked sensitivities by 
chance. However, these scores do not take the relative or absolute potency of the 
compound into account. Thus, we initially observed many connections with significant p-
values, but when looking at the sensitivity distributions, the compounds did not exhibit 
patterns that we were interested in (e.g., all unresponsive). 
This issue was addressed by several steps: 1) filtering out compounds which did not 
show a desirable range of sensitivities. Three filtering criteria were used here: (i) for 
sensitive or resistant enrichments, the AUC ≤ 3.5 or AUC ≥ 5.5 (AUC=7 corresponds to 
no compound effect) for at least one CCL respectively, (ii) AUChighest – AUClowest ≥ 3.0, 
(iii) at least one CCL harboring the genetic feature was tested with the compound; 2) a 
parametric chi-squared test of homogeneity to account for the absolute potency of each 
compound in relation to the distribution of genetic alterations was performed, producing 
a list of potential cancer dependencies with statistical significance with the desired 
compound sensitivity performance. 
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The maximum (worst case) of the two p-values from the non-parametric and parametric 
tests was squared to obtain a significance score for subsequent multi-test correction 
and ranking. To control for multiple hypothesis testing, the Benjamini-Hochberg 
procedure30 was applied within each family of hypotheses (different genetic or lineage 
features sharing a measured AUC distribution). This generated q-values (adjusted 
squared maximum p-values). A false-discovery rate (FDR) cutoff of q < 0.25 was 
applied for Suppl. Table S5.2 (digital), and a more stringent one for the CTRP. 
CCL sub-population analysis: As not all lineage-based sub-populations and 
excluded sub-populations actually required consideration, we checked each lineage and 
sub-lineage by itself, as well as combinations of different lineages and exclusions before 
including them in our analysis. Two steps were taken to assess whether certain sub-
populations of CCLs have non-compound-specific sensitivity characteristics that 
confound our enrichment analyses: 1) identify these sub-populations, regardless of 
specific genetic lesions; 2) determine the influence on the enrichment analyses if 
various sub-populations are analyzed separately vs together. 
Identification of potentially confounding sub-populations: Komolgorov-Smirnov 
(K-S) tests were performed for qualitative (categorical exclusions), asking whether the 
exclusion of growth conditions (adherent, suspension, mixed) or individual lineages had 
significant effects on AUC distributions. Excluding suspension CCLs and excluding 
hematopoetic CCLs was found to be significant (pKS < 3.67×10
-9 and pKS < 2.34×10
-10, 
respectively). 
In order to determine a threshold to identify CCLs with statistically large numbers of 
mutations, it was assumed that these CCLs would have a different sensitivity 
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distribution than all other CCLs. The difference between distributions of CCL sensitivity 
between the i most-frequently-mutated CCLs and the remainder was determined using 
a collection of i two-distribution K-S tests, subject to Bonferroni correction, was used. 33 
CCLs were determined to have ‘genes mut high’, meaning they harbored a fraction of 
mutations greater than the most significant K-S test (pKS < 1.63×10
-11). 
To identify CCLs that were sensitive to many compounds, a similar analysis was done, 
but many K-S test significance values exceeded machine precision. 32 CCLs were thus 
termed ‘frequently sensitive’, meaning that they were sensitive to more than 25% of the 
small molecules. These subsets of CCLs were excluded for parts of the enrichment 
analyses. 
To include a lineage or sub-lineage in the analysis, more than 3 CCLs present in the 
dataset had to be of that lineage or sub-lineage. For lineage and exclusion combination 
analysis, combinations were included if at least 3 CCLs passed one of the four 
exclusion criteria and were present in the respective lineage or sub-lineage. Of the lung 
lineage, the following sub-lineages were tested: adenocarcinoma, broncheoalveolar 
carcinoma, large cell carcinoma, non-small cell carcinoma, small-cell carcinoma, and 
squamous cell carcinoma; and of the hematopoietic lineage: acute myeloid leukemia, 
diffuse large B-cell lymphoma, plasma cell myeloma. 
Global Analysis: Including all lineage/sub-lineage connections, and exclusions 
across all datasets, 397,270 enrichments were identified. Each pair of scores was 
considered using each exclusion and for each compound-gene connection. The score-
pairs were conceptualized as falling into interpretable regions of a scatterplot indicating 
if connections were improved, preserved, or diminished upon running the corresponding 
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exclusion experiment. The number of score-pairs for each region in the scatterplot was 
compared to a randomly permuted score matrix. Only excluding suspension or 
hematopoietic CCLs is independent of the sensitivity data, and thus, only these two 
exclusions were used to qualify connections for the global analysis. If a connection 
improved or preserved when both suspension and hematopoietic lines were excluded, 
the best-scoring connection was used. If either exclusion reduced the connection, the 
reduced score was used, and if either exclusion caused the connection to become 
insignificant, it was removed. Additionally, connections with contradictory scores 
between exclusions and/or the primary analysis were removed. If the same compound-
gene connection was enriched in several datasets, only the best-scoring connection 
was kept. This resulted in a set of connections dominated (in number) by connections 
with relatively weaker q-value scores. Therefore, connections with <3 mutations, <3 
sensitive mutants, or <3 unresponsive mutants, as well as connections where more than 
half of CCLs tested were mutant CCLs, were excluded. The global analysis was thus 
run on 108,635 candidate compound-gene connections. 
To retain the strongest gene-compound connections and protect against type I errors, 
the optimal threshold for a more stringent q-value was determined. This was done by 
varying the q-value between 0 and 0.25 and observed the changes in the number of 
connections in the fraction of remaining connections. These changes were small (i.e., 
relative stability in the connection list was achieved) at a cutoff of q<0.025, which was 
used to determine 16,667 distinct compound-gene connections that qualified for further 
analyses. 
The frequency, sum of scores, and average scores for each gene and compound was 
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calculated individually in both sensitive and unresponsive directions (Suppl. Table 
S5.3a-d (digital)). The number of overlapping genes and compounds and their 
significance (by hypergeometric distribution) was computed for each pair of compounds 
and genes, respectively (Suppl. Table S5.3e-h (digital)). Subsequently, complete-
linkage clustering analysis on the compounds was performed using a cosine similarity 
distance based on the presence or absence of a connection between each compound 
and gene (binary calls) (Suppl. Table S5.3i (digital), Suppl. Figure S5.2). For each gene 
where the compound connection score with the gene ≠ 0, a weight was calculated 
within each cluster. This weight was proportional to the fraction of compounds to which 
the gene connection, e.g., if a gene connected to all (half of all) compounds in a cluster, 
then the weight for that gene was 1 (0.5). The mean q-score of the gene across all 
compounds in the cluster was multiplied with the weight per gene, and the products 
summed. A random score for a cluster of size n over 100 iterations was computed to 
determine the significance of the calculated score. The reported score (Suppl. Table 
S5.3i (digital)) is (si – µrandom,n)/σrandom. All non-zero genes that were associated with 
each reported cluster of compounds and their respective weights (Suppl. Table S5.3j 
(digital)) are also reported. The same was done for the lineage-specific analysis where 
46,175 total qualified connections (involving >2 mutants, >2 examples (across all 
datasets) were used, resulting in 12,518 distinct gene-compound connections. 
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Chapter Six 
 
Mining the cancer dependency resource for novel 
dependencies in recurrently-mutated and fusion genes 
 
 
The Chemical Biology Program and Platform led by Dr. Josh Bittker, Dr. Jaime Cheah, 
Matthew Coletti, Victor Jones, Edmund Price, and Christian Soule collected the data for 
the Phase 2 profiling effort. Dr. Paul Clemons and Nicole Bodycombe processed the 
data. Dr. Michelle Stewart and I collaborated on this project. Together, we prepared the 
input list for recurrent mutations. Dr. Stewart lifted the TCGA files that were in hg18 to 
hg19 and I annotated all mutations in our TCGA and CCLE data files with advice from 
Dr. Lee Lichtenstein. We both analyzed the overlap and determined the list of recurrent 
features to test. Dr. Stewart ran the enrichment analysis of recurrent genes. Dr. Stewart 
and I together picked and retested the CCLs for their response to PI3K and AKT 
inhibitors. I compiled the list of fusion genes and Dr. Clemons ran the enrichment 
analysis for them. 
 
 
 
 
 
 
 140 
 
Expanding the CTRP dataset 
The 242 cancer cell lines (CCLs) profiled in the last chapter already gave rise to 
a number of hypotheses for novel cancer dependencies. Increasing numbers of CCLs 
and compounds profiled will allow more insight into possible dependencies. The 
Chemical Biology Program and Platform at the Broad Institute have engaged in a 
second profiling effort to test 893 human CCLs in 1,536-well format with an Informer Set 
of 495 single agent small molecules and 50 combinations (Suppl. Table S6.1 (digital)), 
the data of which will be publicly available on the CTRP 
(http://www.broadinstitute.org/ctrp). Mining this dataset has uncovered novel challenges 
in interpreting the data and overcoming these has led to new analyses and promising 
hypotheses. 
 
Frequencies of small-number-mutant enrichments 
 When interpreting enrichments from the CCL profiling, the number of mutated 
CCLs per enrichment is an important feature to consider for analysis. Many of the 
enrichments are based on a small number of cell lines that have the enriched feature. 
For example, of the 397,270 enrichments in Suppl. Table S5.2 (digital), 97,781 have a 
single mutant CCL and 87,595 have two mutant CCLs (Figure 6.1a). Often, the CCLs 
with these mutations are not the only sensitive ones and little is known about the impact 
the specific mutations have. Additionally, for many of the enriched features, the 
mutations occur in the same gene, but not at the same amino acid position. Therefore, it 
is not guaranteed that they have the same biological impact. These factors make it hard 
to interpret whether mutations in the enriched gene are the deciding factor for sensitivity. 
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Enrichments with less than three mutant CCLs were therefore excluded for the online 
CTRP. Still, 50% of the remaining enrichments are with smaller numbers of mutant-
CCLs (3-5, Figure 6.1b), and the interpretation challenge remains, especially with 
mutations that lack understanding of biological function. While these might still harbor 
interesting insights which could be explored by trial and error, systematic prioritization of 
enrichments could expedite the discovery of relevant hypotheses. 
Figure 6.1. a) number of enrichments generated in the CTRP shown by number of the 
respective mutant CCLs tested. b) percentages of enrichments generated in the CTRP 
shown number of respective mutant CCLs tested (out of all enrichments for features 
where >2 CCLs with the feature were tested). 
 
Finding biologically relevant mutations 
With this challenge in mind, we thought about ways to prioritize enrichments in 
the data. The CCLE analyzed >1,600 genes known to be frequently mutated in cancer.1 
While some of the mutations in these genes are well-known oncogenes (e.g. KRAS G12 
mutations), the function of many of these mutations is unknown. Some of these 
mutations might have a direct impact on cancer biology (driver mutations), but many 
might also be passenger mutations that do not contribute to tumor development.2,3 The 
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CCLE also captured germline variants, which might account for some of these single 
mutations. Additionally, given that many CCLs have been cultured for decades, it is also 
likely that they acquired mutations over time that patient tumors have not had the time 
to acquire. Consequently, it is known that CCLs have different genetic characteristics 
than patient tumors.4-7 Therefore, one challenge when working with the mutations in 
CCLs is defining which mutations are relevant to tumor biology. In order to sort out 
which mutations are biologically relevant, and which ones are not, we decided to restrict 
the mutations we would look at in two ways: 1) mutations had to have been found in 
patients and 2) mutations had to be recurrent. 
 
CCLE and TCGA dataset overlap 
 The rationale behind limiting ourselves to mutations that are present in patients is 
that if a mutation was caused by extended cultivation in vitro, but has no impact on 
actual tumor biology, it is very unlikely that this mutation would occur in patients as well. 
The patient-derived data was taken from the The Cancer Genome Atlas (TCGA). These 
samples are taken directly from patients and matched with non-cancerous tissues of 
each patient to determine somatic mutations.8 Therefore germline variants would not be 
captured. The mutations in these samples should be more relevant to cancer biology, 
even though some confounding factors, such as random passenger mutations, will also 
exist in them.  
We first set out to determine the overlap of mutations that occur between the 
CCLE and the TCGA datasets. For this purpose, we downloaded all available TCGA 
datasets using the Broad Institute’s Cancer Genome Analysis (CGA) group Firehose 
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tool (http://www.broadinstitute.org/cancer/cga/firehose) as well as the mutational data of 
the CCLE oncomap and hybrid capture datasets.1,9 In order to make sure that all 
mutations were annotated using the same human genome (hg) reference batch and 
protein call, we removed all annotated protein mutation information. We then transferred 
hg18 data to hg19 data using the University of Santa Cruz’s LiftOver Tool 
(http://genome.ucsc.edu/cgi-bin/hgLiftOver).10-12 Subsequently, we annotated all 
mutations into protein changes using the chromosome, start and end positions, mutated 
allele and reference allele for all samples. This was done using the Broad Institute’s 
Oncotator Tool (www.broadinstitute.org/cancer/cga/oncotator).13 We also filtered the 
TCGA data to only include the 1,667 genes that are contained in the CCLE. 
 We then determined how many mutations overlapped using two ways of 
classifying mutations: by exact protein change (e.g. KRAS G12D) and by amino acid 
location (e.g. KRAS G12, mutation could result in any amino acid) (Table 6.1). The 
percentage of CCLE mutations that overlapped with the TCGA is low, but does increase 
when recurrent mutations are examined. The CCLE dataset has many more mutations 
per sample, which could be due to the capturing of private germline variants, and 
extended growth in vitro. Therefore, limiting the mutations to those present in patient 
data could exclude some of these confounding factors. 
 
Recurrent mutations 
The second restriction we used was that mutations had to be recurrent. It has 
been shown that some CCLs are hypermutated and it has been suggested that care 
should be exercised in picking CCLs as models for tumor studies.4 
 144 
 
Table 6.1. overlap between the CCLE and TCGA datasets by protein change and 
location 
number of 
mutations 
TCGA 
(4352 
samples) 
CCLE 
(957 
samples) 
overlap if 
> x in both 
% CCLE 
data 
overlap if 
in TCGA 
% CCLE 
data 
protein change      
all 126835 53564 3940 7.4 
  
> 1 6902 4111 346 8.4 758 18.4 
> 2 1339 1093 149 13.6 328 30.0 
       
location change 
     
all 117466 51516 8254 16.0 
  
> 1 12342 4973 515 10.4 1327 26.7 
> 2 2370 1237 188 15.2 463 37.4 
  
Many studies have been done on the functional impact of recurrent mutations, 
and recurrent mutations are considered to be biologically relevant.14,15 These mutations 
are not only random mutations, and, if they also happen in patient samples, they were 
most likely were selected for by a factor of tumor biology.  
When studying recurring mutations in the CCLE sample, it became clear that 
there are a number of recurrent mutations that occur in a majority of the CCLs (Figure 
6.2a). However, this frequency of recurrent mutations is not reflected in the TCGA data 
(Figure 6.2b) and many of these mutations do not occur in that dataset at all. Some of 
these could be due to sequencing artifacts, which is especially supported given many of 
them are splicing mutations, insertions, or deletions, which are known to be challenging 
to capture correctly.16 Given that many CCLs have been cultured for decades, it is also 
possible that they acquired additional mutations over time that patient tumors have not 
had the time to acquire, or that part of the selection that lets these cells grow in vitro 
requires them to have more mutations in certain genes. Many of the recurrent TCGA 
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Figure 6.2. a) most frequent mutations in CCLE samples. b) most frequent mutations in 
TCGA samples. c) all frequently mutated (> 10) samples in TCGA. Red bars correspond 
to mutations not present in the CCLs.  
 
mutations are well-known to drive cancer. With few exceptions (e.g., the silent MLLT3 
S167S mutation, or NPM1 W288fs mutations), these are also present in CCLs (Figure 
6.2c). Therefore, the CCLE dataset covers most of the main recurrent mutations found 
in tumors and we also chose to restrict our dataset to recurrent mutations. 
 
Enrichment analysis with recurrent mutations and fusion genes 
 Since the CCLs seem to have many mutations that are not present in patient 
samples, prioritizing mutations which overlap between the datasets might give us more 
relevant hypotheses. Additionally, overlapping, recurrent mutations seem to be 
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biologically very relevant. We therefore decided to run the enrichment analysis with two 
new sets of features: 1) all genes with those mutations that also exist in patient data and 
2) all genes with specific recurrent (present in > 2 CCLs tested) mutations in CCLs that 
are also recurrent (> 2 samples) in patient data. We again considered both protein 
change and location as two different sets of features. As CCLs from the 
hematopoietic/lymphoid lineage were generally very sensitive to compounds (Chapter 
5), we decided to exclude them for the purpose of this enrichment.  
One caveat in restricting the dataset in this manner is that there might be more 
mutations in patients that are actually represented in the CCLE dataset, but that are 
being excluded with the current restriction. As more patient samples become available, 
it might therefore be useful to repeat this analysis, as connections with these other 
biologically relevant mutations could exist.  
 Another dataset that was not considered in the original set was that of fusion 
genes. Fusion genes are often involved in cancers and can be strong drivers.17 
Unfortunately, full characterization of fusion genes was not available for the CCLs. The 
Sanger Catalogue of Somatic Mutations in Cancer (COSMIC, www.cancer.sanger.ac.uk) 
has characterized CCLs for some fusion genes that are known to drive cancer.18,19 I 
decided to incorporate this data into the enrichment analysis for those fusion genes for 
which data existed.  
 
Known dependencies are found in the enrichment 
 The enrichment analysis for these three new sets of features gave a large 
number of possible new cancer dependencies (Table 6.2, Suppl. Table S6.2 (digital)). 
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Table 6.2. selected enrichments from new analysis 
compound 
compound 
target 
enrichment 
FDR  
q-value 
heatmap 
vemurafenib 
BRAF 
V600E 
BRAF 
V600E 
1.18·10-21 
 
selumetinib MEK 1/2 
KRAS 
G12 
2.03·10-5 
 
PD318088 MEK1/2 
KRAS 
G12 
9.91·10-5 
 
PD318088 MEK1/2 
NRAS 
Q61 
1.14·10-4 
 
gefitinib EGFR 
EGFR 
location 746 
7.6·10-3 
 
GDC-0941 PI3K 
PIK3CA 
E542K 
1.25·10-3 
 
BYL-719 PI3K- 
PIK3CA 
E542K 
1.04·10-3 
 
AZD6482 PI3K- 
PIK3CA 
H1047R 
3.10·10-2 
 
MK-2206 AKT 
PIK3CA 
E542K 
2.13·10-2 
 
clofarabine 
POLA1/2/E; 
RRM1 
CDC25C 
K244fs 
8.55·10-3 
 
NVP-231 CERK 
CDC25C 
K244fs 
7.86·10-3 
 
austocystin D 
cytotoxic/ 
P450 
activation 
ACVR2A 
K435fs 
2.34·10-2 
 
   legend: 
 
 
The analysis did discover known dependencies of recurrent mutations. For example, 
BRAF V600E-mutant CCLs are very sensitive to vemurafenib, an FDA-approved 
V600E-targeted BRAF inhibitor.20 Other BRAF inhibitors (e.g. PLX-4720, GDC-0879, 
dabrafenib) also show this enrichment of V600E-mutant CCLs (Suppl. Table S6.2 
(digital)). CCLs with mutations in KRAS amino acid position 12 are enriched for the 
MEK 1/2 inhibitor selumetinib, a compound that has shown activity in patients with 
KRAS-mutant cancer.21 Both KRAS G12 and NRAS Q61-mutated CCLs are also 
1 107.5
AUC
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enriched for another MEK1/2 inhibitor, PD318088.22 MEK inhibitors have shown activity 
in patients with KRAS- or NRAS-mutant cancers.23,24 Additionally, CCLs with mutations 
(deletions) in amino acid position 746 of EGFR, show enhanced sensitivity to EGFR 
inhibitors such as gefitinib, as reported.25,26  
 
Some compounds are only effective in CCLs with specific mutations  
When looking at the data, it becomes apparent that some compounds enrich more in 
CCLs with specific mutations rather than all mutants. For example, the PI3K-pan and -
inhibitors GDC-0941 and BYL-719, show enrichment with PIK3CA E542K-mutated 
CCLs, but not with other PI3K mutations (Table 6.2, Figure 6.3a). In contrast, the PI3K 
-inhibitor AZD6482 shows enrichment for PIK3CA H1047R-mutated cell lines (Table 
6.2, Figure 6.3a). GDC-0941 and BYL-719 are in clinical trials for a variety of cancers27 
and AZD6482 has been tested for safety and tolerability.28 While patients in other 
clinical trials have been stratified by PIK3CA mutations in exon 9 (e.g. E542K, E545K), 
or exon 20 (e.g. H1047R),29 the specific locations have not been distinguished and 
neither compound has been connected to specific PIK3CA mutations. If this hypothesis 
holds up, these compounds should preferentially be given to patients with the respective 
PIK3CA mutations. Another compound that shows enrichment with PIK3CA E542K 
mutant CCLs is the AKT inhibitor MK-2206 (Table 6.2, Figure 6.3).30 PI3K and AKT are 
in the same pathway.31,32 It is therefore possible that certain PIK3CA mutations 
influence AKT signaling in different ways. 
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Figure 6.3. Heatmaps for recurrent and all mutations of connections to PIK3CA (a) and 
CDC25C, TNKS2, ACVR2A (b). 
 
More hypotheses that might be of high interest to follow-up on can be found in 
the new enrichment analysis. For example, CCLs harboring 244fs mutations in CDC25C 
are very sensitive to clofarabine, a DNA-polymerase and ribonucleotide reductase 
inhibitor (Table 6.2, Figure 6.3b).33 This compound is already FDA-approved for a 
variety of leukemias.34 Like DNA polymerase, CDC25C is involved in cell division35 and 
this connection could point towards a dependency of CDC25C 244fs-mutant CCLs on 
mitotic processes. Similarly, CCLs harboring this mutation are also very sensitive to 
NVP-231, a ceramide kinase inhibitor.36 Ceramide kinase produces ceramide-1-
phosphates which have been shown to stimulate DNA synthesis.37,38 Another 
connection that the new enrichment analysis suggests is that of ACVR2A 435fs-mutant 
CCLs to austocystin D (Table 6.2, Figure 6.3b). This compound has been shown to be 
selectively activated into a cytotoxic derivative in CCLs with high cytochrome P450 
expression.39 Activin signaling has been shown to interact with different cytochrome 
GDC-0941:
PIK3CA E542K
PIK3CA E545
PIK3CA H1047
BYL-719:
PIK3CA E542K
PIK3CA E545
PIK3CA H1047
MK-2206:
PIK3CA E542K
PIK3CA E545
PIK3CA H1047
AZD6482:
PIK3CA H1047R
PIK3CA E542K
PIK3CA E545
A B
clofarabine:
CDC25C K322fs
CDC25C all mutations
NVP-231:
CDC25C K322fs
CDC25C all mutations
Austocystin D:
ACVR2A K435fs
ACVR2A all mutations
1 107.5
AUC
legend:
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P450 enzymes, both in activating and inactivating functions.40,41 It is possible that the 
frameshift mutations in ACVR2A influence the expression of the enzymes responsible 
for austocystin D activation and thus cause selective killing of these cells.  
 
Retesting PIK3CA-mutant sensitivity 
In order to test the PIK3CA-mutant sensitivity hypotheses, we retested a panel of 
PIK3CA mutant CCLs in 384-well format against these inhibitors. We added several 
other PI3K/AKT inhibitors to the test: BKM120, a pan PI3K inhibitor, CH5132799, a 
PI3K- inhibitor, and GDC-0068, an AKT inhibitor.42-44 We also added one previously 
untested PIK3CA E542K-mutant CCL, BT483. We tested each cell line at 2000 
cells/well, a density that was similar to that used in 1,536 well-format, and at an 
optimized density determined during assay development (Table 6.3). 
In retesting, the trend of PIK3CA E542K mutants being more sensitive than other 
PIK3CA mutants to pan-PI3K or PI3K- inhibitors was confirmed (Figure 6.4a-d, Suppl. 
Figure S6.1). However, the data does not support the original result for AKT inhibitors 
strongly (Suppl. Figure S6.2). The trend of PIK3CA H1047R-mutant CCLs to be more 
sensitive to the PI3K- inhibitor AZD6482 was also confirmed (Figure 6.4e, f). However, 
at optimized densities, there are several non-PIK3CA H1047R-mutant CCLs that are 
more sensitive than the mutant CCLs. This could mean that the hypothesis is incorrect 
and other factors, such as seeding density, influence sensitivity which needs to be 
investigated in further follow-up studies.   
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Table 6.3. CCLs used for PI3K-retest and densities used. 
CCL Lineage 
PIK3CA 
mutation 
optimized density 
(cells/well) 
BC3C urinary tract E545K 500 
BT20 breast H1047R 1000 
BT483 breast E542K 2000 
CAL29 urinary tract H1047R 500 
CAL51 breast E542K 1000 
HCC202 breast E545K 2000 
HCT116 large intestine H1047R 500 
HCT15 large intestine E545K 500 
HCT8 large intestine E545K 250 
HGC27 stomach E542K 500 
HT1197 urinary tract E545K 500 
IM95 stomach E542K 1000 
LS180 large intestine H1047R 1000 
MDAMB361 breast E545K 2000 
MDAMB453 breast H1047R 1000 
MKN1 stomach E545K 500 
NCIH1341 lung E542K 2000 
NCIH460 lung E545K 250 
NCIH508 large intestine E545K 1000 
RKO large intestine H1047R 1000 
SNU407 large intestine H1047R 1000 
SNUC5 large intestine H1047R 2000 
SW948 large intestine E542K 1000 
T84 large intestine E542K 2000 
VMCUB1 urinary tract E542K 500 
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Figure 6.4. Dose-response curves of PI3K inhibitor re-test in 384-well format. All values 
are shown and were generated in two independent experiments run in triplicate (values 
are mean ± SD). Red dose-response curves are of PIK3CA E542K-mutant CCLs, blue 
dose-response curves are of PIK3CA H1047R-mutant CCLs. a-b) dose-response 
curves for GDC-0941 in mutant PIK3CA CCLs at 2000 cells/well (a) or optimized 
densities (b). c-d) dose-response curves for BYL-719 in mutant PIK3CA CCLs at 2000 
cells/well (c) or optimized densities (d). e-f) dose-response curves for AZD6482 in 
mutant PIK3CA CCLs at 2000 cells/well (e) or optimized densities (f). 
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The hypotheses look promising and could be used to increase the benefit of PI3K 
inhibitors in the clinic by treating patients with the correspondingly more sensitive 
mutations. It is important to note that the dose-response curves for many compounds 
were less separated between sensitive and nonresponsive CCLs at optimized seeding 
densities. It has been shown that mutant PIK3CA can allow CCLs to overcome normal 
contact-inhibitory signals.45 It is possible that overgrowth of CCLs changes their 
sensitivity to the compounds. Therefore, more studies are necessary to confirm the 
hypothesis and bring possible benefit to patients. Genomic cell line engineering, using 
tools such as CRISPR,46,47 could help prove a direct cause of the mutation. Additionally, 
since these compounds are in clinical trials, retroactive analyses of trial results might be 
refined to specific mutations, rather than mutational status of the whole gene.  
 
Fusion gene enrichment 
The enrichment analysis of the fusion genes also added new hypotheses. 
NPM1/ALK-translocated CCLs were very sensitive to treatment with NVP-TAE684 and 
crizotinib, two ALK inhibitors (Table 6.4, Suppl. Table S6.3 (digital)).48,49 Crizotinib has 
been shown to be effective in clinical trials in patients with ALK translocations.50 
Therefore, fusion genes are a valid feature to examine in CCL profiling. Because the 
annotation of fusion genes within CCLs is still sparse, not many other hypotheses arise 
from this analysis. NPM1/ALK-translocated CCLs are also sensitive to the CDK inhibitor 
PHA-793887.51 This is contrary to a previous study showing that NPM1/ALK-positive 
CCLs from anaplastic large cell lymphoma are less sensitive than ALK-negative CCLs 
to another CDK inhibitor flavopiridol.52 This discrepancy could arise because the authors
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Table 6.4. selected enrichments from fusion gene analysis 
compound 
compound 
target 
enrichment p-value heatmap 
NVP-TAE684 ALK NPM1/ALK 1.15 ·10-8 
 
crizotinib ALK NPM1/ALK 2.78 ·10-8 
 
PHA-793887 CDK NPM1/ALK 3.33 ·10-7 
 
BRD-
K92856060 
unknown EWSR1/FLI 8.65 ·10-8 
 
   legend: 
 
 
did not study many other CCLs, or because PHA-793887 has a different activity profile, 
causing it to have different effects. However, PHA-793887 has been shown to have 
significant hepatotoxicity in clinical trials,53 so another compound with a similar inhibitory 
profile, but no hepatotoxicity would have to be found in order to benefit from this 
hypothesis. Additionally, EWSR1/FLI1-translocated CCLs are very sensitive to a 
compound called BRD-K92856060. This compound does not have an annotated 
mechanism of action, but a PubChem search (CID: 2945648) shows that it had 
bioactivity in several assays, most notably in 14 assays related to microphthalmia-
associated transcription factor (MITF). 
When studying the annotations that are in COSMIC, it is obvious that many CCLs 
have not yet been annotated properly for fusion genes. For example, the well-known 
fusion gene BCR/ABL, which causes chronic myelogenous leukemia (CML)54-56 is not 
annotated for any CCL, even though some CCLs are of the CML sublineage, according 
to CCLE. Therefore, this analysis should be repeated with full annotations of fusion 
genes once available, as more relevant hypotheses might arise from the process.  
1 107.5
AUC
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Conclusion 
In conclusion, CCL profiling can generate many hypotheses regarding cancer 
dependencies. Some of these hypotheses, if tested accordingly, could change patients’ 
lives quickly, as the compounds involved are already in the clinic. Many more 
hypotheses can be uncovered when carefully searching the data. However, care should 
be exercised when mining the data for relevant hypotheses, as CCLs have many 
confounding mutations. As all hypotheses will need to be confirmed in costly 
experiments, picking the most promising ones is highly desirable. Selecting enrichments 
with strong p- and q-values and prioritizing those with known relevant mutations could 
lead to faster success. Additionally, apart from retesting the effects in more CCLs, 
directed follow-up experiments (e.g., using genomic editing) can help establish direct 
correlation between mutations and their effects in a quick and straightforward manner. 
Moving forward, we plan to follow-up on selected hypotheses using these assay 
systems. 
 
Experimental Section 
Materials and Methods 
 Cell Lines and Reagents: cells were purchased from the Broad Institute 
Biological Samples Platform or ATCC (Manassas, VA, USA). All CCLs were grown at 
37°C/5% CO2 in their specified medium (Suppl. Table S6.1 (digital)). All CCLs were 
tested for mycoplasma using a Takara PCR Mycoplasma Detection Kit (Otsu, Japan). 
Media components and supplements were purchased from ATCC (VA, USA), Cellgro 
 156 
 
(VA, USA), Life Technologies (Carlsbad, CA, USA), EMD Millipore Chemicals (Billerica, 
MA, USA), or Invitrogen (Carlsbad, CA, USA).  
Assay Treatments and Readouts: as described in Chapter 5. In addition:  Plate 
Reader settings used were: luminescence settings 1,536-well: Perkin Elmer (Waltham, 
MA, USA) Viewlux 1430 uHTS Microplate Imager. Compounds were acoustically-
transferred using a Labcyte Echo 555 (1,536-well) or pin-transferred using a CyBio 
(Jena, Germany) Cy-Bi Well Vario (384-well). 
 
Assay Protocols 
Cancer Cell Line (CCL) Profiling: Cells were plated at 500 cells/well, 6 L/well in 
1,536-well opaque, moat-well, white assay plates and incubated overnight at 37C/5% 
CO2. Compound stocks were plated in 1,536-well format in 16-pt, 2-fold concentration 
ranges defined by literature review. Compounds (20 nL) were acoustically-transferred 
into duplicate assay plates and incubated for 72h. The plates were allowed to come to 
room temperature and ATP levels were measured after adding 1.5 L of CellTiter-Glo 
and incubation for 10 min at room temperature, as a surrogate for cell viability. 
 Assay Development for PI3K inhibitor retest: All CCLs were plated in 384-well 
opaque, white assay plates at one column each of 250, 500, 1000, and 2000 cells/well 
in 30 L/well of their specified medium. Assay plates were incubated for 4 days at 
37C/5% CO2. After the incubation period was over, the plates were removed from the 
incubator and allowed to come to room temperature. Subsequently, 30 L of a 1:2 
dilution of CellTiter-Glo reagent in PBS was added to each well and the plates were 
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shaken at room temperature for a few seconds. The plates were then incubated at room 
temperature for at least 10 min and read out using luminescence 384-well settings. 
PI3K inhibitor retest: To confirm the effect of the PI3K and AKT inhibitors on the 
PIK3CA-mutant CCLs, a retest was performed. CCLs were seeded in opaque, white 
384 well plates at 2,000 cells/well and their optimized (Table 6.3) density in 30 L/well 
of their specified medium (Suppl. Table S6.1 (digital)). Cells were incubated for 24 h at 
37°C/5% CO2 and the compounds were pinned at their respective concentrations with 
100 nL/well. The plates were subsequently incubated at 37°C/5% CO2 for 72 hours. 
After the incubation period was over, the plates were removed from the incubator and 
allowed to come to room temperature. Subsequently, 30 L of a 1:2 dilution of CellTiter-
Glo reagent in PBS was added to each well and the plates were shaken at room 
temperature for a few seconds. The plates were then incubated at room temperature for 
at least 10 min and read out using luminescence 384-well settings. 
 
Data Analysis 
Data processing: As described in Chapter 5, using 3- or 4-parameter non-linear 
regressions to a sigmoid function (MATLAB) for fitting concentration-response curves of 
percent-viability scores. 
Several steps for quality control for concentration points/curves were employed before 
final AUC calculation: 1) if compound-transfer events were reported as failed by the 
instrument, the respective data was removed; 2) plate data were reviewed visually in 
GeneData and wells or whole plates that had faulty readouts were masked; 3) during 
curve-fitting, a QC method based on Cook's distance was employed and outlier points 
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were eliminated; 4) at least 5 concentration-data points were required to fit a curve. 
Genetic Data: as described in Chapter 5. TCGA data was downloaded from the 
Broad Institute’s Cancer Genome Analysis (CGA) group 
(http://www.broadinstitute.org/cancer/cga). All available data on 10/31/2013 was 
downloaded, which included samples from the following lineages: acute myeloid 
leukemia (197 samples), bladder urothelial carcinoma (28 samples), breast invasive 
carcinoma (776 samples), cervical squamous cell carcinoma and endocervical 
adenocarcinoma (39 samples), colon adenocarcinoma (155 samples), glioblastoma 
multiforme (291 samples), head and neck squamous cell carcinoma (306 samples), 
kidney renal clear cell carcinoma (417 samples), kidney renal papillary cell carcinoma  
(112 samples), lung adenocarcinoma (229 samples), lung squamous cell carcinoma 
(178 samples), ovarian serous cystadenocarcinoma (316 samples), pancreatic 
adenocarcinoma (57 samples), prostate adenocarcinoma (83 samples), rectum 
adenocarcinoma (69 samples), skin cutaneous melanoma (266 samples), stomach 
adenocarcinoma (221 samples), thyroid carcinoma (405 samples), uterine corpus 
eendometrial carcinoma (248 samples), unspecified lineage (5 samples) 
Overlap calculations: All available TCGA datasets from the Broad Institute’s 
Cancer Genome Analysis (CGA) group using the firehose tool 
(www.broadinstitute.org/cancer/cga/firehose) as well as the mutational data of the 
CCLE (www.broadinstitute.org/ccle) oncomap and hybrid capture datasets were used.1,9 
All annotated protein information was removed. hg18 data was transferred to hg19 data 
using the University of Santa Cruz’s LiftOver Tool (http://genome.ucsc.edu/cgi-
bin/hgLiftOver).10-12 All mutations were re-annotated into protein changes with the 
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chromosome, start and end positions, mutated allele and reference allele for all samples 
using the Oncotator Tool (www.broadinstitute.org/cancer/cga/oncotator) from the Broad 
Institute’s CGA group.13 Of note, some location positions and protein changes were 
annotated conflictingly using this tool. This was done consistently however, and 
therefore did not influence later analyses. The errors were manually corrected in the 
final data file to reflect the position as given by the “canonical” sequence on UniProt 
(Suppl. Table S6.2 (digital)). The TCGA data was filtered to only include the 1,667 
genes also contained in the CCLE files. Overlap of mutations was determined by protein 
change and by amino acid location. 
Enrichment analysis recurrent genes: p-values that quantify the enrichment of 
genetic alterations relative to ranked sensitivities measured for a single compound 
across many CCLs were calculated using a sorting-based enrichment-scoring 
algorithm.57 The p-value for each compound and each genetic feature corresponds to 
the likelihood of seeing that pattern of alterations (or a stronger one) enriched among 
the ranked sensitivities by chance. To control for multiple hypothesis testing, the 
Benjamini-Hochberg procedure58 was applied. This generated q-values (adjusted 
squared maximum p-values) and a false-discovery rate (FDR) cutoff q < 0.1 was applied 
for Suppl. Table S6.2 (digital). 
Enrichment analysis fusion genes: To determine enrichments for the fusion 
genes, all AUC values were split into several sets of sensitive and non-responsive CCLs 
using cutoffs at the AUC value of each mutant CCL for each compound. P-values were 
calculated using Fisher exact test for the separation between the sensitive and the non-
sensitive CCL sets at each AUC cutoff. The lowest p-value calculated for each 
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compound was determined to be the p-value of enrichment and the corresponding AUC 
cutoff was noted. A cutoff of p < 0.05 was applied for Suppl. Table S6.3 (digital). 
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Chapter Seven 
 
Further outlook into small-molecule probe development for 
cancer 
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Summary of research presented 
This thesis describes an effort to develop novel small-molecule probes and their 
application to research in cancer biology. Many small-molecule probes have been 
discovered by the Chemical Biology community. In order to use them as reliable tools, 
quality-control measures have been defined.1,2 In Chapter Two, I describe the 
characterization of several small molecules previously annotated as probes, which were 
hits in a high-throughput screen for novel Hedgehog (Hh) pathway inhibitors. Some of 
these compounds most likely act on the Hh pathway through cross-signaling of their 
annotated targets. However, I showed that several of these compounds displace 
BODIPY-cyclopamine, a fluorescently labeled Smoothened (Smo) inhibitor, suggesting 
that they also interact with Smo. This additional activity should be considered when 
using them as probes to determine biological effects. For some of these compounds, 
adjusting the concentration can avoid the problem, but for others, additional probes 
might be necessary to confirm results. 
The high-throughput screen not only presented known compounds but also 
provided a class of compounds with interesting stereochemistry-based structure–activity 
relationships (SAR) as inhibitors of the Hh pathway, as described in Chapter Three. We 
interpreted this striking stereochemical effect as indirect evidence for a selective 
interaction with cellular target(s). Further building-block based SAR generated two 
probes, BRD50837 and BRD9526, both of which inhibit the Hh pathway potently.  
In Chapter Four, I investigated the mechanism of action of the two probes 
discovered in Chapter Three. They were tested in several epistasis and competition 
experiments, which showed that they acted similarly to the traditional pathway inhibitor 
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cyclopamine in some aspects, but different in others. These results are puzzling when 
interpreting the pathway using the traditional canonical model. However, the pathway 
has been shown to be very complex. Non-canonical signaling models are present and 
several small-molecule inhibitors target the same receptor, but cause different cellular 
outcomes.3-5 This puzzling result is most likely due to the complexity of this enigmatic 
pathway. Identifying the compounds’ target can realize their full potential as probes and 
enable further elucidation of the pathway. First studies to identify this target gave rise to 
a family of proteins, glutathione S-transferase  (GSTMs) as potential interacting 
proteins.  
In order to apply small-molecule probes directly to cancer research, a cancer 
cell-line (CCL) profiling effort is described in Chapter Five. Here, the response of 242 
CCLs was assessed against an Informer Set of 355 compounds. Using publicly 
available genetic characterizations of the CCLs, novel hypotheses of cancer 
dependencies were generated with enrichment and clustering analyses. This approach 
detected already-known cancer dependencies, which gave us confidence in the process.  
One important question arising from the data generated in Chapter Five and in 
an additional profiling effort by the Broad Institute’s Chemical Biology Program and 
Platform was how to prioritize which hypothesis to pursue. For many hypotheses, little 
was known about the effects of enriched mutations or their biological relevance. 
Chapter Six describes a way to focus the enrichment on biologically relevant mutations. 
This new enrichment analysis generated hypotheses for specific mutations of several 
genes and showed that these enrichments would not have been found using all 
mutations in a certain gene. One hypothesis arising was that of differential sensitivity of 
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PIK3CA-mutant CCLs to PI3K and AKT inhibitors. In a retest of several PIK3CA-mutant 
CCLs, this differential sensitivity to PI3K inhibitors, but not to AKT inhibitors could be 
confirmed. 
 
Future directions 
In order to elucidate the Hh pathway further, identifying the target of BRD50837 
and BRD9526 is necessary. A family of proteins, GSTMs, has been identified by 
biochemical affinity purification as interacting with the probes in cell lysates. More 
experiments are needed to determine the nature of the interaction and possible impacts 
on the Hh pathway. This could include biochemical assays to test inhibition of the 
enzyme in vitro as well as cellular assays to determine if the compounds’ effect on cells 
is the same as with known inhibitors of GSTMs. Further experiments could include 
knock-down or overexpression of GSTMs and comparison of the resulting phenotype to 
that of small-molecule inhibition. Direct binding interactions could be studied using 
surface plasmon resonance or isothermal calorimetry. If the interaction of the probes 
with GSTMs is relevant to the Hh pathway, these experiments will give additional insight 
into Hh signaling. 
The CCL profiling effort has generated many novel hypotheses of potential 
cancer dependencies. If these were to be confirmed, new ways of targeting cancer 
could be found for patients. One good experimental follow-up for this would be genetic 
editing using CRISPR.6,7 We are currently working on proving differential sensitivity of 
PIK3CA-mutant CCLs to PI3K inhibitors by changing the mutational status of PIK3CA-
mutant CCLs using genome editing. We are also attempting the same for CDC25C-
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mutant CCLs and their sensitivity to clofarabine. If successful, retrospective analysis of 
data from clinical trials could be used to determine if patients show a similarly 
differential response and could alter the target group of the respective drugs.  
Therefore, using small-molecule probes in research, our understanding of 
diseases can directly be altered. In some cases, new hypotheses can be generated that 
could rapidly translate into the clinic. In order to do so, the compounds must be reliable 
tools, and careful confirmation experiments have to be designed. However, the success 
of probe development and its influence on drug discovery show that the path is 
worthwhile to follow and many new discoveries can be made that ultimately change 
patients’ lives. 
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Supplementary Figures 
 
Figure S2.1. Inhibition of Shh-conditioned medium-induced Gli1 gene reporter 
luciferase activity treatment in Shh Light II cells with previously-annotated compounds 
and cyclopamine as a control after 30h. All values are shown and generated one 
experiment run in duplicate. 
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Figure S2.2. Viability of Shh Light II cells in response to 30 h treatment with previously 
annotated compounds and cyclopamine as a control. All values are shown and 
generated from two independent experiments run in duplicate (values are calculated 
average ± SD). 
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Figure S3.1. a) Dose response curve for inhibition of Gli1 gene reporter luciferase 
activity after 30 h treatment with BRD50837 in Shh Light II cells. All values are shown 
and generated from one independent experiment run in duplicate. b) Viability of Shh 
Light II cells in response to 30 h treatment with BRD50837. All values are shown and 
generated from two independent experiments run in duplicate (values are calculated 
average ± SD). c) Inhibition of Shh conditioned medium (CM) induced differentiation of 
C3H10T1/2 cells for all eight stereoisomers of BRD50837. The RSR and the SSR 
isomers are active with the RSR isomer being the more potent isomer. All values are 
shown and generated from three independent experiments run in duplicate (values are 
calculated average ± SD). 
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Figure S3.2. Gli expression for C3H10T1/2 cells induced with Shh-conditioned medium, 
treated for 48 hours with DMSO, 10 M cyclopamine, 10 M GANT-61, 1 M 
BRD50837, or 1 M BRD9526. All values are shown and generated from three 
independent experiments run in triplicate (c) (values are calculated average ± SD). 
 
 
 
Figure S4.1. All values are shown and generated from three independent experiments 
run in duplicate (values are calculated average ± SD). a) Viability of SAG-induced 
C3H10T1/2 cells in response to 48 h treatment with BRD50837, BRD9526, or 
cyclopamine. b) Viability of Ptch-/- cells in response to 48 h treatment with BRD50837, 
BRD9526, or cyclopamine.  
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Figure S5.1. Properties of CCL profiling and genetic data. Area under concentration-
response curves (AUC) accounts for both EC50 and strength of effect (A). At low percent 
effect (i.e., when cell viability is relatively unaffected by compound treatment), AUC is 
essentially independent of relative EC50. In contrast, as percent effect increases, the 
dependence of AUC on EC50 (as judged by the slope of their correlation) increases such 
that at 100% effect, changes in AUC are equivalent to changes in log(EC50) (slope=1). 
Data presented represent a summary of 37,592 curve-fits (74.1% of all experiments in 
this study) for which the EC50 estimate was greater than 1/8 of the lowest concentration 
tested and less than 8X the highest concentration tested. Relative EC50s were 
computed relative to the highest concentration tested for each compound, and strengths 
of effect were binned into groups centered on the indicated values for trellis display. 
Distributions of unique lesions (B) and frequencies of genes mutated in CCLs tested (C). 
The median CCL has mutations in 75 genes (5 percent of total genes sequenced). A 
large fraction of genes has several unique lesions. 
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Figure S5.2. Properties of global connections. Dendrogram of all compounds used in 
the global analysis (using cosine distance in complete-linkage analysis); boxed cluster 
is described in the main text. 
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Figure S6.1. Dose-response curves of PI3K inhibitor re-test in 384-well format. All 
values are shown and were generated in two independent experiments run in triplicate 
(values are mean ± SD). Red dose-response curves are of PIK3CA E542K-mutant 
CCLs. a-b) dose-response curves for BKM120 in mutant PIK3CA CCLs at 2000 
cells/well (a) or optimized densities (b). c-d) dose-response curves for CH5132799 in 
mutant PIK3CA CCLs at 2000 cells/well (c) or optimized densities (d). 
 
-8 -7 -6 -5 -4
0.0
0.5
1.0
1.5
CH5132799
optimized cell numbers
log(concentration/uM)
A
T
P
 L
e
v
e
ls
  
(n
o
rm
a
li
z
e
d
 t
o
 D
M
S
O
)
-8 -7 -6 -5 -4
0.0
0.5
1.0
1.5
CH5132799
2000 cells per well
log(concentration/uM)
A
T
P
 L
e
v
e
ls
  
(n
o
rm
a
li
z
e
d
 t
o
 D
M
S
O
)
-8 -7 -6 -5 -4
0.0
0.5
1.0
1.5
BKM120
2000 cells per well
log(concentration/M)
A
T
P
 L
e
v
e
ls
  
(n
o
rm
a
li
z
e
d
 t
o
 D
M
S
O
)
-8 -7 -6 -5 -4
0.0
0.5
1.0
1.5
BKM120
optimized cell numbers
log(concentration/M)
A
T
P
 L
e
v
e
ls
  
(n
o
rm
a
li
z
e
d
 t
o
 D
M
S
O
)
A B
C D
 181 
 
 
Figure S6.2. Dose-response curves of AKT inhibitor re-test in 384-well format. All 
values are shown and were generated in two independent experiments run in triplicate 
(values are mean ± SD). Red dose-response curves are of PIK3CA E542K-mutant 
CCLs. a-b) dose-response curves for MK2206 in mutant PIK3CA CCLs at 2000 
cells/well (a) or optimized densities (b). c-d) dose-response curves for GDC-0068 in 
mutant PIK3CA CCLs at 2000 cells/well (c) or optimized densities (d). 
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Supplementary Schemes 
Scheme S3.1. Building blocks used for N-capping. 
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Supplementary Tables 
Table S3.1. Dose response curves of osteoblast differentiation and viability of 
C3H10T1/2 cells induced to differentiate by Hh conditioned medium (CM), EC50 of 
inhibition of osteoblast differentiation and viability, and PBS solubility of analogs of 
BRD50837 
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Table S3.1. (Continued) 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
15 
(BRD 
9526) 
A 
 
 
 
  
0.06 7.84 57.4 
16 A 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
20 A 
  
 
  
0.03 2.00 5.5 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
25 A 
  
 
  
0.18 2.71 - 
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0.22 b 0.7 
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b b - 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
30 C 
 
 
 
  
b b - 
31 A 
  
 
  
1.29 b - 
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1.06 6.24 - 
33 A 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
35 A 
 
 
 
  
0.71 b - 
36 A 
  
 
  
0.78 b - 
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4.75 b - 
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1.87 b - 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
40 A 
 
 
 
  
0.41 b - 
41 A 
  
 
  
5.14 b - 
42 A 
  
 
  
6.20 b - 
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0.73 b - 
44 A 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
45 B 
  
 
  
3.96 b - 
46 A 
 
 
 
  
0.98 b - 
47 A 
  
 
  
1.71 b - 
48 A 
  
 
  
3.63 b - 
49 C 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
50 A 
  
 
  
2.15 b - 
51 A 
  
 
  
3.61 b - 
52 A 
 
 
 
  
2.12 b - 
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3.64 b - 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
55 A 
  
 
  
0.29 b - 
56 A 
  
 
  
0.91 b - 
57 A 
  
 
  
0.90 b - 
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0.97 b - 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
60 A 
 
 
 
  
1.26 b - 
61 A 
 
 
 
  
0.38 b - 
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63 A 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
65 C 
  
 
  
1.45 b - 
66 A 
  
 
  
2.06 b - 
67 A 
  
 
  
1.42 b - 
68 A 
  
 
  
0.93 b - 
69 A 
  
 
  
5.36 b - 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
70 A 
  
 
  
5.24 b - 
71 A 
  
 
  
3.23 b - 
72 A 
  
 
  
0.42 b - 
73 A 
 
 
 
  
b b - 
74 A 
  
 
  
1.55 b - 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
75 A 
  
 
  
0.82 b - 
76 A 
 
 
 
  
1.82 b - 
77 A 
  
 
  
0.89 b - 
78 A 
  
 
  
1.13 b - 
79 A 
  
 
  
0.42 3.48 - 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
80 A 
  
 
  
2.75 b - 
81 A 
  
 
  
1.11 b - 
82 A 
 
 
 
  
0.25 b - 
83 A 
  
 
  
0.35 b - 
84 C 
  
 
  
2.63 b - 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
85 A 
  
 
  
4.52 b - 
86 A 
  
 
  
2.02 b - 
87 A 
  
 
  
0.30 b - 
88 A 
  
 
  
0.86 b - 
89 A 
  
 
  
0.49 b - 
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Table S3.1. (Continued) 
com-
pound 
scaf-
fold # 
Rx Ry Rz 
osteoblast differentiation 
(CM activation) 
viability in C3H10T1/2 cells  
(CM activation) 
res-
ponse 
EC50 
(M) 
via-
bilty 
EC50 
(M) 
PBS 
solu-
bility 
(M)
a
 
90 A 
  
 
  
1.78 b - 
91 A 
  
 
  
2.46 b - 
92 A 
 
 
 
  
1.59 b - 
a) solubility was measured for compounds that were considered for subsequent experimentation based 
on their EC50; b) dose-response curve did not pass EC50, so an EC50 value was not calculated. 
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